<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<base target="_blank">
<link rel=File-List href="Epilepsi_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="Epilepsi_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>EP&#304;LEPS&#304;</title>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="metricconverter"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>bet�lbaykan</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>bono</o:LastAuthor>
  <o:Revision>6</o:Revision>
  <o:TotalTime>2958</o:TotalTime>
  <o:Created>2010-04-25T18:14:00Z</o:Created>
  <o:LastSaved>2010-04-27T18:51:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>28153</o:Words>
  <o:Characters>160474</o:Characters>
  <o:Lines>1337</o:Lines>
  <o:Paragraphs>376</o:Paragraphs>
  <o:CharactersWithSpaces>188251</o:CharactersWithSpaces>
  <o:Version>10.2625</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:DontDisplayPageBoundaries/>
  <w:HideSpellingErrors/>
  <w:GrammarState>Clean</w:GrammarState>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if !mso]><object
 classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:+mn-ea;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 207.65pt right 415.3pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-AU;
	mso-fareast-language:KO;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-parent:"A�\0131klama Metni";
	mso-style-next:"A�\0131klama Metni";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;
	font-weight:bold;}
p.paper, li.paper, div.paper
	{mso-style-name:paper;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.title1, li.title1, div.title1
	{mso-style-name:title1;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:41.25pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.authors1, li.authors1, div.authors1
	{mso-style-name:authors1;
	margin-top:3.6pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:41.25pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.source1, li.source1, div.source1
	{mso-style-name:source1;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:41.25pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.ListeParagraf, li.ListeParagraf, div.ListeParagraf
	{mso-style-name:"Liste Paragraf";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.ListeParagrafCxSp\0130lk, li.ListeParagrafCxSp\0130lk, div.ListeParagrafCxSp\0130lk
	{mso-style-name:"Liste ParagrafCxSp\0130lk";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.ListeParagrafCxSpOrta, li.ListeParagrafCxSpOrta, div.ListeParagrafCxSpOrta
	{mso-style-name:"Liste ParagrafCxSpOrta";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
p.ListeParagrafCxSpSon, li.ListeParagrafCxSpSon, div.ListeParagrafCxSpSon
	{mso-style-name:"Liste ParagrafCxSpSon";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:TR;
	mso-fareast-language:TR;}
span.ti2
	{mso-style-name:ti2;
	mso-ansi-font-size:11.0pt;
	mso-bidi-font-size:11.0pt;}
span.journalname
	{mso-style-name:journalname;}
span.Absatz-Standardschriftart
	{mso-style-name:Absatz-Standardschriftart;
	mso-style-parent:"";}
ins
	{mso-style-type:export-only;
	text-decoration:none;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@page Section2
	{size:841.9pt 595.3pt;
	mso-page-orientation:landscape;
	margin:70.9pt 70.9pt 70.9pt 70.9pt;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-paper-source:0;}
div.Section2
	{page:Section2;}
@page Section3
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section3
	{page:Section3;}
 /* List Definitions */
 @list l0
	{mso-list-id:204950721;
	mso-list-template-ids:-1817250408;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:243339399;
	mso-list-template-ids:-1910447478;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2
	{mso-list-id:274144404;
	mso-list-template-ids:112200194;}
@list l2:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3
	{mso-list-id:318730469;
	mso-list-template-ids:-1115798864;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l4
	{mso-list-id:442268069;
	mso-list-template-ids:522991374;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l5
	{mso-list-id:487089857;
	mso-list-template-ids:-1450290694;}
@list l5:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l5:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6
	{mso-list-id:493837757;
	mso-list-template-ids:-396570326;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l6:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l6:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7
	{mso-list-id:522285101;
	mso-list-template-ids:-2021127694;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l7:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l7:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l7:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8
	{mso-list-id:540410495;
	mso-list-template-ids:-1222347590;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l8:level2
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-style:normal;}
@list l8:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9
	{mso-list-id:548617095;
	mso-list-template-ids:-131018578;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l10
	{mso-list-id:553085214;
	mso-list-template-ids:-957158292;}
@list l10:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l10:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11
	{mso-list-id:573515829;
	mso-list-template-ids:1783145622;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l12
	{mso-list-id:594171121;
	mso-list-template-ids:-1100996634;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l13
	{mso-list-id:647634135;
	mso-list-template-ids:1348470084;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l13:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l14
	{mso-list-id:661392100;
	mso-list-template-ids:216565472;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l14:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l15
	{mso-list-id:692614231;
	mso-list-template-ids:557369974;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l16
	{mso-list-id:701902519;
	mso-list-template-ids:-850474904;}
@list l17
	{mso-list-id:731200501;
	mso-list-type:hybrid;
	mso-list-template-ids:-665833414 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:54.0pt;
	mso-level-number-position:left;
	margin-left:54.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18
	{mso-list-id:735936408;
	mso-list-template-ids:-2039949872;}
@list l18:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l18:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l19
	{mso-list-id:758256243;
	mso-list-template-ids:-376827010;}
@list l19:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l20
	{mso-list-id:789936138;
	mso-list-template-ids:-591755514;}
@list l20:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l20:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21
	{mso-list-id:797646904;
	mso-list-type:hybrid;
	mso-list-template-ids:543484882 986371088 69140505 69140507 69140495 69140505 69140507 69140495 69140505 69140507;}
@list l21:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:18.0pt;
	text-indent:-18.0pt;
	mso-ansi-font-weight:bold;}
@list l21:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22
	{mso-list-id:809398708;
	mso-list-type:hybrid;
	mso-list-template-ids:-2025145286 1879357682 -801452934 52055694 860943644 -245488546 -2007963348 -814553642 -244024700 -1787797968;}
@list l22:level1
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Comic Sans MS";}
@list l22:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23
	{mso-list-id:831676167;
	mso-list-template-ids:-822964714;}
@list l23:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l23:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24
	{mso-list-id:877467885;
	mso-list-template-ids:-214409006;}
@list l24:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l24:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l25
	{mso-list-id:935986667;
	mso-list-template-ids:-1986228126;}
@list l25:level1
	{mso-level-start-at:10;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26
	{mso-list-id:952251120;
	mso-list-type:hybrid;
	mso-list-template-ids:-1196377942 69140495 69140505 69140507 69140495 69140505 69140507 69140495 69140505 69140507;}
@list l26:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l26:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27
	{mso-list-id:1012683143;
	mso-list-template-ids:-428032326;}
@list l27:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l28
	{mso-list-id:1066957345;
	mso-list-template-ids:728671784;}
@list l28:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l29
	{mso-list-id:1067722882;
	mso-list-template-ids:1683253406;}
@list l29:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l30
	{mso-list-id:1132597486;
	mso-list-type:hybrid;
	mso-list-template-ids:1204459398 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l30:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:71.4pt;
	mso-level-number-position:left;
	margin-left:71.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l30:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l31
	{mso-list-id:1142233742;
	mso-list-template-ids:-95546940;}
@list l31:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l32
	{mso-list-id:1170873453;
	mso-list-template-ids:1643943916;}
@list l32:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l33
	{mso-list-id:1199320399;
	mso-list-template-ids:-896336518;}
@list l34
	{mso-list-id:1202671580;
	mso-list-template-ids:-7432356;}
@list l34:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l34:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l34:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35
	{mso-list-id:1210993710;
	mso-list-template-ids:-1563921944;}
@list l35:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l35:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l35:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l36
	{mso-list-id:1221671199;
	mso-list-template-ids:1024616404;}
@list l36:level1
	{mso-level-start-at:15;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l37
	{mso-list-id:1273052191;
	mso-list-template-ids:-1991841510;}
@list l37:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l38
	{mso-list-id:1298101887;
	mso-list-template-ids:1638685794;}
@list l38:level1
	{mso-level-start-at:8;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l39
	{mso-list-id:1448699081;
	mso-list-template-ids:1772750756;}
@list l39:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l40
	{mso-list-id:1480416041;
	mso-list-template-ids:16516860;}
@list l40:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l40:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l41
	{mso-list-id:1496919046;
	mso-list-template-ids:1172612298;}
@list l41:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l42
	{mso-list-id:1506556259;
	mso-list-template-ids:-1651495892;}
@list l42:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l43
	{mso-list-id:1549033282;
	mso-list-template-ids:1790333894;}
@list l43:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l43:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44
	{mso-list-id:1558392939;
	mso-list-template-ids:-1995926642;}
@list l44:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l44:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l45
	{mso-list-id:1569606328;
	mso-list-template-ids:1677773324;}
@list l45:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l45:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46
	{mso-list-id:1580824598;
	mso-list-template-ids:-2007491250;}
@list l46:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l46:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l46:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l46:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47
	{mso-list-id:1599488321;
	mso-list-template-ids:1122671820;}
@list l47:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l47:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l48
	{mso-list-id:1640837338;
	mso-list-template-ids:-1198369804;}
@list l48:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l49
	{mso-list-id:1641108515;
	mso-list-template-ids:662754302;}
@list l49:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l50
	{mso-list-id:1645235229;
	mso-list-template-ids:-1756576218;}
@list l50:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l50:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l50:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l51
	{mso-list-id:1673991924;
	mso-list-template-ids:-1863958648;}
@list l51:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l52
	{mso-list-id:1677489497;
	mso-list-type:hybrid;
	mso-list-template-ids:971021752 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l52:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l52:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l52:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l53
	{mso-list-id:1711959186;
	mso-list-template-ids:-255585342;}
@list l53:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l53:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l53:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l53:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l53:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l53:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l53:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l53:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l53:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l54
	{mso-list-id:1716200718;
	mso-list-template-ids:1966488706;}
@list l54:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l54:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l54:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l54:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l54:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l54:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l54:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l54:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l54:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l55
	{mso-list-id:1770154420;
	mso-list-template-ids:-476132000;}
@list l55:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l56
	{mso-list-id:1777863362;
	mso-list-template-ids:-794264518;}
@list l56:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l56:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l56:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l56:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l56:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l56:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l56:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l56:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l56:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l57
	{mso-list-id:1782414282;
	mso-list-template-ids:-1577659242;}
@list l57:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l58
	{mso-list-id:1839534702;
	mso-list-template-ids:1558895932;}
@list l58:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l59
	{mso-list-id:1851066246;
	mso-list-template-ids:-1673380806;}
@list l59:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l59:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l59:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60
	{mso-list-id:1876579259;
	mso-list-type:hybrid;
	mso-list-template-ids:-1821624206 69140495 -1949820898 2025904322 275537564 -307071770 291034634 -367988264 -2058602604 -1347093960;}
@list l60:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level2
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Tahoma;
	mso-bidi-font-family:"Times New Roman";}
@list l60:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l60:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61
	{mso-list-id:1894349217;
	mso-list-template-ids:-1236920448;}
@list l61:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l61:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l61:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l62
	{mso-list-id:1912231228;
	mso-list-template-ids:1428225816;}
@list l62:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l63
	{mso-list-id:1929121855;
	mso-list-template-ids:-286339854;}
@list l63:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l63:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l63:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l64
	{mso-list-id:1966540934;
	mso-list-template-ids:1491518250;}
@list l64:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l64:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l65
	{mso-list-id:1967737644;
	mso-list-template-ids:1393864208;}
@list l65:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l65:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l65:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66
	{mso-list-id:2009599725;
	mso-list-template-ids:-1489992182;}
@list l66:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l66:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l66:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67
	{mso-list-id:2020310324;
	mso-list-type:hybrid;
	mso-list-template-ids:-369204326 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l67:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l67:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l67:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l67:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68
	{mso-list-id:2061905791;
	mso-list-template-ids:-1267839864;}
@list l68:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l68:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l68:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l68:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69
	{mso-list-id:2074769978;
	mso-list-type:hybrid;
	mso-list-template-ids:-1943361508 -481520824 -668699610 1197370202 -342450256 -1183175896 199231768 1521679078 -755879548 480903276;}
@list l69:level1
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Comic Sans MS";}
@list l69:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l69:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l70
	{mso-list-id:2100787567;
	mso-list-template-ids:-570262340;}
@list l70:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l70:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l70:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l71
	{mso-list-id:2120222121;
	mso-list-type:hybrid;
	mso-list-template-ids:-1733676196 -1580040152 445276532 -102858668 2114864052 -792658370 1230659576 327344594 -524766742 3408748;}
@list l71:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F097;
	mso-level-tab-stop:53.4pt;
	mso-level-number-position:left;
	margin-left:53.4pt;
	text-indent:-18.0pt;
	font-family:"Wingdings 2";}
@list l71:level2
	{mso-level-start-at:942;
	mso-level-number-format:bullet;
	mso-level-text:\25E6;
	mso-level-tab-stop:89.4pt;
	mso-level-number-position:left;
	margin-left:89.4pt;
	text-indent:-18.0pt;
	font-family:Verdana;}
@list l71:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l71:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l71:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l71:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l71:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l71:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l71:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l72
	{mso-list-id:2139954928;
	mso-list-template-ids:626835268;}
@list l72:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
table.MsoTableGrid
	{mso-style-name:"Tablo K\0131lavuzu";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	border:solid black 1.0pt;
	mso-border-alt:solid black .5pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid black;
	mso-border-insidev:.5pt solid black;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
table.AkListe-Vurgu5
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-tstyle-rowband-size:1;
	mso-tstyle-colband-size:1;
	border:solid #4BACC6 1.0pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
table.AkListe-Vurgu5FirstRow
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-table-condition:first-row;
	mso-tstyle-shading:#4BACC6;
	mso-para-margin-top:auto;
	mso-para-margin-bottom:auto;
	line-height:normal;
	color:white;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkListe-Vurgu5LastRow
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-table-condition:last-row;
	mso-tstyle-border-top:2.25pt double #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;
	mso-para-margin-top:auto;
	mso-para-margin-bottom:auto;
	line-height:normal;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkListe-Vurgu5FirstCol
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-table-condition:first-column;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkListe-Vurgu5LastCol
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-table-condition:last-column;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkListe-Vurgu5OddColumn
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-table-condition:odd-column;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;}
table.AkListe-Vurgu5OddRow
	{mso-style-name:"A�\0131k Liste - Vurgu 5";
	mso-table-condition:odd-row;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;}
table.AkKlavuz-Vurgu5
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-tstyle-rowband-size:1;
	mso-tstyle-colband-size:1;
	border:solid #4BACC6 1.0pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:1.0pt solid #4BACC6;
	mso-border-insidev:1.0pt solid #4BACC6;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
table.AkKlavuz-Vurgu5FirstRow
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:first-row;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:2.25pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;
	mso-tstyle-border-insideh:cell-none;
	mso-tstyle-border-insidev:1.0pt solid #4BACC6;
	mso-para-margin-top:auto;
	mso-para-margin-bottom:auto;
	line-height:normal;
	font-family:Times-Roman;
	mso-ascii-font-family:Times-Roman;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Times-Roman;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkKlavuz-Vurgu5LastRow
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:last-row;
	mso-tstyle-border-top:2.25pt double #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;
	mso-tstyle-border-insideh:cell-none;
	mso-tstyle-border-insidev:1.0pt solid #4BACC6;
	mso-para-margin-top:auto;
	mso-para-margin-bottom:auto;
	line-height:normal;
	font-family:Times-Roman;
	mso-ascii-font-family:Times-Roman;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Times-Roman;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkKlavuz-Vurgu5FirstCol
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:first-column;
	font-family:Times-Roman;
	mso-ascii-font-family:Times-Roman;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Times-Roman;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkKlavuz-Vurgu5LastCol
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:last-column;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;
	font-family:Times-Roman;
	mso-ascii-font-family:Times-Roman;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Times-Roman;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.AkKlavuz-Vurgu5OddColumn
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:odd-column;
	mso-tstyle-shading:#D2EAF1;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;}
table.AkKlavuz-Vurgu5OddRow
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:odd-row;
	mso-tstyle-shading:#D2EAF1;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;
	mso-tstyle-border-insidev:1.0pt solid #4BACC6;}
table.AkKlavuz-Vurgu5EvenRow
	{mso-style-name:"A�\0131k K\0131lavuz - Vurgu 5";
	mso-table-condition:even-row;
	mso-tstyle-border-top:1.0pt solid #4BACC6;
	mso-tstyle-border-left:1.0pt solid #4BACC6;
	mso-tstyle-border-bottom:1.0pt solid #4BACC6;
	mso-tstyle-border-right:1.0pt solid #4BACC6;
	mso-tstyle-border-insidev:1.0pt solid #4BACC6;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="21506">
  <o:colormenu v:ext="edit" strokecolor="black"/>
 </o:shapedefaults></xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:35.4pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
padding:1.0pt 4.0pt 0cm 4.0pt'>

<p class=MsoNormal style='text-align:justify;border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 0cm 4.0pt'><b><span lang=TR
style='font-size:18.0pt;font-family:Tahoma'>EP&#304;LEPS&#304;</span></b><b><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></b></p>

<p style='text-align:justify;border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 0cm 4.0pt'><span lang=TR
style='font-family:Tahoma'>Yazanlar: <b>Bet�l BAYKAN, Nerses BEBEK, Candan
G�RSES, Ay&#351;en G�KY&#304;&#286;&#304;T</b> <o:p></o:p></span></p>

<p style='text-align:justify;border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 0cm 4.0pt'><span lang=TR
style='font-family:Tahoma'>Son g�ncelle&#351;tirme tarihi: 03.03.2010<o:p></o:p></span></p>

</div>

<p style='text-align:justify'><a name="Tan&#305;mlama_ve"></a><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma'>TANIMLAMA VE
EP&#304;DEM&#304;YOLOJ&#304;<o:p></o:p></span></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi;
beyindeki sinir h�crelerinin artm&#305;&#351; uyar&#305;labilirli&#287;inden (n�ronal
hiperekstabilite) kaynaklanan klinik bir durumdur. <i style='mso-bidi-font-style:
normal'>Epilepsi n�beti</i>; gri maddedeki artm&#305;&#351;, h&#305;zl&#305; ve
yerel elektriksel bo&#351;al&#305;mlardan k�ken al&#305;r ve klinikte belli bir
s�reye s&#305;n&#305;rl&#305; olarak, bilin�, davran&#305;&#351;, duygu,
hareket veya alg&#305;lama fonksiyonlar&#305;nda ani ba&#351;layan, k&#305;sa
s�reli ve ge�ici stereotipik de&#287;i&#351;iklik durumu g�zlenir. <i
style='mso-bidi-font-style:normal'>Epilepsi</i> ise kronik olarak tekrarlayan,
tetiklenmemi&#351; (non-provoke) n�betlerle giden tabloyu tan&#305;mlar, bu
nedenle tek bir tetiklenmemi&#351; n�bet epilepsi anlam&#305;na gelmez.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>N�betler
zaman i�inde her hasta i�in belli bir kal&#305;pta, genellikle
kendili&#287;inden veya baz&#305; tetikleyen fakt�rler zemininde tekrarlar.
N�betler aras&#305;nda hasta genellikle normal ya&#351;ant&#305;s&#305;n&#305;
s�rd�r�r. N�bet aral&#305;klar&#305; ve tipleri son derece de&#287;i&#351;ken
olabilir. Ancak ayn&#305; hastada genellikle ayn&#305; veya belirli birka�
n�bet tipi tekrarlama e&#287;ilimi g�sterir. <o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>Epilepsi sendromu</span></i><span
lang=TR style='font-family:Tahoma'> belli n�bet tipleriyle birlikte ona
e&#351;lik eden klinik ve laboratuvar bulgular&#305;n&#305;n t�m�n�
tan&#305;mlar; Etyoloji, oda&#287;&#305;n anatomik yerle&#351;imi, n�beti
tetikleyen fakt�rler, ba&#351;lang&#305;� ya&#351;&#305;, prognoz, tedaviye
yan&#305;t ve EEG bulgular&#305; sendromun belirlenmesinde �nem
ta&#351;&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>Epilepsi
hastal&#305;&#287;&#305;</span></i><span lang=TR style='font-family:Tahoma'>
ise iyi tan&#305;mlanm&#305;&#351;, �zg�l tek bir etyolojisi olan durumdur.
�rne&#287;in progresif miyoklonus epilepsileri sendromu belirtirken, Lafora
hastal&#305;&#287;&#305; �zg�n epilepsi hastal&#305;&#287;&#305;d&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsinin
insidensi toplumdan topluma de&#287;i&#351;mekle birlikte genellikle y&#305;lda
20-50/100.000 olarak bildirilmektedir. Aktif epilepsi prevalans&#305; ise
4-10/1000 olarak verilmektedir. Ya&#351;am boyu birikmi&#351; insidens ise yakla&#351;&#305;k
%3 olarak saptan&#305;r ki bu farkl&#305;l&#305;k epilepsinin baz&#305;
hastalarda ge�ici bir do&#287;as&#305; olmas&#305;ndan kaynaklanmaktad&#305;r.
Epilepsi insidensinin en y�ksek oldu&#287;u iki d�nem, ya&#351;am&#305;n ilk
y&#305;l&#305; ve 60 ya&#351; sonras&#305;d&#305;r. Epilepsi �ocukluk ve
ergenlik �a&#287;&#305;nda en s&#305;k, eri&#351;kinlerde ise beyin damar
hastal&#305;klar&#305;n&#305;n ard&#305;ndan ikinci, en s&#305;k rastlanan
n�rolojik hastal&#305;k olarak belirmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><a name=Temel></a><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma'>TEMEL MEKAN&#304;ZMALAR<o:p></o:p></span></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Hayvan
deneylerinde ve insanda yap&#305;lan �al&#305;&#351;malarda kortikal
n�ronlar&#305;n membran potansiyellerinde ve ate&#351;lenme &#351;ekillerinde
baz&#305; karakteristik bozukluklar saptanm&#305;&#351;t&#305;r. �Paroksizmal
depolarizasyon kaymas&#305; (PDK)� olarak bilinen bu durumda membran&#305;
depolarize eden postsinaptik potansiyelin anormal &#351;ekilde uzamas&#305; ve
b�y�mesi s�z konusudur. Bunun sonucu olarak n�ronlar gruplar halinde
ate&#351;lenebilir ve etraflar&#305;ndaki n�ronlar&#305; benzer &#351;ekilde
ate&#351;leyebilecek bir kapasiteye ula&#351;&#305;rlar. PDK�n&#305;n eksitat�r
n�rotransmitterler olan glutamat ve aspartat ile inhibit�r n�rotransmitter GABA
sistemleri aras&#305;ndaki dengesizlikten kaynakland&#305;&#287;&#305; ileri
s�r�lmektedir. Bunun d&#305;&#351;&#305;nda membranlardaki iyon
kanallar&#305;ndaki bozukluklar&#305;n da PDK�n&#305;n ortaya
�&#305;kmas&#305;nda etkili oldu&#287;u d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epileptojenik
odak olarak adland&#305;r&#305;lan bu b�lgede &quot;pacemaker&quot; h�creler
yer almaktad&#305;r ve bu h�creler tam olarak bilinmeyen nedenlerle,
artm&#305;&#351; uyar&#305;lma ve anormal ate&#351;lenme �zelli&#287;i
g�sterirler, etraflar&#305;ndaki h�creleri de bu ate&#351;lenmeye ortak
edebilecek g��leri vard&#305;r.<span style='mso-spacerun:yes'>� </span>Sonradan
kat&#305;lan bu n�ronlar&#305;n miktar&#305;; tablonun EEG'de bir interiktal
(n�bet aras&#305; d�nem) dikenle s&#305;n&#305;rl&#305; kalmas&#305;n&#305; ya
da yeterli miktara ula&#351;abildi&#287;inde EEG'de ve klinikte n�bet
aktivitesinin olu&#351;mas&#305;n&#305; belirler. Epileptik bir n�bet
s&#305;ras&#305;nda beyindeki n�ronlar&#305;n hipersenkron ve tekrarlay&#305;c&#305;
aktivasyonu s�z konusudur.</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> </span><span lang=TR style='font-family:Tahoma'>EEG'de
g�r�len diken artm&#305;&#351; eksitasyonu, dikeni izleyen yava&#351; dalga ise
inhibisyonu g�stermektedir. �zetle, fokal kortikal bir n�bet aktivitesinin
olu&#351;abilmesi i�in ilgili n�ronlarda 2 temel fizyopatolojik �zellik (1-
hipereksitabilite, 2- senkronizasyon) birlikte bulunmal&#305;d&#305;r. N�bet
aktivitesinin yay&#305;lmas&#305; ise eksitasyon alan&#305;n&#305; �evreleyen
inhibit�r n�ronlar&#305;n inaktivasyonu (�evresel inhibisyon alan&#305;n&#305;n
kayb&#305;) ile ger�ekle&#351;mektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bug�n
i�in eskiden kabul g�ren santrensefalik epilepsi, yani jeneralize ve santral
yerle&#351;imli bir epilepsi jenerat�r� oldu&#287;u kavram&#305;
tart&#305;&#351;mal&#305;d&#305;r ve yerini korteksin �n planda rol
ald&#305;&#287;&#305; kortikoretik�ler teoriye b&#305;rakm&#305;&#351;t&#305;r.
Baz&#305; n�bet tipleri i�in (�rne&#287;in, tipik absans n�betleri) talamusta
yer alan T-tipi Ca kanallar&#305;n&#305;n rol� kan&#305;tlanm&#305;&#351; olsa
da, b�t�n epilepsi n�betlerinin kortikal mekanizmalarla tetiklendi&#287;i
g�r�&#351;� giderek a&#287;&#305;rl&#305;k kazanmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>Jeneralize epilepsilerde beyinsap&#305; retik�ler
formasyonundan, orta hat talamus nukleuslar&#305; �zerinden ta&#351;&#305;nan
yayg&#305;n bir girdinin a&#351;&#305;r&#305; uyar&#305;lm&#305;&#351;
durumdaki kortekse etkisi �zerinde durulmakta ve baz&#305; asendan biojenik
aminlerin rolleri vurgulanmaktad&#305;r. Baz&#305;
ara&#351;t&#305;rmac&#305;lar ise tetikleyici b�lgenin b�y�k
olas&#305;l&#305;kla kortikal oldu&#287;unu ve anterograd veya retrograd yolla
senkron aktivitenin talamusa yay&#305;ld&#305;&#287;&#305;n&#305; savunmaktad&#305;rlar.
</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>N�bete e&#351;lik eden anormal de&#351;arjlar&#305;n fizyolojisi
konusunda bilgimiz olmas&#305;na kar&#351;&#305;n epileptogenezden sorumlu
h�cresel mekanizmalar halen bilinmemektedir. &#304;stirahat membran
potansiyelinin instabilitesine neden olan primer bir n�ronal membran defekti
�zerinde durulmaktad&#305;r. Buna neden oldu&#287;u d�&#351;�n�len
mekanizmalar; potasyum iletiminde bozukluk, voltaja duyarl&#305; kalsiyum
kanallar&#305;nda defekt veya ATPaza ba&#287;l&#305; iyon transportunda
bozukluk olarak �zetlenmektedir. GABAerjik inhibit�r sistemlerin primer defekti
olas&#305;l&#305;&#287;&#305; veya eksitat�r n�rotransmisyonda rol alan
resept�rlerin duyarl&#305;l&#305;&#287;&#305; ve d�zenlenmesindeki olas&#305;
defektler �zerinde de durulmaktad&#305;r. Eksitat�r n�rotransmisyonla
yak&#305;ndan ili&#351;kili olan �mossy fiber� sistemindeki morfolojik
de&#287;i&#351;iklikler g�sterilmi&#351;tir. </span><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Epileptik n�betlerde paroksizmal de&#351;arjlarla ilgili olarak
b�lgesel beyin kan ak&#305;m&#305;n&#305;n artt&#305;&#287;&#305; uzun zamandan
beri bilinmektedir. N�bet s&#305;ras&#305;nda ATP azal&#305;rken AMP, ADP,
laktik asid gibi maddeler �o&#287;almaktad&#305;r. Yine h�cre i�i kalsiyumun
artmas&#305;yla aktive olan fosfolipazlar serbest ya&#287; asidlerinin
artmas&#305;na yol a�makta ve prostaglandinler de art&#305;&#351;
g�stermektedir. ADP ve prostaglandinlerin vazodilatasyondaki rolleri g�z �n�ne
al&#305;n&#305;rsa, iktal d�nemdeki b�lgesel beyin kan ak&#305;m&#305;n&#305;n
art&#305;&#351;&#305;n&#305; a�&#305;klamak kolayla&#351;maktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;mso-line-height-alt:10.0pt'><b><span
lang=TR style='font-family:Tahoma'>EP&#304;LEPTOGENEZ <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;mso-line-height-alt:10.0pt'><b><span
lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:10.0pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>Epileptogenez,
tekrarlay&#305;c&#305; spontan n�betlerin olu&#351;tu&#287;u uzun s�reli beyin
transformasyonudur. </span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Normal bir beynin zaman i�inde bir dizi h�cresel-molek�ler,
yap&#305;sal ve/veya fonksiyonel de&#287;i&#351;ikliklere maruz kalarak
epileptik bir beyin haline d�n�&#351;mesi, kal&#305;c&#305; bir &#351;ekilde ve
spontan olarak n�bet olu&#351;turabilme �zelli&#287;i kazanmas&#305; s�recini
ifade eder. <span style='mso-bidi-font-weight:bold'>Beynin fokal bir b�lgesini
(parsiyel epilepsi) veya t�m beyni (jeneralize epilepsi) i�erebilir. Epileptogenez
mekanizmas&#305; ilerleyici bir s�re�tir, ba&#351;lang&#305;�
hasar&#305;n&#305; takiben sessiz bir d�nem olu&#351;ur. Takiben belli bir s�re
sonra spontan n�betler ortaya �&#305;kar. Bu d�nemlerde ya&#351;, cins, genetik
fakt�rlerin etkisiyle h�cre �l�m�, aksonlarda filizlenme, sinaptik
reorganizasyon, farkl&#305; tipteki lokal resept�rlerin �zelliklerinde
de&#287;i&#351;iklikler meydana gelir. T�m bu s�re� g�nler-aylar veya
y&#305;llar i�inde geli&#351;ir (</span><b style='mso-bidi-font-weight:normal'>&#350;ekil
1</b><span style='mso-bidi-font-weight:bold'>). Ge�mi&#351;te epileptogenezin
kronik bir s�re� oldu&#287;u d�&#351;�n�lmekteydi. Son y&#305;llarda
yap&#305;lan �al&#305;&#351;malar akut epileptogenezin de
varl&#305;&#287;&#305;n&#305; ortaya koymu&#351;tur. Akut epileptogenez
dakikalar veya saatler i�inde geli&#351;ir ve geri d�n�&#351;l� olabilir.
Epileptogenez de&#287;i&#351;ik mekanizmalarla olu&#351;abilir. Genel olarak
bunlar genetik ve edinsel mekanizmalard&#305;r.<o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Genetik mekanizmalar:</span></i></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>
Bug�n i�in, idyopatik epilepsi sendromlar&#305;yla ili&#351;kili oldu&#287;u
g�sterilmi&#351; onu a&#351;k&#305;n iyon kanal alt �nitesi geni mutasyonu
vard&#305;r. Bu hastal&#305;klar&#305;n ortak �zelli&#287;i voltaj veya ligand
kap&#305;l&#305; kanal genlerindeki mutasyonlara ba&#287;l&#305;
olmas&#305;d&#305;r. Dolay&#305;s&#305;yla epileptogenez s�recinin kanal
patolojilerine ba&#287;l&#305; oldu&#287;u d�&#351;�n�lmektedir. Farkl&#305;
dokularda, kanal ekspresyonundan sorumlu spesifik genler vard&#305;r ve
inhibit�r ve eksitat�r a&#287;lar kompleks bir ileti&#351;ime yol a�ar. Aksonal
ileti voltaj kap&#305;l&#305; kanallarla (aksiyon potansiyeli), sinyal iletimi
ise ligand kap&#305;l&#305; kanallarla sa&#287;lan&#305;r (sinaptik
transmisyon). Ancak son y&#305;llarda iyon kanallar&#305;ndan
ba&#287;&#305;ms&#305;z baz&#305; genlerin de epilepsiye neden olabildi&#287;i
yani noniyonik mekanizmalar&#305;n varl&#305;&#287;&#305; genetik
�al&#305;&#351;malarla kan&#305;tlanm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Edinsel
epileptogenez mekanizmalar&#305;:</span></i></b><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'> </span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semptomatik epilepsilerde
de �evresel fakt�rlerin yaratt&#305;&#287;&#305; h�cresel d�zeydeki
hasar&#305;n epilepsiye yol a�abilmesinin; ki&#351;inin genetik �zelliklerine
ba&#287;l&#305; oldu&#287;u d�&#351;�n�lmektedir. Fokal n�betlerin % 60-70�i temporal
lob kaynakl&#305;d&#305;r ve bu grupta en s&#305;k rastlanan patoloji mezyal
temporal sklerozdur (MTS). MTS s�reci sinaptik ve aksonal reorganizasyonda
de&#287;i&#351;imler g�sterir. Ancak geli&#351;im mekanizmas&#305; tam olarak
bilinmemektedir; �evresel ve genetik fakt�rlerin etkisi net olarak
ayd&#305;nlat&#305;lamam&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>Akut epileptogenez hayvan
deneyleriyle ortaya konmu&#351;tur. Bu ama�la uygulanan baz&#305; stimuluslar,
kullan&#305;lan konv�lzan ila�lar ve iyon konsantrasyonlar&#305; hipokampus,
amigdala ve neokortekste epileptiform bo&#351;al&#305;mlara yol a�ar.
Mekanizman&#305;n NMDA resept�r aktivasyonu ve AMPA-NMDA sinaptik
transmisyonundaki art&#305;&#351; sonucu kalsiyum ak&#305;&#351;&#305;,
GABA�erjik sinaptik inhibit�r transmisyonda azalma sonucunda eksitat�r etkide
art&#305;&#351;la ili&#351;kili oldu&#287;u d�&#351;�n�lmektedir. Ayr&#305;ca
nonsinaptik olarak �gap-junction coupling�i, demir arac&#305;l&#305; Ca
osilasyonunda veya glutamat sal&#305;n&#305;m&#305;nda de&#287;i&#351;imler,
serbest oksijen radikallerinin yay&#305;l&#305;m&#305; di&#287;er
mekanizmalard&#305;r. Sonu�ta, ilaca yan&#305;tl&#305; epilepsi veya ilaca
diren�li epilepsi geli&#351;ebilir ya da epilepsi geli&#351;meyebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:10.0pt'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;tab-stops:321.75pt'><b><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil1.jpg" target="_blank">&#350;ekil 1<span style='font-weight:normal;
mso-bidi-font-weight:bold'>:</span></a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue;mso-bidi-font-weight:
bold'> </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-bidi-font-weight:bold'>Epileptogenezin basitle&#351;tirilmi&#351;
geli&#351;im &#351;emas&#305;<span style='mso-tab-count:1'>����������������� </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><a name="Epilepsi_N�betlerinin_ve_Epilepsi_Sendro"></a><b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma'>EP&#304;LEPS&#304;
N�BETLER&#304;N&#304;N VE EP&#304;LEPS&#304; SENDROMLARININ SINIFLANDIRILMASI<o:p></o:p></span></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi
s�zc�&#287;�n�n eski Yunan dilindeki &quot;epilepsia&quot;dan t�redi&#287;i ve
n�bet anlam&#305;na geldi&#287;i bilinmektedir. &#304;nsanl&#305;k tarihi kadar
eski olan ve Hipokrat zaman&#305;ndan beri bilinen bu hastal&#305;&#287;&#305;n
s&#305;n&#305;fland&#305;r&#305;lmas&#305; antik �a&#287;lardan beri
u&#287;ra&#351;&#305;lan konulardan biridir. &#304;.�.175'de Galen, beyinden
kaynaklanan idyopatik n�betlerden ve v�cudun herhangi bir b�lgesinden
kaynaklanan semptomatik n�betlerden s�z etmi&#351;tir. 19. yy sonlar&#305;nda
sendrom yakla&#351;&#305;m&#305; olgular&#305;n ya&#351;, cins, n�bet
�zellikleri ile s&#305;n&#305;rl&#305;yken, 20. yy ikinci yar&#305;s&#305;ndan
sonra EEG ve g�r�nt�leme olanaklar&#305;n&#305;n artmas&#305;, 21. yy�da ise
insan genom �al&#305;&#351;malar&#305; ve teknolojik geli&#351;melerin
&#305;&#351;&#305;&#287;&#305;nda daha detayl&#305; hale gelmi&#351;tir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Modern
s&#305;n&#305;flama �al&#305;&#351;malar&#305; ortak bir terminoloji
olu&#351;turarak ileti&#351;imi kolayla&#351;t&#305;rma, eldeki t�m verileri
ortak havuzlarda toplayarak kar&#351;&#305;la&#351;t&#305;rma ve tedavi
se�iminde bu verileri en do&#287;ru &#351;ekliyle kullanabilme iste&#287;inden
do&#287;mu&#351; ve e<span style='mso-bidi-font-style:italic'>pilepsi ile
ilgilenenlerin �ncelikli sorunlar&#305;ndan biri haline gelmi&#351;tir.
Epilepsinin farkl&#305; ve benzer �zellikleri olan bir�ok hastal&#305;k grubunu
i�ermesi nedeniyle s&#305;n&#305;flama bize sistemli bir yakla&#351;&#305;m
sa&#287;lar. Sonu� olarak epilepsilerin s&#305;n&#305;flanmas&#305;: <o:p></o:p></span></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Kavrama,
e&#287;itim ve �&#287;retim<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>&#304;leti&#351;im:
Meslekta&#351;lar aras&#305;nda ayn&#305;-ortak dili kullanmak <o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Patofizyolojik
a�&#305;dan ortak ve ayr&#305; y�nleri saptamak<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Etyolojik
yakla&#351;&#305;ma katk&#305;<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Ortak
bilimsel �al&#305;&#351;malar i�in gereklilik<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Prognoz
ve tedavi hakk&#305;nda yol g�sterme<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l69 level1 lfo2;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Epilepsi
n�betlerinin sebebini anlamada ilerleme sa&#287;lama a�&#305;lar&#305;ndan
�nemlidir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>1960'l&#305;
y&#305;llardan ba&#351;layarak uluslararas&#305; epilepsi
uzmanlar&#305;n&#305;n bir araya gelmeleriyle epileptik n�betlerin ve
epilepsilerin s&#305;n&#305;fland&#305;r&#305;lmas&#305;n&#305;n ilk temelleri
at&#305;lm&#305;&#351;t&#305;r. �International League Against Epilepsy� (ILAE)
ilk olarak 1970'te epileptik n�betler ve epilepsi
s&#305;n&#305;flamalar&#305;n&#305; olu&#351;turmu&#351;tur; uzun y&#305;llar
s�ren �al&#305;&#351;malar&#305; sonucunda 1981 y&#305;l&#305;nda epileptik
n�betlerin klinik ve elektroensefalografik s&#305;n&#305;flamas&#305; bug�n
i�in ge�erli olan son &#351;eklini alm&#305;&#351;t&#305;r <b style='mso-bidi-font-weight:
normal'>(Tablo 1)</b>. Burada ana b�l�nme n�betin <i style='mso-bidi-font-style:
normal'>parsiyel</i> olarak ya da <i style='mso-bidi-font-style:normal'>jeneralize</i>
ba&#351;lamas&#305;na g�redir. Jeneralize n�betlerin �ok say&#305;da tipi
vard&#305;r. Parsiyel n�betler ise bilincin korunmas&#305;na g�re <i
style='mso-bidi-font-style:normal'>basit parsiyel</i> (BP) veya bilin�
kayb&#305; olmas&#305; halinde <i style='mso-bidi-font-style:normal'>kompleks
parsiyel</i> (KP) olarak adland&#305;r&#305;l&#305;r. Parsiyel ba&#351;layan
n�betler jeneralize olabilir. Bug�n kullan&#305;lan bu
s&#305;n&#305;flaman&#305;n semiyoloji bak&#305;m&#305;ndan yararl&#305;
oldu&#287;u ku&#351;kusuzdur. Ancak zaman i�inde artan &#351;ekilde
ele&#351;tirildi&#287;i baz&#305; y�nler vard&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ba&#351;l&#305;ca
ele&#351;tiriler</span></b><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'> bu s&#305;n&#305;flama ile lokalizasyon konusunda hi�bir ipucu
olmamas&#305; ve kimi zaman bilin� kayb&#305; veya
de&#287;i&#351;ikli&#287;inin net saptanamamas&#305;, ayr&#305;ca bunun klinik
a�&#305;dan �ok b�y�k �nem ta&#351;&#305;mamas&#305; gibi noktalar �zerinde
yo&#287;unla&#351;m&#305;&#351;t&#305;r. �rnek vermek gerekirse bilin�
kayb&#305; ile giden ancak ba&#351;lang&#305;�ta �Jacksonien� fokal motor
semptomlar veren frontal lob k�kenli olan bir n�bet ile tipik olarak temporal
lob lokalizasyonu d�&#351;�nd�ren �rne&#287;in �deja vu� ile ba&#351;layan ve bilin�
kayb&#305; eklenen �ok farkl&#305; 2 n�bet bu s&#305;n&#305;flamaya g�re sadece
kompleks parsiyel n�bet olarak s&#305;n&#305;flanabilir ve bu a�&#305;dan
baz&#305; de&#287;erli bilgiler kaybedilmi&#351; olur. &#304;kinci
ele&#351;tiri a�&#305;s&#305;ndan bak&#305;l&#305;rsa afazik n�bet ge�iren
hastan&#305;n bilin� durumu hakk&#305;nda sa&#287;l&#305;kl&#305; bir yorum
yapman&#305;n g�� oldu&#287;u a�&#305;kt&#305;r. �zellikle �ocuk veya mental
retarde hastalarda &#351;uur durumunu de&#287;erlendirmek her zaman kolay
olmamaktad&#305;r. Bazen de hasta belli bir d�nemde bilin� kayb&#305; oldu&#287;u
halde her &#351;eyi an&#305;msad&#305;&#287;&#305;n&#305; sanabilmektedir.</span><span
lang=TR style='font-family:Tahoma'> </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Di&#287;er �nemli bir yan&#305;lg&#305; KP n�betlerle
jeneralize n�betlerin kar&#305;&#351;t&#305;r&#305;lmas&#305;d&#305;r.
Hastan&#305;n ifadesiyle n�bet jeneralize olarak alg&#305;lanabilmekte, hatta
deneyimli merkezlerdeki hekimler taraf&#305;ndan dahi yanl&#305;&#351;
tan&#305;mlanabilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Bu nedenlerle en ba&#351;ta n�betin �ok iyi tan&#305;mlanmas&#305;
gerekir. Genellikle hasta ve yak&#305;nlar&#305;n&#305;n ifadeleriyle
s&#305;n&#305;rl&#305; olan bilgiler ev kameralar&#305; gibi teknolojik
imkanlar&#305;n kullan&#305;lmas&#305;, video EEG tekni&#287;inin yayg&#305;nla&#351;mas&#305;
ile daha objektif ve katk&#305; sa&#287;lay&#305;c&#305; hale gelmi&#351;tir.
Dalma n�betlerinin KP n�bet mi yoksa absans n�beti mi oldu&#287;u EEG�nin
yard&#305;m&#305; olmadan kolay anla&#351;&#305;lamamaktad&#305;r. Ayr&#305;ca
hastada birden fazla n�bet tipinin bir arada bulunabilece&#287;i de
unutulmamal&#305;d&#305;r. �zellikle idyopatik jeneralize epilepsilerde
(&#304;JE) absans, miyokloni ve jeneralize tonik klonik n�betler (JTKN) bir
arada olabilir.</span><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semiyolojik N�bet
S&#305;n&#305;flamas&#305; (H. L�ders ve ark; 1998): </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>ILAE s&#305;n&#305;flamalar&#305;na
en ciddi ele&#351;tiriyi getiren Dr. L�ders ve arkada&#351;lar&#305;, sadece
g�r�len n�bete ya da tarifine bakarak n�beti s&#305;n&#305;flamay&#305; �nermektedir.
Bu s&#305;n&#305;flama ��yatak ba&#351;&#305; rehberi�� olarak
de&#287;erlendirilebilir. N�betin detayl&#305; tan&#305;mlanmas&#305; n�beti
olu&#351;turan b�lgeyi, yay&#305;l&#305;m&#305; g�sterebilir. Burada EEG ve
di&#287;er ara&#351;t&#305;rma y�ntemleri kat&#305;lmadan g�zleme dayanan bir
tan&#305;mlama s�z konusudur. �� n�bet �zelli&#287;i, n�bet evol�syonuna
i&#351;aret edecek &#351;ekilde, en fazla 2 ok kullan&#305;larak belirtilir.
Ayr&#305;ca sa&#287; ve solun ve bilin� kayb&#305;n&#305;n belirtilmesi ek
bilgiler sa&#287;lamaktad&#305;r. Dialeptik n�bet kavram&#305; da bu grup�a
kullan&#305;ma sunulmu&#351; ve izole &#351;uur kayb&#305; ataklar&#305;n&#305;
tan&#305;mlad&#305;&#287;&#305; belirtilmi&#351;tir. Bu s&#305;n&#305;flamaya
y�ntemi ile g�r�ld�&#287;� gibi semiyolojik olarak bir�ok bilgi elde
edilebilmektedir. �rnek olarak: <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>G�rsel aura</span><span lang=TR style='font-size:10.0pt;font-family:
Wingdings;mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:
Tahoma;mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span
style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>�</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>tonik sol<span
style='mso-spacerun:yes'>� </span>(Bilin� Kayb&#305;: BK)<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Psi&#351;ik aura</span><span lang=TR style='font-size:10.0pt;
font-family:Wingdings;mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;
mso-bidi-font-family:Tahoma;mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span
style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>�</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>otomotor (BK) (sa&#287;
hemisfer)<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Klonik sa&#287; kol</span><span lang=TR style='font-size:10.0pt;
font-family:Wingdings;mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;
mso-bidi-font-family:Tahoma;mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span
style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>�</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>sa&#287; bacak (BK yok)<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Di&#287;er
taraftan epilepsilerde klinik seyir, prognoz, etyoloji ve dolay&#305;s&#305;yla
tedavi yakla&#351;&#305;m&#305;n&#305;n �ok farkl&#305; �zellikler
g�sterebilece&#287;i dikkate al&#305;nd&#305;&#287;&#305;nda yaln&#305;zca
n�betlerin s&#305;n&#305;fland&#305;r&#305;lmas&#305; yetersiz
kalmaktad&#305;r. Ayn&#305; zamanda yeni belirlenen ve iyi
tan&#305;mlanm&#305;&#351; epilepsi sendromlar&#305;n&#305;n say&#305;lar&#305;
da giderek artmaktad&#305;r. Bu nedenle y&#305;llar i�inde �abalar epilepsileri
ve epileptik sendromlar&#305; s&#305;n&#305;flama y�n�nde
yo&#287;unla&#351;m&#305;&#351;t&#305;r. 1985'deki ilk
s&#305;n&#305;flamay&#305; 1989'da yap&#305;lan yeni s&#305;n&#305;flama
izlemi&#351;tir (<b>Tablo 2</b>).<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>ILAE
1989 epilepsi sendrom s&#305;n&#305;flamas&#305;nda 2 ana ay&#305;r&#305;m
vurgulanmaktad&#305;r: <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>1-Fokal
kortikal bir lokalizasyondan kaynaklanan parsiyel epilepsiler ile jeneralize
olanlar&#305;n ay&#305;r&#305;m&#305; <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>2-&#304;dyopatik
ya da primer olanlarla semptomatik ya da sekonder olan epilepsilerin
ay&#305;r&#305;m&#305; <o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>&#304;dyopatik</span></i><span lang=TR
style='font-family:Tahoma'> (nedeni kendinden olan veya genetik olarak
belirlendi&#287;i varsay&#305;lan) sendromlara genelde ba&#351;ka bir n�rolojik
disfonksiyon e&#351;lik etmez, geli&#351;me basamaklar&#305; normal ilerler,
altta g�sterilebilen herhangi bir patolojik s�re� yoktur; n�rolojik muayene ve
g�r�nt�leme normaldir. Ailesel �zellik genellikle dikkat �eker, n�betler g�rece
daha seyrek ve tedaviye yan&#305;t daha iyidir. EEG interiktal d�nemde normal
temel aktivite g�sterir. &#304;dyopatik form daha genelde iyi bir prognoz g�sterir
ve remisyon olas&#305;l&#305;&#287;&#305; vard&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Buna
kar&#351;&#305;n <i style='mso-bidi-font-style:normal'>semptomatik </i>epilepside
altta yatan bir beyin hastal&#305;&#287;&#305; ve buna ba&#287;l&#305;
n�rolojik bozukluklar, EEG'de temel aktivitede yava&#351;lama saptan&#305;r.
�yk�de n�bete neden olabilecek bir merkezi sinir sistemi (MSS)
hastal&#305;&#287;&#305;, ge�irilmi&#351; kafa travmas&#305; (KT), infeksiyon,
geli&#351;mekte olan t�m�r, dejeneratif hastal&#305;klar bulunur. Tedaviye
cevap �ok de&#287;i&#351;kendir ve spontan sonlanma (remisyon)
olas&#305;l&#305;&#287;&#305; d�&#351;�kt�r. <o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Kriptojenik</span></i><span lang=TR
style='font-family:Tahoma'> (nedeni belirlenemeyen) epilepsi kognitif etkilenme
veya n�rolojik defisitin oldu&#287;u, edinsel bir nedeni olmas&#305;
gerekti&#287;i d�&#351;�n�len ancak saptanamayan epilepsiler i�in
kullan&#305;lan bir terimdir (Lennox Gastaut Sendromu, Doose Sendromu vb). <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Hastay&#305;
doktora getiren n�bet ge�irmesidir ve n�bet tipi tutulan sinir sistemi b�lgesinin
�r�n�d�r. Benzer epileptik n�bet tipleri hem idyopatik hem de semptomatik
epilepsilerde g�r�lebilmektedir. Ana soru prognoz (tek bir n�betin tekrarlama
olas&#305;l&#305;&#287;&#305;, tedavinin gereklili&#287;i, tedavinin
sonland&#305;r&#305;lmas&#305; veya hastal&#305;&#287;&#305;n gelecek
ku&#351;aklara kal&#305;t&#305;mla ta&#351;&#305;nmas&#305;
olas&#305;l&#305;&#287;&#305; gibi akla gelebilecek t�m sorular) ve ortada
g�r�len epileptik n�betin alt&#305;nda yatan nedensel fakt�rle
ili&#351;kilidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>Di&#287;er bir deyi&#351;le epilepsileri
yaln&#305;zca n�bet tipi ve s&#305;kl&#305;&#287;&#305;na g�re
s&#305;n&#305;flamak �nemli bilgileri g�z ard&#305; eder. Ba&#351;lang&#305;�
lokalizasyonla ilgili (parsiyel, fokal) veya jeneralize olabilir. Ancak
n�betlerin ba&#351;lang&#305;� ya&#351;&#305;, aile �yk�s�, EEG ve beyin
g�r�nt�leme (tercihen MRG) ile temporal, frontal, oksipital gibi loblara
anatomik olarak lokalize edilmesi de gereklidir. N�rolojik muayene, tetikleyen
fakt�rler, etyoloji (idyopatik-kriptojenik-semptomatik) de �nem
ta&#351;&#305;r. S&#305;k g�r�len ve iyi bilinen �� ayr&#305; epileptik sendrom
(�rnek olarak iyi huylu �ocukluk �a&#287;&#305; parsiyel epilepsileri; j�venil
miyoklonik epilepsi ve mezyal temporal lob epilepsisi)
kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda, ���n�n ortak bir
�zelli&#287;i olmad&#305;&#287;&#305;, tedavilerinin farkl&#305; oldu&#287;u
a�&#305;k�a anla&#351;&#305;lmaktad&#305;r. &#304;yi huylu �ocukluk �a&#287;&#305;
parsiyel epilepsilerinde n�betler �ok seyrek, genelde uykuda oldu&#287;u i�in
ve spontan remisyon beklendi&#287;i i�in tedavi k&#305;sa s�relidir veya gerek
yoktur. Buna kar&#351;&#305;n j�venil miyoklonik epilepside (JME) uygun
se�ilmi&#351; d�&#351;�k doz tek bir antiepileptik ila� (AE&#304;)�la n�betler
tamamen �nlenebilir. Karbamazepin (KBZ) parsiyel epilepside birinci se�enek
oldu&#287;u halde JME�de n�betleri k�t�le&#351;tirebilir. Ayr&#305;ca JME de
tedavi �ok daha uzun s�reli gereklidir, ��nk� ila� kesilince n�ks
s&#305;kt&#305;r. Mezyal temporal lob epilepsisi (MTLE) ele
al&#305;nd&#305;&#287;&#305;nda ba&#351;l&#305;ca nedeni hipokampal skleroz
olan bu sendromda n�betler ba&#351;lang&#305;�tan bir s�re sonra ila�
tedavisine diren�li duruma gelir ve cerrahi tedavi gerektirebilir. &#304;yi
huylu parsiyel epilepsili normal zekas&#305; olan bir �ocukla, Rasmussen,
Lennox-Gastaut, veya Sturge-Weber gibi sendromlar&#305; olan �ocuklar&#305;
n�bet benzer bile olsa ay&#305;rt etmek kolayd&#305;r. <i style='mso-bidi-font-style:
normal'>Epilepside yap&#305;lmamas&#305; gereken &#351;ey terminoloji,
tan&#305; ve tedaviyi genellemektir.<o:p></o:p></i></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi
sendrom s&#305;n&#305;flamas&#305;nda temel al&#305;nan �zellikler
&#351;unlard&#305;r: <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l56 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>N�bet tipleri <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l56 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>Ba&#351;lang&#305;� ya&#351;&#305; <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l56 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>EEG bozuklu&#287;unun tipi <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l56 level1 lfo5;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>E&#351;lik eden n�rolojik bulgular <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma;mso-bidi-font-weight:
bold'>Spesifik n�bet tipi-tipleri</span><span lang=TR style='font-family:Tahoma'>nin
lokalizasyonu, s&#305;kl&#305;&#287;&#305;, olaylar&#305;n basamaklar&#305;,
sirkadyen da&#287;&#305;l&#305;m, tetikleyen fakt�rler, ba&#351;lang&#305;�
ya&#351;&#305;, kal&#305;t&#305;m &#351;ekli, e<span style='mso-bidi-font-weight:
bold'>&#351;lik eden f</span>iziksel <span style='mso-bidi-font-weight:bold'>�zellikler,
p</span>rognoz, tedaviye yan&#305;t, d<span style='mso-bidi-font-weight:bold'>o&#287;al
seyir di&#287;er tan&#305;mlanan �zelliklerdir. <o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>Bu sendromlar&#305;n belirlenmesinin getirdi&#287;i yararlar
ba&#351;l&#305;ca &#351;unlard&#305;r: <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l6 level1 lfo8;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>Prognozun ba&#351;lang&#305;�tan
     �ng�r�lebilmesi <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l6 level1 lfo8;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>Etkin tedavi se�imi <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l6 level1 lfo8;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>Etyolojik k�kenin belirlenmesi <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>Epileptolojide epileptik sendromlar&#305;n tan&#305;nmas&#305;, uygun
tan&#305; ve do&#287;ru tedavi a�&#305;s&#305;ndan en �nemli geli&#351;medir.
Do&#287;ru tan&#305;n&#305;n alt&#305;n kural oldu&#287;u, �d�n
verilemeyece&#287;i unutulmamal&#305;d&#305;r. Klinik uygulamada epilepsi veya
n�bet tan&#305;m&#305; ile s&#305;n&#305;rl&#305; kal&#305;nmamal&#305;,
hastal&#305;&#287;&#305;n a&#287;&#305;rl&#305;&#287;&#305;, tedavi
kararlar&#305;, genetik tan&#305; ve dan&#305;&#351;ma a�&#305;s&#305;ndan,
�zellikle ki&#351;isel, sosyal hayat, e&#287;itim, mesle&#287;e olan etkiler
g�z �n�nde bulundurulmal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>Belirli sendromlar&#305;n �ok iyi tan&#305;nmas&#305; sayesinde
baz&#305;lar&#305;n&#305;n insan genomundaki yerleri bulunmu&#351;tur.
Bunlar&#305;n ilk �rnekleri 20. kromozoma lokalize edilen ailesel
yenido&#287;an konv�lz�yonlar&#305; ve 6. kromozomun k&#305;sa koluna lokalize
edilen JME�dir. Bu geli&#351;meler �zg�n tedaviye gidi&#351;in ilk
ad&#305;mlar&#305; olarak de&#287;erlendirilebilir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Yeni geli&#351;meler &#305;&#351;&#305;&#287;&#305;nda mevcut
s&#305;n&#305;flamalardaki yetersizlikleri ve �eli&#351;kileri gidermek
amac&#305;yla ILAE S&#305;n&#305;flama ve Terminoloji Komisyonu taraf&#305;ndan
5 eksenli yeni bir tan&#305; &#351;emas&#305; �nerilmi&#351;tir. Ancak bu
s&#305;n&#305;flama genel kabul g�rmemi&#351; ve prati&#287;e
ge�irilememi&#351;tir. <b>ILAE 2001 �nerisi:</b> I. Semiyoloji, II. N�bet tipi,
III. Sendrom, IV. Etyoloji ve V. �z�rl�l�&#287;� i�erir. Getirdi&#287;i kabul
g�ren ba&#351;l&#305;ca yeniliklerden biri eski s&#305;n&#305;flamadaki KP
n�bet kavram&#305;na ili&#351;kindir. Bu terimin getirdi&#287;i
belirsizliklerin en �nemli k&#305;sm&#305; lokalizasyonla ili&#351;kilidir;
frontal ve temporal k�kenli n�betleri ay&#305;rt edememektedir. Bu yeni �neride
otomatizmal&#305; parsiyel-fokal n�betler L�ders s&#305;n&#305;flamas&#305;na
benzer &#351;ekilde ayr&#305;nt&#305;land&#305;r&#305;lm&#305;&#351;t&#305;r.
Hipermotor-hiperkinetik otomatizmal&#305; n�bet: frontal k�kenli n�beti
d�&#351;�nd�r�r. Otomotor- tipik temporal lob otomatizmal&#305; n�betler,
temporal lob k�keni d�&#351;�nd�r�r. Bir di&#287;er �nemli nokta parsiyel
yerine �fokal� teriminin tekrar kullan&#305;lmas&#305; ve febril konv�lz�yon
yerine febril n�bet denmesidir. 2001 �nerisindeki bir ba&#351;ka �nemli
de&#287;i&#351;iklik de kriptojenik s�zc�&#287;�n�n kald&#305;r&#305;lmas&#305;
ve yerine olas&#305; semptomatik epilepsi tan&#305;mlamas&#305;n&#305;n
getirilmesidir. �te yandan genetik bilgilerin &#305;&#351;&#305;&#287;&#305;nda
d<span style='mso-bidi-font-weight:bold'>aha �nce olmayan ve eklenen
sendromlar&#305;n yer ald&#305;&#287;&#305; dikkati �ekmektedir. Febril n�bet
art&#305; jeneralize epilepsi (</span>GEFS+; Generalised epilepsy with febrile
seizure plus) ba&#351;l&#305;ca �rne&#287;i te&#351;kil etmektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'><o:p>&nbsp;</o:p></span></b></p>

<b><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";color:black;mso-ansi-language:TR;mso-fareast-language:TR;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always'>
</span></b>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>Tablo 1. Epileptik n�betlerin klinik ve elektroensefalografik
s&#305;n&#305;flamas&#305;, (ILAE 1981)</span></b><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-fareast-language:EN-US'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:#CC0000'>I-Parsiyel (fokal, lokal) n�betler</span></b><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>A. Basit parsiyel n�betler (bilin� durumu
bozulmaks&#305;z&#305;n)</span></b><span lang=TR style='font-family:Tahoma'> <b><span
style='color:#CC0000'><o:p></o:p></span></b></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:white;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>1-Motor
  semptomlu</span></b><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>a)Fokal
  motor</span><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>b)Yay&#305;lan
  fokal motor (Jacksonyen)</span><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>c)Versif</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>d)Postural</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>e)Fonatuvar
  (vokalizasyon veya konu&#351;man&#305;n durmas&#305;)</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>2-Somatosensoryel
  veya �zel duysal semptomlu</span></b><span lang=TR style='font-family:Tahoma'>
  <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>a)Somatosensoryel</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>b)G�rsel </span><span
  lang=TR style='font-family:Tahoma'><span style='mso-spacerun:yes'>�</span><br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>c)&#304;&#351;itsel</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>d)Olfaktor</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>e)Gustatuvar</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>f)Vertigo
  hissi</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>3-Otonomik
  semptomlu</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>4-Psi&#351;ik
  semptomlu</span></b><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>a)Disfazik</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>b)Dismnezik
  (�r:d�ja-vu )</span><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>c)Kognitif
  (hayal durumu, zaman hissinin bozulmas&#305;)</span><span lang=TR
  style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>d)Afektif
  (korku, �fke vb)</span><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>e)&#304;l�zyonlar
  (�r:makropsi)</span><span lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>f)
  Hal�sinasyonlar (�r:m�zik par�alar&#305;)</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>B. Kompleks parsiyel n�betler (bilin� bozuklu&#287;u ile
giden)</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:white;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>1-Basit parsiyel
  ba&#351;lang&#305;c&#305; izleyen bilin� bozuklu&#287;u</span></b><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>a)Basit
  parsiyel �zelliklerin ard&#305;ndan bilin� bozuklu&#287;u</span><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>b)Otomatizmlerle
  giden</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td valign=top style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>2-Bilin�
  durumunun ba&#351;lang&#305;�tan itibaren bozulmas&#305;</span></b><span
  lang=TR style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>a)Sadece
  bilin� bozuklu&#287;u ile giden</span><span lang=TR style='font-family:Tahoma'><br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>b)Otomatizmlerle
  giden</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>C. Sekonder jeneralize
n�bete d�n�&#351;en</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>1-Basit parsiyel n�betin (A)
jeneralize n�bete d�n�&#351;mesi</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>2-Kompleks parsiyel n�betin (B)
jeneralize n�bete d�n�&#351;mesi</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>3-Basit parsiyel n�betin kompleks
parsiyel n�bete d�n�&#351;mesi ve ard&#305;ndan jeneralize n�bete
d�n�&#351;mesi</span><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:#CC0000'>II-Jeneralize n�betler (konv�lzif veya non-konv�lzif)</span></b><span
lang=TR style='font-family:Tahoma'>&nbsp; <o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:white;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>A.1-Absans n�betleri</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>a)Sadece bilin� bozuklu&#287;u ile giden</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>b)Hafif klonik komponentli</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>c)Atonik komponentli</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>d)Tonik komponentli</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>e)Otomatizmli</span><span lang=TR
  style='font-family:Tahoma'> <br>
  </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>f)Otonomik
  komponentli</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td valign=top style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>2-Atipik absans</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>a)Tonus de&#287;i&#351;ikli&#287;i A.1 den daha belirgin
  olan</span><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>b)Ba&#351;lang&#305;� ve/veya sonlanman&#305;n ani
  olmamas&#305;</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>B.Miyoklonik n�betler (tek veya
  �ok)</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>C.Klonik n�betler</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>D.Tonik n�betler</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>E.Tonik-klonik n�betler</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>F.Atonik n�betler (astatik)</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
  Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:#CC0000'>III-S&#305;n&#305;fland&#305;r&#305;lamayan epileptik n�betler (yetersiz
bilgi)</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-fareast-language:EN-US'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><br>
<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]><o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:TR;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'>Tablo 2.</span></b><span lang=TR
style='font-family:Tahoma;color:black'> <b>Epilepsilerin ve epileptik
sendromlar&#305;n uluslararas&#305; s&#305;n&#305;flamas&#305; (ILAE, 1989)</b></span><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:0cm;mso-text-indent-alt:
0cm;mso-list:none;mso-list-ins:nerses 20091224T2242'><span lang=TR
style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:white;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0cm;margin-bottom:
  6.0pt;margin-left:0cm;text-align:justify'><b><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma;color:#CC0000'>I. Lokalizasyona ba&#287;l&#305; (
  fokal, lokal,parsiyel) epilepsiler ve sendromlar</span></b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'> <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>1.1.
  &#304;dyopatik (ya&#351;a ba&#287;l&#305; ba&#351;lang&#305;�)</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'> <br>
  *Santrotemporal dikenli selim �ocukluk �a&#287;&#305; epilepsisi <br>
  *Oksipital paroksizmli �ocukluk �a&#287;&#305; epilepsisi <br>
  *Primer okuma epilepsisi <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>1.2.
  Semptomatik</span></b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>
  <br>
  *Temporal lob epilepsisi <br>
  *Frontal lob epilepsisi <br>
  *Parietal lob epilepsisi <br>
  *Oksipital lob epilepsisi <br>
  *�ocukluk �a&#287;&#305;n&#305;n kronik progresif epilepsia parsiyalis
  kontinuas&#305; <br>
  *Spesifik fakt�rlerle uyar&#305;lan n�betlerle karakterize sendromlar <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>1.3.
  Kriptojenik</span></b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>
  <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;color:#CC0000'>II.
  Jeneralize epilepsiler ve sendromlar</span></b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'> <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>2.1.
  &#304;dyopatik (ya&#351;a ba&#287;l&#305; ba&#351;lang&#305;�-ya&#351;
  s&#305;ras&#305;na g�re s&#305;ralanm&#305;&#351;t&#305;r)</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'> <br>
  *Selim ailesel yenido&#287;an konv�lz�yonlar&#305; <br>
  *Selim yenido&#287;an konv�lz�yonlar&#305; <br>
  *S�t �ocuklu&#287;unun selim miyoklonik epilepsisi <br>
  *�ocukluk �a&#287;&#305; absans epilepsisi (piknolepsi) <br>
  *J�venil absans epilepsisi <br>
  *J�venil miyoklonik epilepsi (impulsif petit mal) <br>
  *Uyan&#305;rken gelen grand mal n�betli epilepsi <br>
  *Di&#287;er jeneralize idyopatik epilepsiler <br>
  *Belirli aktivasyon y�ntemleriyle uyar&#305;lan epilepsiler <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>2.2.
  Kriptojenik veya semptomatik (ya&#351; s&#305;ras&#305;na g�re)</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'> <br>
  *West sendromu (infantil spazmlar, Blitz-Nick-Salaam Kraempfe) <br>
  *Lennox-Gastaut sendromu <br>
  *Miyoklonik astatik n�betli epilepsi <br>
  *Miyoklonik absansl&#305; epilepsi <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>2.3.
  Semptomatik</span></b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>
  <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>2.3.1.
  Spesifik olmayan etyolojili</span></b><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'> <br>
  *Erken miyoklonik ensefalopati <br>
  *(Supression-burst)' lu erken infantil epileptik ensefalopati <br>
  *Di&#287;er semptomatik jeneralize epilepsiler <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>2.3.2.
  Spesifik sendromlar</span></b><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'> <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;color:#CC0000'>III.
  Fokal veya jeneralize oldu&#287;u belirlenemeyen epilepsiler</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'> <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>3.1.
  Jeneralize ve fokal<span style='mso-spacerun:yes'>� </span>n�betli
  epilepsiler</span></b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>
  <br>
  *Yenido&#287;an konv�lz�yonlar&#305; <br>
  *S�t �ocu&#287;unun a&#287;&#305;r miyoklonik epilepsisi <br>
  *Yava&#351; dalga uykusu s&#305;ras&#305;nda devaml&#305; diken-dalgal&#305;
  epilepsi <br>
  *Edinsel epileptik afazi (Landau-Kleffner sendromu) <br>
  *Di&#287;er belirlenemeyen epilepsiler <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>3.2.
  Jeneralize veya fokal �zelli&#287;i ay&#305;rdedilemeyenler</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'> (uykuda gelen grand mal
  n�bet olgular&#305; gibi)<o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma;color:#CC0000'>IV.
  �zel (�zg�n) sendromlar</span></b><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'> <o:p></o:p></span></p>
  <p style='margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:
  0cm'><b><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>4.1. Duruma
  ba&#287;l&#305; n�betler (Gelegenheitsanfaelle)</span></b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'> <br>
  *Febril konv�lz�yonlar *&#304;zole n�bet veya izole status epileptikus *Akut
  metabolik veya toksik nedenlere ba&#287;l&#305; n�betler</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>PARS&#304;YEL
T&#304;PTE EP&#304;LEPS&#304; N�BETLER&#304;N&#304;N LOKAL&#304;ZASYON
DE&#286;ER&#304;</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Beyin
fonksiyonlar&#305;n&#305;n dinamik yap&#305;s&#305; g�z �n�ne
al&#305;nd&#305;&#287;&#305;nda beynin anatomik olarak loblara b�l�nmesi
yetersiz kalmaktad&#305;r. Karma&#351;&#305;k entegrasyonlar&#305; olan n�ral
yollar yapay anatomik s&#305;n&#305;rlarla �rt�&#351;medi&#287;inden epileptik
n�betlerin klinik profillerinin belirlenmesinde anatomik b�l�mlemenin yeterli
bir �l��t olamayaca&#287;&#305; ve klinik belirtilerin �ok de&#287;i&#351;ken
olabilen yay&#305;l&#305;m &#351;ekilleri sonucunda ortaya
�&#305;kt&#305;&#287;&#305; unutulmamal&#305;d&#305;r. Bu nedenlerle korteksin
�e&#351;itli b�lgelerinden benzer �zellik g�steren n�betler ortaya
�&#305;kabilmekte ya da birbirinden farkl&#305; n�betler ayn&#305; kortikal
odaktan kaynaklanabilmektedir. Bu karma&#351;&#305;k n�ronal entegrasyon ve
yay&#305;lma paternleri konusunda bug�nk� bilgilerimiz yetersiz kalmakta ve
derin elektrot �al&#305;&#351;malar&#305; ve ayr&#305;nt&#305;l&#305; klinik
veriler &#305;&#351;&#305;k tutmaktad&#305;r. A&#351;a&#287;&#305;da anatomik
lokalizasyonlara g�re epileptik odaklar&#305;n lokalizasyonuna k&#305;saca
de&#287;inilecektir. <o:p></o:p></span></p>

<p style='margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l21 level1 lfo10'><a name="1-Frontal_lob_k�kenli_parsiyel_epilepsi"></a><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-fareast-font-family:Tahoma'><span
style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><![endif]><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Frontal lob k�kenli parsiyel epilepsi
n�betleri</span></i></b><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'>
(Tablo 3)<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bug�nk�
bilgilerimize g�re beynin en gizemli ve b�y�k b�l�m� olan frontal loblardan kaynaklanan
bir n�beti akla getiren ba&#351;l&#305;ca semptomlar &#351;unlard&#305;r: <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Tonik
ve post�ral olabilen motor belirtiler s&#305;kt&#305;r (%50-60). �zellikle
bilin� korunmu&#351;ken tonik ba&#351; d�nmesi frontal lob n�beti i�in tipik
kabul edilir. Ancak ba&#351; d�nmesinin lateralize edici de&#287;eri di&#287;er
parsiyel motor tonik veya klonik n�betlere g�re belirgin &#351;ekilde
d�&#351;�kt�r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Ba&#351;lang&#305;�ta
kompleks hareketler (�rne&#287;in: pedal �evirme, ko&#351;ma, tekme atma v.b.)
&#351;eklinde otomatizmalar s&#305;k g�r�l�r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Epileptik
bo&#351;al&#305;m bilateral oldu&#287;unda s&#305;kl&#305;kla d�&#351;me
e&#351;lik eder. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Post-iktal
Todd paralizisi s&#305;k g�r�l�r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Konu&#351;man&#305;n
durmas&#305; ve vokalizasyonlar g�r�lebilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-S&#305;kl&#305;kla
uyku s&#305;ras&#305;nda ve bazen k�me halinde g�r�l�rler. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Kimi
zaman n�bet tablosu histeri ile kar&#305;&#351;t&#305;r&#305;lacak kadar atipik
olabilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-family:Tahoma'>Sa�l&#305;
deriden kaydedilen y�zey EEG'sinin kimi olgularda iktal d�nemde bile negatif
kalabildi&#287;i unutulmamal&#305;d&#305;r.</span></i><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Orbitofrontal
b�lgeden kaynaklanan n�betlerin fasciculus uncinatus veya gyrus cinguli yoluyla
temporal loba yay&#305;lma g�stermesi frontal n�betlerin temporal n�betlerle
kar&#305;&#351;t&#305;r&#305;lmas&#305;na yol a�maktad&#305;r, y�zey EEG'si de
�o&#287;u zaman bu ay&#305;r&#305;m&#305; sa&#287;lamada yetersiz
kalmaktad&#305;r <b style='mso-bidi-font-weight:normal'>(Tablo 4)</b>. Kallozal
veya subkortikal yollarla kar&#351;&#305; hemisfere h&#305;zl&#305;
yay&#305;l&#305;m sonucu g�r�len sekonder bilateral senkroni nedeniyle bazen
idyopatik jeneralize epilepsilerle de
kar&#305;&#351;t&#305;r&#305;labilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Frontal
lobun &quot;sessiz&quot; b�lgelerinden kaynaklanan n�betler ancak kom&#351;u
yap&#305;lara veya di&#287;er loblara yay&#305;lma g�sterdikten sonra klinik
belirti vermektedirler. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>Tablo 3.</span></b><span lang=TR style='font-family:Tahoma;
color:black'> <b>Frontal lobdan kaynaklanan n�betlerin klinik �zellikleri </b></span><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;background:white;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;height:40.65pt'>
  <td style='padding:.75pt .75pt .75pt .75pt;height:40.65pt'>
  <p class=MsoNormal style='mso-outline-level:1'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
  italic'>Rolandik b�lge&nbsp;(primer motor alan)<o:p></o:p></span></b></p>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt;height:40.65pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-bidi-font-style:italic'>Kontralateral fokal klonik aktivite, somatotopik;
  Jacksonien<span style='mso-spacerun:yes'>� </span>yay&#305;l&#305;m
  g�sterebilir.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:italic'>Dorsolateral&nbsp;</span></b><b
  style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-bidi-font-style:italic'>Zorlu d�&#351;�nce, bilin�li adversiyon,
  &quot;ps�doabsans&quot; veya kompleks parsiyel n�bet, h&#305;zl&#305;
  jeneralizasyon</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:italic'>SMA
  (ek motor alan) (&quot;supplementary &quot;)<o:p></o:p></span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-bidi-font-style:italic'>Spesifik olmayan duysal aura, bilin�li adversiyon
  ve tonik/distonik post�r, eskrimci post�r�, konu&#351;ma durmas&#305;,
  vokalizasyonlar</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:italic'>Frontopolar</span></b><b
  style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-bidi-font-style:italic'>Erken bilin� kayb&#305;, &quot;ps�doabsans&quot;,
  h&#305;zl&#305; jeneralizasyon</span><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:italic'>Singulat</span></b><b
  style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-bidi-font-style:italic'>Korku, ps�doabsans, erken el hareketlerine
  ili&#351;kin otomatizmlerle giden kompleks parsiyel n�betler, jeneralize
  tonik klonik n�bet</span><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:italic'>Orbitofrontal</span></b><b
  style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></b></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-bidi-font-style:italic'>Nokt�rnal k�meler halinde, ani ba&#351;lang&#305;�,
  g��l� afekt (korku), tuhaf motor otomatizmler (bimanuel, bipedal),
  vokalizasyonlar (k�f�r, �&#305;&#287;l&#305;k)</span><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l21 level1 lfo10'><a name="2-Temporal_lob_k�kenli_parsiyel_epilepsi"></a><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-fareast-font-family:Tahoma'><span
style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><![endif]><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Temporal lob k�kenli parsiyel epilepsi
n�betleri</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Parsiyel
n�betlerin %50'den fazlas&#305;n&#305; olu&#351;turan temporal lob n�betleri zengin
ve ilgin� semptomatolojisi nedeniyle �zerinde en �ok ara&#351;t&#305;rma
yap&#305;lan parsiyel epilepsi t�r�n� olu&#351;turur. �zge�mi&#351;te febril
n�bet �yk�s� ve pozitif aile �yk�s�ne s&#305;k rastlan&#305;r. N�betler
genellikle y&#305;&#287;&#305;nlar halinde belli aral&#305;klarla gelmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'>Tablo 4. Frontal ve temporal lob k�kenli
kompleks parsiyel n�betlerin ayr&#305;m&#305;</span></b><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>&nbsp; <o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0 width=603
 style='width:452.25pt;mso-cellspacing:2.2pt;background:white;mso-padding-alt:
 5.25pt 5.25pt 5.25pt 5.25pt'>
 <tr style='mso-yfti-irow:0'>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-right:none;mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:
  solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt;background:
  #DAEEF3;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
  Tahoma'>&nbsp;<o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  mso-border-top-alt:solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt;
  background:#DAEEF3;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>TEMPORAL</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-left:none;mso-border-top-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;background:
  #DAEEF3;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>FRONTAL</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Aura</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>s&#305;k,
  de&#287;i&#351;ken, ama tipiktir, ba&#351;lang&#305;� b�lgesi hakk&#305;nda
  ipucu verebilir</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>spesifik
  olmayan, m�phem sefalik duyumsamalar, zorlu d�&#351;�nce</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>S�re</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>1-2
  dakika</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>10-60
  saniye</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>S&#305;kl&#305;k</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>haftada/ayda
  bir �ok kez</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>g�nde
  bir �ok kez, �o&#287;unlukla k�meler halinde</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ba&#351;lang&#305;�</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>donarak
  durma, veya erken oroalimentar otomatizmler</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>vokalizasyon,
  korkulu y�z g�r�n�m�</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Otomatizma</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>basit,
  oroalimentar, giysilerini �eki&#351;tirme</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>tuhaf,
  yar&#305;-ama�l&#305;, kompleks, bimanuel, bipedal, seks�el</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Vokalizasyon</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>basit,
  konu&#351;ma olabilir</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>tuhaf
  (�&#305;&#287;l&#305;k, k�f�r)</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width="21%" valign=top style='width:21.0%;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Jeneralizasyon</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>nadir</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>s&#305;k</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-yfti-lastrow:yes'>
  <td width="21%" valign=top style='width:21.0%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt;
  padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Postiktal</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="39%" valign=top style='width:39.0%;border:none;border-bottom:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>konf�zyon,
  letarji, afazi, 30 dakika kadar s�rebilir</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:5.25pt 5.25pt 5.25pt 5.25pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>minimal
  veya yok </span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Temporal
lob epilepsisini akla getiren ba&#351;l&#305;ca n�bet semptomlar&#305;
&#351;unlard&#305;r: (<b style='mso-bidi-font-weight:normal'>Tablo 5</b>)<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Otonom
ve/veya psi&#351;ik semptomlar ve baz&#305; �zel duysal fenomenler,
�rne&#287;in koku ve i&#351;itsel ill�zyonlarla giden basit parsiyel n�betler
s&#305;k g�r�l�r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Hemen
her duysal modalitede basit veya kompleks ill�zyon ve hal�sinasyon g�r�lebilir.
En s&#305;k olarak (%20) g�rsel ill�zyon ve hal�sinasyonlara rastlan&#305;r.
Oksipital b�lgeden kaynaklananlarla k&#305;yaslan&#305;nca daha
karma&#351;&#305;k yap&#305;da olduklar&#305; saptanm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-S&#305;kl&#305;kla
motor durma ile ba&#351;lay&#305;p tipik oroalimanter otomatizmalarla devam
eden ve s&#305;kl&#305;kla di&#287;er otomatizmalar&#305;n eklendi&#287;i
kompleks parsiyel n�betler g�r�l�r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Kompleks
auralar ve viseral duyumsama &#351;eklinde uyar&#305;c&#305; semptomlar
g�r�lmesi �nemlidir. En s&#305;k olan y�kselen epigastrik duyumsamad&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Dismneziler
(&quot;d�ja vu&quot;, &quot;jamais vu&quot; vb.), �e&#351;itli kognitif ve
afektif semptomlar gibi �ok de&#287;i&#351;ken formlar g�r�lebilmekle birlikte
her hasta i�in stabil olan bir n�bet paterni genellikle vard&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Konu&#351;man&#305;n
durmas&#305;, dizartri ve afazi gibi konu&#351;ma bozukluklar&#305;
g�r�lebilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Temporal
lob epilepsisinin di&#287;er bir �nemli boyutu da bildirilmi&#351; olan
interiktal ki&#351;ilik de&#287;i&#351;iklikleridir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>Tablo 5.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:black'> </span><b><span lang=TR style='font-family:
Tahoma;color:black'>Lateral ve mezyal temporal n�bet ba&#351;lang&#305;�
ayr&#305;m&#305; i�in kullan&#305;lan klinik �zellikler </span></b><span
lang=TR style='font-family:Tahoma'><span style='mso-spacerun:yes'>�</span><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width="100%"
 style='width:100.0%;mso-cellspacing:1.5pt;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Mezyal temporal</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Korku, &quot;d�ja/jamais vu&quot;,
  duygulan&#305;mlar, olfaktor hal�sinasyonlar, epigastrik duyumsama, otonom
  de&#287;i&#351;iklikler (operk�ler/ins�ler ba&#351;lang&#305;�la da g�r�lebilir.)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes;height:43.3pt'>
  <td style='padding:.75pt .75pt .75pt .75pt;height:43.3pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Lateral temporal</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt;height:43.3pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Basit duysal, i&#351;itsel, vestib�ler veya
  gustatuvar hal�sinasyonlar, reseptif afazi, fokal sensorimotor fenomenler<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l21 level1 lfo10'><a name="3-Pariyetal_lob_k�kenli_parsiyel_epileps"></a><![if !supportLists]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-fareast-font-family:Tahoma'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></i></b><![endif]><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Pariyetal lob k�kenli parsiyel epilepsi
n�betleri</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Pariyetal
lob orijinli n�betler esas olarak kontralateral hemiferdeki odaktan kaynaklanan
somatosensoryel n�betlerden olu&#351;ur. Ancak nadir de olsa bilateral ve
ipsilateral n�betler g�r�lebilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Elementer
paresteziler en s&#305;k g�r�len somatosensoryel n�bet
semptomlar&#305;d&#305;r. Pozitif fenomenler olarak kar&#305;ncalanma,
elektriklenme ke�ele&#351;me ve i&#287;nelenme gibi duyumsamalar
s&#305;n&#305;rl&#305; veya Jacksonien tarzda olabilir. Negatif fenomenler
�rne&#287;in hissizlik g�r�lebilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-A&#287;r&#305;
iktal bir semptom olarak g�r�lebilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Nadiren
termal alg&#305; &#351;eklinde n�betler olabilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Parasantral
tutulumda baz&#305; seks�el n�betler g�r�lebilir. Bunlar temporal k�kenli
n�betlerin tersine genellikle ho&#351; olmayan, korkutucu veya
a&#287;r&#305;l&#305; &#351;ekildedir ve genellikle kad&#305;nlarda g�r�l�rler.
<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Yine
tat duyumsamas&#305; da temporal lob k�kenli n�betlerin yan&#305; s&#305;ra
parietal operk�ler b�lgeden kaynaklanabilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-V�cudun
belli bir b�l�m�n� hareket ettirememe hissi &#351;eklindeki n�betlerin
suprasilviyen b�lgedeki ikinci duysal alan k�kenli olduklar&#305;
d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Beden
imaj&#305; bozuklu&#287;u veya asomatognozi &#351;eklindeki fenomenlerin
genelde nondominan hemisferden kaynakland&#305;&#287;&#305;
d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Vertigo
hissi de genelde inferior parietal lobdan kaynaklan&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>4. Oksipital lob k�kenli parsiyel epilepsi
n�betleri</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Genellikle
g�rsel; negatif (iktal k�rl�k, skotom, hemianopsi) veya pozitif
(&#305;&#351;&#305;klar, renkler v.b.) elementer veya kompleks olabilen
belirtilerle giden n�betlerdir. Bu fenomenler tek yanl&#305; oldu&#287;unda
oda&#287;&#305;n genellikle kontralateralinde rastlan&#305;rlar. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-&#304;ktal
k�rl�k s&#305;k olarak g�r�l�r ve migrenle ili&#351;kisi
tart&#305;&#351;&#305;lmaktad&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Elementer
viz�el hal�sinasyonlar ve kompleks viz�el hal�sinasyonlar �ok �e&#351;itli
formlarda n�bet semptomu olarak kar&#351;&#305;m&#305;za �&#305;kabilirler.
Epileptik orijinli olduklar&#305;nda genellikle k&#305;sa s�relidirler ve hasta
bunlar&#305;n ger�ek olmad&#305;&#287;&#305;n&#305;n bilincindedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Viz�el
ill�zyonlar&#305; da basit ve kompleks formlara ay&#305;rmak m�mk�nd�r. �ok
farkl&#305; &#351;ekillerde olabilirler. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Epileptik
nistagmusun pariyeto-oksipital korteksten kaynakland&#305;&#287;&#305;
g�sterilmi&#351;tir. G�zlerin kar&#351;&#305; tarafa d�nmesi, g�z k&#305;rpma
ve g�zlerde hareket hissi oksipital lob n�bet semptomlar&#305; olarak
g�r�lebilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Di&#287;er
loblara yay&#305;l&#305;m �zellikle inferior longitudinal fasik�l yoluyla
temporal loba yay&#305;l&#305;m ve sekonder jeneralizasyon s&#305;kt&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi
n�betlerinin lokalizasyonu ve lateralizasyonu
tart&#305;&#351;&#305;ld&#305;&#287;&#305;nda de&#351;arjlar&#305;n h&#305;zla
yay&#305;labildi&#287;i ve semptomlar&#305;n primer oda&#287;&#305; de&#287;il
yay&#305;l&#305;m b�lgesini g�sterebilece&#287;i g�z �n�nde tutulmal&#305;d&#305;r.
<o:p></o:p></span></p>

<p style='text-align:justify'><a name="Ana_epileptik"></a><b><span lang=TR
style='font-family:Tahoma'>EP&#304;LEPS&#304; SENDROMLARI</span></b><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bu
b�l�mde seyir, prognoz, etyoloji, tedaviye yan&#305;t bak&#305;m&#305;ndan �ok
farkl&#305; davranabilen �e&#351;itli epilepsi t�rleri aras&#305;nda iyi
tan&#305;mlanm&#305;&#351;, belirli epilepsi sendromlar&#305;ndan
baz&#305;lar&#305; hakk&#305;nda k&#305;saca bilgi verilecektir. S&#305;ralama <b
style='mso-bidi-font-weight:normal'>Tablo 2</b>�de yer alan s&#305;n&#305;flama
esas al&#305;narak yap&#305;lm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><a name="a._&#304;dyopatik_parsiyel_epilepsi"></a><b><span
lang=TR style='font-family:Tahoma;color:black'>a. &#304;dyopatik Parsiyel
Epilepsi Sendromlar&#305;</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Santrotemporal dikenli selim �ocukluk
�a&#287;&#305; epilepsisi (Rolandik epilepsi)</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p><span lang=TR style='font-family:Tahoma'>�ocukluk �a&#287;&#305;n&#305;n en
s&#305;k g�r�len parsiyel epilepsisidir ve �o&#287;unlukla remisyonla
sonlan&#305;r. &#304;dyopatik parsiyel epilepsilerin prototipi olan ve
�sensorimotor sistem� epilepsisi olarak kabul edilen bu tipik tablonun
tan&#305;nmas&#305; �ok �nemlidir. Genellikle 4-10 ya&#351;lar&#305;nda
n�rolojik a�&#305;dan normal bir �ocukta ba&#351;lar, erkeklerde biraz daha
s&#305;kt&#305;r. Tipik n�bet �zellikleri y�z�n bir yar&#305;s&#305;nda �zellikle
dil, bo&#287;az ve dudaklarda uyu&#351;ma ve/veya taraflarda tek yanl&#305;
motor bulgularla seyreder. Farinks, larinks ve dil kaslar&#305;n&#305;n
tutulmas&#305; nedeniyle konu&#351;ma durur veya dizartrikle&#351;ir, t�k�r�k
art&#305;&#351;&#305; e&#351;lik edebilir. Bu n�bet s&#305;ras&#305;nda
hastan&#305;n bilinci korunmu&#351;tur. Genellikle uyku s&#305;ras&#305;nda
gelen n�betler bazen jeneralize tonik klonik n�bete (JTKN) d�n�&#351;ebilir.
Tipik interiktal EEG bulgusu tek yanl&#305;, bazen iki yanl&#305; ama
birbirinden ba&#287;&#305;ms&#305;z ve yer de&#287;i&#351;tirebilen y�ksek
amplit�dl� santrotemporal lokalizasyon veren diken/ diken-yava&#351; dalga
aktivitesi &#351;eklindedir ve bu aktivite genellikle uykuda artma g�sterir (<b>&#350;ekil
2</b>). N�betleri genelde seyrek oldu&#287;u i�in ve ergenlikte remisyonla
sonland&#305;&#287;&#305; i�in baz&#305; olgularda tedavi verilmeyebilir.
Tedavi gereken durumlarda valproik asidi ye&#287;leyenler oldu&#287;u gibi
karbamazepini �st�n bulanlar da vard&#305;r. <br>
&nbsp; <o:p></o:p></span></p>

<p style='margin-left:35.4pt;text-align:justify'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue'><a href="sekil2a.jpg">&#350;ekil
<span style='mso-bidi-font-weight:normal'>2a</span><span style='font-weight:
normal'>.</span></a></span></u></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> Rolandik epilepsi tan&#305;s&#305;yla izlenen bir olguda
uyan&#305;kl&#305;k s&#305;ras&#305;nda sol santrotemporal b�lgede faz d�nmesi
g�steren az say&#305;da keskin ve keskin-yava&#351; dalgalar g�r�lmektedir. <b
style='mso-bidi-font-weight:normal'><u><span style='color:blue'><a
href="sekil2b.jpg">&#350;ekil 2b.</a></span></u></b> Ayn&#305; olguda uyku ile
sol taraftaki oda&#287;&#305;n s&#305;kla&#351;arak diziler
olu&#351;turdu&#287;u, amplit�d�n artt&#305;&#287;&#305; g�r�lmektedir.
Ayr&#305;ca sa&#287; orta temporal b�lgede faz d�nmesi g�steren
ba&#287;&#305;ms&#305;z bir epileptojenik odak daha tabloya eklenmi&#351;tir.<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Oksipital paroksizmli selim �ocukluk
�a&#287;&#305; epilepsisi</span></i></b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;dyopatik
parsiyel epilepsilerin ikincisi olan bu tablonun eskiden
san&#305;ld&#305;&#287;&#305;ndan daha s&#305;k g�r�ld�&#287;�
anla&#351;&#305;lmaktad&#305;r. Tipik n�betler k�rl�k, ill�zyon veya
hal�sinasyon gibi, migrenle kar&#305;&#351;t&#305;r&#305;lmas&#305;na yol a�an
�e&#351;itli g�rsel semptomlarla ba&#351;lar. Hemiklonik kas&#305;lmalar,
ba&#351;a&#287;r&#305;s&#305;, bulant&#305; ve konf�zyon tabloya e&#351;lik
edebilir. Baz&#305; n�betler olduk�a uzun s�rebilir. EEG�de g�zler
kapat&#305;l&#305;nca oksipital b�lgede, tipik y�ksek amplit�dl� s&#305;k sivri
dalga dizileri izlenir <b style='mso-bidi-font-weight:normal'>(&#350;ekil 3)</b>.
Ailede epilepsi ve migren �yk�s� �ok s&#305;kt&#305;r. 2001 ILAE
s&#305;n&#305;flama �nerisinde iki farkl&#305; tip �ocukluk �a&#287;&#305;
idyopatik oksipital lob epilepsisi oldu&#287;u belirtilmi&#351;tir. Otonomik ve
g�rsel sistemlerin a&#287;&#305;rl&#305;kl&#305; tutulumu ay&#305;r&#305;mda
tipiktir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>1- Panayiotopoulos
tipi: (Erken ba&#351;lang&#305;�l&#305; olanlar: otonom sistem).
S&#305;kl&#305;kla 3-6 ya&#351;lar aras&#305;nda ba&#351;lar, b�y�me
geli&#351;mesi normal olan �ocuklarda �o&#287;unlukla gece uyku
s&#305;ras&#305;nda, ba&#351;l&#305;ca bulant&#305; kusma
yak&#305;nmalar&#305;n&#305; tonik g�z deviasyonu ile giden n�betler izler. N�betler
uzun s�reli (40% olguda en az 30 dakika) olabilmektedir. EEG�de
&#305;&#351;&#305;&#287;a duyarl&#305;l&#305;k g�r�lmez ve yer
de&#287;i&#351;tirebilen multifokal dikenler g�r�lebilir. Otonom status
epileptikus geli&#351;ebilmekte ve ay&#305;r&#305;c&#305; tan&#305;da sorun
ya&#351;anabilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>2-
Gastaut tipi: (Ge� ba&#351;lang&#305;�l&#305; olanlar: g�rsel sistem). Gastaut
taraf&#305;ndan 1982�de tan&#305;mlanm&#305;&#351;t&#305;r. 8-10
ya&#351;lar&#305;nda ba&#351;lar. N�betler g�nd�zleri de g�r�lebilir ve
ba&#351;l&#305;ca g�rsel semptomlar bulunur, postiktal
ba&#351;a&#287;r&#305;s&#305; s&#305;k g�r�l�r, prognoz erken
ba&#351;lang&#305;�l&#305;lar kadar iyi de&#287;ildir, otonom bulgular burada
s&#305;k de&#287;ildir. <o:p></o:p></span></p>

<p style='margin-left:35.25pt;text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil3.jpg">&#350;ekil 3.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> Normal bir �ocukta geli&#351;en
g�rsel n�betler nedeniyle yap&#305;lan bu EEG incelemesinde g�zler a�&#305;kken
normal bir temel aktivite varken g�z kapatmay&#305; izleyerek iki yanl&#305;
oksipital b�lgelerde y�ksek amplit�dl� sivri-yava&#351; dalga
de&#351;arjlar&#305; belirmektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Di&#287;er
idyopatik parsiyel epilepsiler aras&#305;nda say&#305;lan ve �ok nadir tablolar
olan <i style='mso-bidi-font-style:normal'>primer okuma epilepsisi</i> ve
s&#305;n&#305;flamaya sonradan giren <i style='mso-bidi-font-style:normal'>idyopatik
fotosensitif oksipital lob epilepsisi </i>refleks epilepsiler
ba&#351;l&#305;&#287;&#305; alt&#305;nda ele al&#305;nm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>�zel bir semptomatik parsiyel sendrom:
&quot;Epilepsia partialis continua&quot; ve Rasmussen sendromu </span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>ILAE
s&#305;n&#305;flamas&#305;nda, semptomatik epilepsiler aras&#305;nda �ocukluk
�a&#287;&#305;n&#305;n kronik progresif epilepsia parsiyalis kontinuas&#305;
ad&#305;yla yer alan �ok nadir ancak k�t� seyirli bir tablodur.</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Epilepsia parsiyalis kontinua genellikle hayat&#305;n ilk on
y&#305;l&#305;nda ba&#351;layan, ancak hemen her ya&#351;ta g�r�lebilen bir
parsiyel epilepsi &#351;eklidir. Hastada neredeyse devaml&#305; bir
&#351;ekilde s�ren basit parsiyel n�betler g�r�l�r. Genelde bu n�betin
ba&#351;lamas&#305; Rasmussen ensefaliti ad&#305;n&#305; ta&#351;&#305;yan,
sadece bir hemisferi tutan kronik bir ensefalitin bulgusu olarak g�r�l�r.
Etyolojide bu kronik ensefalitten ba&#351;ka kortikal displazi, t�m�rler,
vask�ler lezyonlar sorumlu olabilir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Rasmussen ensefalitinde yava&#351; progresif bir n�rolojik
k�t�le&#351;me izlenir. Hemiparezi, mental retardasyon ve dominant hemisfer
tutulmu&#351;sa disfazi olur. Hastalar&#305;n %50�sinde ilk y&#305;l n�rolojik
k�t�le&#351;me ile birlikte n�betler ba&#351;lar. Radyolojik olarak da
yava&#351; progresif seyirli, genellikle tek yanl&#305; serebral atrofi
tipiktir <b style='mso-bidi-font-weight:normal'>(&#350;ekil 4).</b> Patolojik
olarak viral ensefalit bulgular&#305;n&#305;n olmas&#305; tan&#305;y&#305;
koydurur. Ancak Rasmussen ensefaliti tan&#305;mland&#305;ktan sonra bir�ok
atipik olgu bildirimi olmu&#351;tur. &#304;lk n�betler jeneralize tonik klonik
n�betler (%30), jeneralize veya fokal motor status epileptikus (%20)
&#351;eklindedir. Tipik olgularda ila�lara diren�li tek yanl&#305; fokal motor
n�betler ve/ veya temporal lob n�betleri ortaya �&#305;kar. En s&#305;k olarak
yukar&#305;da da belirtildi&#287;i gibi, fokal motor status epileptikus olan
�epilepsia parsiyalis kontinua� tablosu g�r�l�r. Atipik olarak g�rece
yava&#351; seyirli olan, eri&#351;kin ya&#351;ta ba&#351;layan veya epilepsia
parsiyalis kontinuan&#305;n miyoklonik formlar&#305; ile ortaya �&#305;kan
klinik bulgular olabilir. Kranyal g�r�nt�lemede kontralateral atrofi bazen
beklenen kadar belirgin olmayabilir, bazen de bilateral tutulum g�r�lebilir.
EEG�de etkilenen hemisferde en �ok temporal ve santral olmak �zere polimorfik
delta frekans&#305;nda yava&#351; dalgalar g�r�l�r. Klinik n�betin
kontralateralinde elektrografik n�betler izlenebilir. Beyin omurilik
s&#305;v&#305;s&#305;n&#305;n (BOS) incelemesinde olgular&#305;n
yakla&#351;&#305;k %50�sinde protein art&#305;&#351;&#305; ve lenfosit
a&#287;&#305;rl&#305;kl&#305; h�cre art&#305;&#351;&#305; vard&#305;r.
Oligoklonal band hastalar&#305;n %0-67 sinde g�r�l�r. Glutamat resept�r� subunit
3�e kar&#351;&#305; olu&#351;an antikor (anti-Glu3R) saptanabilmekle birlikte
bu hastal&#305;k i�in spesifik de&#287;ildir ve tan&#305; i�in art&#305;k
kullan&#305;lmamaktad&#305;r. Beyin biyopsisi sadece &#351;�pheli olgularda
klinik ve radyolojik destek yok ise tan&#305;y&#305; do&#287;rulamak i�in
yap&#305;l&#305;r. N�ropsikolojik testlerin tan&#305; i�in de&#287;eri yoktur,
ancak takipte progresyonu g�stermek i�in �nemli yer tutar.
Ay&#305;r&#305;c&#305; tan&#305;da unilateral epileptik n�betlere yol a�an
tablolardan kortikal malformasyonlar, Sturge-Weber sendromu, inme,
hemikonv�lziyon-hemipleji-epilepsi sendromu, gliomatozis serebri gibi t�m�rler,
metabolik bozukluklar (MELAS) veya inflamatuar durumlar (vask�lit, HIV, Rus
ilkbahar-yaz meningoensefaliti vb) d�&#351;�n�lmelidir. Tedavide antiepileptik
ila�lar ba&#351;lan&#305;r, ancak genelde ila�lara diren�li n�betlerdir.
Beraberinde kortikosteroid, intraven�z imm�noglobulin, plazmaferez veya oral
takrolimus verilir. Olgu say&#305;s&#305; az oldu&#287;u i�in kontroll�
�al&#305;&#351;malar yap&#305;lamamaktad&#305;r. Ancak, �nceden tavsiye
edilmi&#351; olan hemisferektomi /hemisferetomi bu olgularda art&#305;k pek
tercih edilmemektedir. Uzun d�nem imm�noterapi &#351;u an i�in cerrahinin
yerini alm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p style='margin-left:35.4pt;text-align:justify'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue'><a href="sekil4a.jpg">&#350;ekil
4a<span style='font-weight:normal;mso-bidi-font-weight:bold'>.</span></a></span></u></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>
Rasmussen olgusunda MR �rne&#287;i: 15 ya&#351;&#305;nda erkek, 3 y&#305;l �nce
ba&#351;layan jeneralize konv�lz�yonlara, 2 y&#305;l �nce solda devaml&#305; fokal
motor n�betler eklenmi&#351;. Sa&#287; hemisferde frontal, temporal loblarda ve
derin ak maddede belirgin olmak �zere vol�m kayb&#305; dikkati �ekmektedir. <o:p></o:p></span></p>

<p style='margin-left:35.4pt;text-align:justify'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue'><a href="sekil4b.jpg">&#350;ekil
4b<span style='font-weight:normal;mso-bidi-font-weight:bold'>.</span></a></span></u></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>
Ayn&#305; hastan&#305;n EEG incelemesinde sa&#287; parietal b�lgede sol
hemisfere de yay&#305;lan n�bet aktivitesi g�r�lmektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><a name="b._&#304;dyopatik_jeneralize_epilepsi"></a><b><span
lang=TR style='font-family:Tahoma;color:black'>b. &#304;dyopatik Jeneralize
Epilepsi Sendromlar&#305;</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Selim ailesel yenido&#287;an
konv�lz�yonlar&#305;</span></i></b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>�ok
nadir g�r�lmekle birlikte tamamen selim olmas&#305; ve genetik a�&#305;dan
mutasyonlar&#305;n&#305;n belirlenmi&#351; olmas&#305; nedeniyle �nem
ta&#351;&#305;maktad&#305;r. Hayat&#305;n 2. veya 3. g�n�nde genellikle
jeneralize tipte g�nde 20'ye dek varan s&#305;kl&#305;kta n�betler g�r�l�r, 1-6
ay i�inde kaybolur. N�rolojik a�&#305;dan normal geli&#351;en bu
hastalar&#305;n 1/7'sinde sonradan epilepsi geli&#351;ebilir. Otozomal dominant
(OD) ve y�ksek penetransl&#305; olan bu hastal&#305;&#287;&#305;n geninin 20.
kromozomda oldu&#287;u saptanm&#305;&#351;t&#305;r. Ard&#305;ndan ba&#351;ka
bir grup taraf&#305;ndan 8. kromozomda da bir defekt g�sterilmi&#351;tir.
Sorumlu genlerin her iki kromozomda yer alan farkl&#305; (KCNQ2, KCNQ3)
potasyum kanal genleri oldu&#287;u 1998'de kan&#305;tlanm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Selim yenido&#287;an konv�lz�yonlar&#305;
(5.g�n n�betleri)</span></i></b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Nadirdir,
s&#305;k klonik ve sinsi, �rne&#287;in apneik n�betler g�r�l�r. Bebeklerin
geli&#351;imi tamamen normaldir ve ard&#305;ndan epilepsi geli&#351;imi
g�r�lmez. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Piridoksin
ba&#287;&#305;ml&#305;l&#305;&#287;&#305;</span></i></b><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>�ok
nadir g�r�lmekle birlikte spesifik tedavisi oldu&#287;undan �nem
ta&#351;&#305;yan bu tabloda n�betler hayat&#305;n ilk 24 saatinde ba&#351;lar.
&#304;n utero veya birka� ay i�inde ba&#351;lang&#305;� bildirilmi&#351;tir.
Genellikle jeneralize tipte olan n�betler t�m antiepileptik tedavilere
diren�lidir. IV 100 mg piridoksine �ok h&#305;zla yan&#305;t al&#305;n&#305;r
ve EEG'de normale d�ner. Baz&#305; olgularda erken tedaviye ra&#287;men mental
gerilik kalabilir. &#350;�phelenildi&#287;i durumlarda tedavi denemesi
yap&#305;lmal&#305;d&#305;r. Piridoksin yani B6 vitamini inhibit�r
n�rotransmitter GABA'n&#305;n sentezinde rol alan glutamik asit dekarboksilaz
enziminin kofakt�r�d�r ve otozomal resesif eksikli&#287;inin bu tabloya rol
a�t&#305;&#287;&#305; d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>S�t �ocuklu&#287;unun selim miyoklonik
epilepsisi</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Hayat&#305;n
ilk 2 y&#305;l&#305; i�inde jeneralize miyoklonus ataklar&#305; ile
karakterizedir. Aile �yk�s� genellikle vard&#305;r ve n�betler kolayca kontrol
alt&#305;na al&#305;n&#305;r. Genellikle ba&#351;ka n�bet tipleri e&#351;lik
etmez ama ergenlik d�neminde JTKN g�r�lebilir. Tedavide valproat tercih edilir.
<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>�ocukluk �a&#287;&#305; absans epilepsisi
(piknolepsi)</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Tipik
absans n�betleri ile giden bu tablo �ocukluk �a&#287;&#305; n�betlerinin
yakla&#351;&#305;k %4'�n� olu&#351;turur. Ba&#351;lang&#305;� ya&#351;&#305;
3-9 aras&#305;d&#305;r, k&#305;zlarda biraz daha s&#305;kt&#305;r. N�betler her
�e&#351;it mental aktivitenin aniden durmas&#305; ve saniyeler sonra
kald&#305;&#287;&#305; yerden devam etmesi &#351;eklinde olur. Bu s&#305;rada
hastan&#305;n cevaps&#305;z ve hareketsiz oldu&#287;u, bo&#351; bir
&#351;ekilde bakt&#305;&#287;&#305; g�zlenir. Sadece bilin� kayb&#305; ile
seyreden n�betlere <i style='mso-bidi-font-style:normal'>basit absans</i>;
bilin� kayb&#305; ile birlikte hafif klonik, atonik, tonik, ve otonom
komponentlerin ve otomatizmlerin oldu&#287;u n�betlere <i style='mso-bidi-font-style:
normal'>kompleks absans n�betleri</i> denir. Tipik absans n�betlerinin EEG
bulgusu bilateral, genelikle d�zenli ve simetrik 3 (2.5-4) Hz diken-dalga
kompleksleri; bazen multipl diken-yava&#351; dalgalar &#351;eklindedir; temel
aktivite normaldir (Bak&#305;n&#305;z: Sinir Sistemi Semiyolojisi, EEG, <b
style='mso-bidi-font-weight:normal'><u>&#350;ekil 2</u></b>). <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Genellikle
normal zeka d�zeyinde olan bu hastalar s&#305;k n�betleri nedeniyle okul
ba&#351;ar&#305;s&#305;nda d�&#351;me g�sterebilirler. Tedaviye iyi cevap (%80
olguda tam kontrol) al&#305;nan bu tabloda uygun ila�lar sadece absans n�beti
olanlarda etos�ksimid veya valproik asid, di&#287;er n�bet tipleri e&#351;lik
etti&#287;inde ise valproatt&#305;r. Ender g�r�len diren�li absans n�betlerinde
lamotrijin, etos�ksimid veya di&#287;er geni&#351; spektrumlu anti-epileptikler
birlikte kullan&#305;labilir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>J�venil absans epilepsi</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>�ocukluk �a&#287;&#305; absans epilepsine (�AE) olduk�a benzer. Absans
n�betleri �AE'den uzun ve g�rece daha hafiftir. 8-16 ya&#351; aras&#305; normal
�ocuk ve ergenlerde g�r�len bu tabloda n�betler y&#305;llar i�inde hafifler ama
�AE�deki gibi remisyon beklenmez, JTKN ve seyrek miyokloni olabilir ama geri
plandad&#305;r. EEG �AE�ye benzer ama multipl diken olabilir (<b>&#350;ekil 5</b>).&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><b><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil5.jpg">&#350;ekil 5.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'> 12
ya&#351;&#305;ndaki olguda EEGde izlenen, 7 saniye s�reli, 4 Hz jeneralize,
hemisfer �n yar&#305;lar&#305;nda belirgin multi-diken-dalga
de&#351;arjlar&#305; s&#305;ras&#305;nda dalma ve g�zlerinde aralanma ve
k&#305;rp&#305;&#351;t&#305;rma g�r�lm�&#351;t�r. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>J�venil miyoklonik epilepsi</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Genellikle
8-26 ya&#351; aras&#305;nda, en s&#305;k olarak 12-15 ya&#351;lar&#305;nda bir
hastada tipik olarak sabah uyand&#305;ktan sonra, &#351;uuru yerindeyken,
yayg&#305;n, tekrarlay&#305;c&#305;, genellikle kollarda belirgin olan
miyoklonilerle ba&#351;lar. Aniden uyand&#305;r&#305;lma ve uykusuzluk ile
tetiklenen bu n�betler bazen hastan&#305;n elindekileri d�&#351;�rmesine yol
a�ar. Miyoklonik n�betleri sinirlilik, yorgunluk y�z�nden elde titreme gibi a�&#305;klamalarla
�o&#287;u hasta �nemsemez ve bir doktora ba&#351;vurmaz. Bu nedenle bu
n�betlerin anla&#351;&#305;labilmesi i�in ayr&#305;nt&#305;l&#305; bir
&#351;ekilde sorgulanmas&#305; gerekmektedir. Miyokloniler baz&#305; hastalarda
tek n�bet tipi olarak kalabildi&#287;i gibi �o&#287;u hastada bir y&#305;l
i�inde yine benzer tetikleyici etkenlere ba&#287;l&#305; olarak ortaya
�&#305;kan JTKN tabloya eklenir. Bu sendromda g�r�lebilen 3. n�bet tipi
olgular&#305;n yakla&#351;&#305;k 1/3'�nde g�r�len ve genellikle daha erken
ya&#351;larda ortaya �&#305;kan absans n�betleridir. Baz&#305; hastalarda n�bet
s&#305;ras&#305;nda hafif fokal bulgular saptanabilir. I&#351;&#305;k uyarana
duyarl&#305;l&#305;k bu sendromda �zellikle kad&#305;n olgularda s&#305;k
olarak g�r�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bu
idyopatik jeneralize epilepsi sendromu t�m epilepsilerin %4-10
kadar&#305;n&#305; olu&#351;turmaktad&#305;r, buna kar&#351;&#305;n s&#305;k
olarak tan&#305; konmas&#305;nda gecikme ve g��l�kler ortaya �&#305;kar. &#304;lk
tan&#305; sorunu daha �ncede belirtildi&#287;i gibi hastan&#305;n miyoklonileri
�nemsemeyip genellikle ilk b�y�k n�beti ge�irince doktora ba&#351;vurmas&#305;
ve miyokloniler doktor taraf&#305;ndan sorulmazsa bahsetmemesi nedeniyledir. Bu
arada hasta �e&#351;itli yanl&#305;&#351; tan&#305;lar alabilir, �rne&#287;in
parsiyel bir epilepsi san&#305;labilir. Karbamazepin ve fenitoin tedavileri bu
sendromda olumsuz etki yaratarak absans ve miyoklonileri
artt&#305;rmaktad&#305;r. Do&#287;ru tan&#305; konduktan sonra
yap&#305;lmas&#305; gereken ilk �nce hastan&#305;n n�beti artt&#305;ran
fakt�rler a�&#305;s&#305;ndan uyar&#305;lmas&#305;d&#305;r. Bu fakt�rler
aras&#305;nda uykusuzluk, ani uyanma, yorgunluk, alkol al&#305;m&#305;, parlak
&#305;&#351;&#305;k uyar&#305;, televizyon veya bilgisayar oyunlar&#305; ve
nadir baz&#305; olgularda baz&#305; mental fonksiyonlar (okuma, oyun oynama
vb...) yer al&#305;r. Her hasta bu fakt�rlerin bir veya birka�&#305;ndan
etkilenebilir. Kad&#305;n hastalar menstruasyon s&#305;ras&#305;nda n�bet
art&#305;&#351;&#305;ndan yak&#305;nabilirler. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bu
sendromda do&#287;ru ila� tedavisi valproik asid ile olur, fakat yan etkiler
nedeniyle sorun ya&#351;anabilir. Yakla&#351;&#305;k %80 olgu bu ila� ile tam
olarak kontrol alt&#305;na al&#305;n&#305;r. Ancak �m�r boyu s�rd�&#287;�
bilinen bu hastal&#305;kta ila� kesme ve tetikleyici fakt�rlere ba&#287;l&#305;
olarak n�ksler g�r�lmektedir. EEG de tipik bulgu 3-6 Hz jeneralize �ok
diken-dalga de&#351;arjlar&#305; g�r�lmesidir, fotosensitivite de �nemlidir
(Bak&#305;n&#305;z: Sinir Sistemi Semiyolojisi, EEG,<b> &#351;ekil 7, 8</b>).
Ancak 1/3 olguda ilk EEG normal bulunur. Kesin tan&#305; i�in EEG� nin
tekrarlanmas&#305; yararl&#305;d&#305;r. Baz&#305; olgularda EEG�de asimetrik
ve fokal anomalilere rastlanabilir ve deneyimsiz bir g�z taraf&#305;ndan
yanl&#305;&#351; sonu�lara var&#305;labilir. Genetik olarak yeri ilk
�al&#305;&#351;malarda 6. kromozomun k&#305;sa kolunda bulunmu&#351;, ancak
ba&#351;ka lokuslar da eklenmi&#351;tir. Bir ailede GABRA1 gen
mutasyonlar&#305; yan&#305; s&#305;ra 2004 y&#305;l&#305;nda EFHC1 geni, takip
eden y&#305;lda Ser1 resept�r geninde mutasyonlar saptanm&#305;&#351;t&#305;r.
Uzun takip �al&#305;&#351;malar&#305; 40 ya&#351;&#305;ndan sonra miyoklonik
n�betlerin �o&#287;u olguda ortadan kalkt&#305;&#287;&#305;n&#305; veya
hafifledi&#287;ini g�stermi&#351;tir. Psikiyatrik ek sorunlar&#305; olan ve 3
n�bet tipi olan olgular %15 oran&#305;nda g�r�lebilen diren�li seyir
a�&#305;s&#305;ndan risk ta&#351;&#305;rlar. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Uyan&#305;rken gelen grand mal n�betli
epilepsi</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Genellikle
10-20 ya&#351; aras&#305;nda ba&#351;layan ve di&#287;er idyopatik jeneralize
epilepsilerle ortak �zellikler ta&#351;&#305;yan bu sendromda n�betlerin
%90'&#305; uyanma d�nemleri ve uykusuz kalma ile ili&#351;kilidir.
Ak&#351;am�st� dinlenme saatlerinde de n�bet g�r�lebilir. Ailede epilepsi
�yk�s� genellikle bulunur, iyi seyirlidir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Tipik absans n�betleri birbirinden farkl&#305; klinik tablolar&#305;,
prognozlar&#305; ve tedaviye cevaplar&#305; olan �e&#351;itli epileptik
sendromlarda g�r�l�r. ILAE (<b style='mso-bidi-font-weight:normal'>Tablo 2</b>)
taraf&#305;ndan tipik absans n�betleriyle giden 4 sendrom
tan&#305;mlanm&#305;&#351;t&#305;r: </span><span lang=TR style='font-family:
Tahoma'><o:p></o:p></span></p>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l59 level2 lfo13;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>�ocukluk
      �a&#287;&#305; absans epilepsisi</span><span lang=TR style='font-family:
      Tahoma'> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l59 level2 lfo13;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>J�venil absans
      epilepsisi</span><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l59 level2 lfo13;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>J�venil miyoklonik
      epilepsi</span><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l59 level2 lfo13;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Miyoklonik absans
      epilepsisi</span><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></li>
 </ul>
</ol>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Ancak son y&#305;llarda g�z kapa&#287;&#305; miyoklonili absans
epilepsi sendromu ba&#351;ta olmak �zere bir �ok farkl&#305; absans epilepsi
sendromunun oldu&#287;u Panayiotopoulos ve arkada&#351;lar&#305;
taraf&#305;ndan bildirilmi&#351;tir. Bu tablo 2001 s&#305;n&#305;flamas&#305;na
da n�bet tipi olarak girmi&#351;tir. &#350;ekilde tipik EEG bulgusu g�sterilmi&#351;
olan bu sendromda hastalar&#305;n g�z kapamay&#305; izleyen k&#305;sa s�reli
absans n�betleri s&#305;ras&#305;nda g�z k&#305;rpma ritmik olarak tekrarlar,
g�z k�releri yukar&#305; deviye olur, ayr&#305;ca fotosensitif olduklar&#305;,
s&#305;k JTKN ge�irdikleri ve prognozlar&#305;n&#305;n g�rece daha k�t� oldu&#287;u
bilinmektedir. (<b>&#350;ekil 6</b>). Di&#287;er baz&#305; yeni
tan&#305;mlanm&#305;&#351; absans epilepsi sendromlar&#305; aras&#305;nda
perioral miyoklonili absans epilepsi, fantom absans ve ge�
ba&#351;lang&#305;�l&#305; jeneralize konv�lz�yonlar gibi tablolar
say&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><b><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil6.jpg">&#350;ekil 6<span style='font-weight:normal;mso-bidi-font-weight:
bold'>.</span></a></span></u></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:blue;mso-bidi-font-weight:bold'> </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>G�z
kapa&#287;&#305; miyoklonili absans epilepsili bir olguda g�z kapamay&#305;
takiben ortaya �&#305;kan 1.5-2 sn s�reli jeneralize diken-dalga
de&#351;arjlar&#305;<span style='color:blue'> </span></span><span lang=TR
style='font-family:Tahoma;color:blue'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Hasta ve ailelerini absans n�betinin remisyona girece&#287;i ya da
devam edece&#287;i a�&#305;s&#305;ndan ayd&#305;nlatabilmek �ok �nem
ta&#351;&#305;maktad&#305;r. Yap&#305;lan �al&#305;&#351;malar uzun takipli
hasta gruplar&#305;nda normal IQ, normal n�rolojik muayene, erken
ba&#351;lang&#305;�, JTKN olmamas&#305; (sadece absans n�beti ile %64 remisyon,
JTKN varl&#305;&#287;&#305;nda ise %34 remisyon g�r�l�r), absans statusu
olmamas&#305;, &#305;&#351;&#305;&#287;a duyarl&#305;l&#305;k olmamas&#305;,
aile �yk�s� olmamas&#305; gibi fakt�rlerin prognostik a�&#305;dan olumlu
oldu&#287;unu g�stermi&#351;tir..<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>GEFS+: Jeneralize epilepsi ve febril n�bet
art&#305; sendromu<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;dyopatik
jeneralize epilepsi �zelliklerini ta&#351;&#305;yan ve genetik
�al&#305;&#351;malar sayesinde yeni tan&#305;mlanm&#305;&#351; heterojen
�zellikte bir sendromdur. Febril n�betler beklenenden daha erken veya ge�
ya&#351;ta ba&#351;layabilir, 6 ya&#351;&#305;ndan sonra da ate&#351;li veya
ate&#351;siz olarak devam edebilir ve farkl&#305; epilepsi n�betleri ayn&#305;
ailede farkl&#305; bireylerde izlenebilir. Absans, miyoklonik n�betler, atonik
n�betler ve bazen a&#287;&#305;r olgularda miyoklonik-astatik n�betler
g�r�lebilir. Otozomal dominant kal&#305;t&#305;m &#351;ekli g�steren, 6
ya&#351;&#305;ndan sonra da devam eden s&#305;k febril n�betler ve farkl&#305;
n�bet tipleri ile birliktelik g�steren ilk geni&#351; aile 1997�de <a
href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T34-4FCSDR3-2&amp;_coverDate=02%2F28%2F2005&amp;_alid=341580277&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_qd=1&amp;_cdi=4936&amp;_sort=d&amp;view=c&amp;_acct=C000041838&amp;_version=1&amp;_urlVersion=0&amp;_userid=747273&amp;md5=748ca07a26a12ead307c70b5809c32cb#bib11"
target="_parent"><span style='color:windowtext;text-decoration:none;text-underline:
none'>Scheffer </span></a><a
href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T34-4FCSDR3-2&amp;_coverDate=02%2F28%2F2005&amp;_alid=341580277&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_qd=1&amp;_cdi=4936&amp;_sort=d&amp;view=c&amp;_acct=C000041838&amp;_version=1&amp;_urlVersion=0&amp;_userid=747273&amp;md5=748ca07a26a12ead307c70b5809c32cb#bib11"
target="_parent"><span style='color:windowtext;text-decoration:none;text-underline:
none'>ve </span></a><a
href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T34-4FCSDR3-2&amp;_coverDate=02%2F28%2F2005&amp;_alid=341580277&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_qd=1&amp;_cdi=4936&amp;_sort=d&amp;view=c&amp;_acct=C000041838&amp;_version=1&amp;_urlVersion=0&amp;_userid=747273&amp;md5=748ca07a26a12ead307c70b5809c32cb#bib11"
target="_parent"><span style='color:windowtext;text-decoration:none;text-underline:
none'>Berkovic taraf&#305;ndan tan&#305;mlanm&#305;&#351;t&#305;r. </span></a><span
style='mso-spacerun:yes'>�</span>Voltaj kap&#305;l&#305; sodyum kanal&#305;
SCN1A ve SCN1B sub�nite genlerinde, GABA resept�r &#947;-2 subunit geninde
(GABRG2) ayr&#305;ca &#945;-2 subunit geninde, SCN2A1 geninde mutasyonlar
bildirilmi&#351;tir. Bu konuda �al&#305;&#351;malar halen devam etmekte,
fakl&#305; ailelerde farkl&#305; mutasyonlar saptanmaktad&#305;r. Genetik �al&#305;&#351;malar&#305;n
sendrom s&#305;n&#305;flamas&#305;n&#305; etkiledi&#287;ini g�stermesi
a�&#305;s&#305;ndan bu sendrom �nemli bir �rnek olu&#351;turmaktad&#305;r.
Ancak &#351;u an i�in tam olarak klinik �zellikleri ve s&#305;n&#305;rlar&#305;
anla&#351;&#305;lamam&#305;&#351; geni&#351; spektrumlu bir genetik sendrom
�zelli&#287;i g�stermektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><a name="c._Kriptojenik_veya_semptomatik_jenerali"></a><b><span
lang=TR style='font-family:Tahoma;color:black'>c. Kriptojenik veya Semptomatik
Jeneralize Epilepsi Sendromlar&#305;</span></b><span lang=TR style='font-family:
Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>West sendromu<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><span
style='mso-spacerun:yes'>�</span></span></b><span lang=TR style='font-family:
Tahoma'>Bu tablonun tipik 3 ana belirtisi &#351;unlard&#305;r: <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l63 level1 lfo16;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>&#304;nfantil spazmlar <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l63 level1 lfo16;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>Mental gerilik <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l63 level1 lfo16;tab-stops:list 36.0pt'><span
     lang=TR style='font-family:Tahoma'>EEG'de hipsaritmi denen multifokal
     odaklar, yayg&#305;n ve fokal yava&#351; aktivite ile giden kaotik tablo <b
     style='mso-bidi-font-weight:normal'>(&#350;ekil 7)</b> <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:18.0pt;text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'><a href="sekil7.jpg">&#350;ekil
7.</a></span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>
West sendromlu bir olguda hipsaritmi �rne&#287;i. EEG aktivitesinin y�ksek
amplit�dl�,<span style='mso-spacerun:yes'>� </span>multifokal ve kaotik
�zellikte oldu&#287;una dikkat ediniz.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>&#304;nfantil spazmlar fleks�r, ekstans�r, klonik veya miyoklonik
tiplerde olabilir, bazen hafif bir ba&#351; hareketi &#351;eklinde olup
ba&#351;lang&#305;�ta ailenin ve doktorun dikkatinden ka�abilir. &#304;nsidensi
yakla&#351;&#305;k olarak 5000'de 1 olarak bildirilen bu tablonun
ba&#351;lang&#305;� ya&#351;&#305; 3-12 ayd&#305;r; 3-7 aylar aras&#305;nda ve
erkek �ocuklarda nispeten s&#305;k rastlan&#305;r. Olgular&#305;n
yakla&#351;&#305;k 3/4�nde etyolojik bir neden g�sterilebilir. Bu semptomatik
olarak adland&#305;r&#305;lan West olgular&#305;nda s&#305;k olarak saptanan
fakt�rler hipoksik-iskemik ensefalopati (perinatal asfiksi), serebral
malformasyonlar (�zellikle tuberoz skleroz), merkezi sinir sistemi infeksiyonlar&#305;
ve �e&#351;itli metabolik-toksik nedenlerdir. Kriptojenik olarak
adland&#305;r&#305;lan grupta ise yap&#305;lan t�m ara&#351;t&#305;rmalara
ra&#287;men etyolojik bir fakt�r bulunmaz. Bu grubun %5 kadar&#305;nda ailede
infantil spazm �yk�s� bulunmaktad&#305;r. Prognoz semptomatik grupta ve tedavi
gecikmesinde �zellikle daha belirgin olmak �zere genellikle k�t�d�r.
&#304;nfantil spazmlar antiepileptik ila�lara genellikle diren� g�sterirler.
Steroidler, tedavi mekanizmas&#305; bilinmemekle birlikte (ACTH veya prednison)
daha iyi sonu�lar verir. Ancak son y&#305;llarda �zellikle vigabatrin tedavisi
ile olumlu sonu�lar bildirilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Lennox-Gastaut sendromu</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>West
sendromunun bir uzant&#305;s&#305; gibi d�&#351;�nmek m�mk�nd�r. Bu tabloda
atipik absans, miyoklonik, tonik n�betler, atonik ve tonik-klonik n�bet
tiplerinin birden fazlas&#305; bir arada g�r�l�r. EEG�de yava&#351; (1-2.5Hz)
diken-dalga g�r�n�m� tipiktir <b style='mso-bidi-font-weight:normal'>(&#350;ekil
8)</b>. Olgular&#305;n b�y�k k&#305;sm&#305;nda belirgin motor-mental gerilik
s�z konusudur. West sendromunun etyolojisinde s�z edilen nedenlerin �o&#287;u
ayn&#305; zamanda Lennox-Gastaut sendromuna yol a�abilir. Baz&#305; olgular
West sendromundan ge�erek bu tabloya girerler. N�betler genellikle ila�
tedavisine diren�lidir. D�&#351;me n�betleri �zellikle k�t� prognoza
i&#351;aret eder, morbiditeye yol a�ar ve bu tip baz&#305; olgularda anterior
kallozotomi giri&#351;imi ile olumlu sonu�lar elde edilebilmektedir. <o:p></o:p></span></p>

<p style='margin-left:35.25pt;text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil8.jpg">&#350;ekil 8.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> Lennox-Gastaut sendromu i�in tipik
olan yava&#351; dalga dikenler ve yetersiz temel aktivite g�r�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Tipik absans n�betleriyle atipik absans n�betleri klinik planda; atipik
absans n�betlerinin ba&#351;lang&#305;� ve sonlanmas&#305;n&#305;n �ok kesin
olmamas&#305;, tonus de&#287;i&#351;ikliklerinin �ok daha belirgin olmas&#305;
ile ayr&#305;l&#305;r. Ayr&#305;ca atipik absanslar genellikle mental retarde
ve di&#287;er n�bet tipleri olan hastalarda g�r�l�r. Atipik absans n�betlerinde
iktal EEG �ok daha heterojendir; d�zensiz, yava&#351; diken-dalga kompleksleri,
h&#305;zl&#305; aktivite vb g�r�l�r, bilateral olmakla birlikte asimetrik ve
d�zensizdir, zemin genellikle anormaldir.</span><span lang=TR style='font-family:
Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Miyoklonik-astatik n�betli epilepsi</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Nadir
g�r�len bu sendromda normal bir �ocukta aniden d�&#351;me n�betleri
ba&#351;lar. N�betler miyoklonik, astatik, miyoklonik-astatik ve tonik klonik
olabilir. Status epileptikus ve ailede benzer �yk� s&#305;kt&#305;r. EEG'de
d�zensiz h&#305;zl&#305; diken-dalga veya �ok diken dalga g�r�l�r. Seyir ve
prognoz �ok de&#287;i&#351;kendir. Baz&#305; olgular remisyona girerken
baz&#305;lar&#305; Lennox-Gastaut sendromu ile kesi&#351;me g�sterir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Miyoklonik absans epilepsisi</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Nadir
rastlanan bu tabloda ba&#351;lang&#305;� genellikle 5-8 ya&#351;
aras&#305;ndad&#305;r, erkeklerde biraz daha fazlad&#305;r. Tipik absanslara
ciddi bilateral klonik atmalar e&#351;lik eder. EEG �zellikleri �AE'den
farkl&#305; de&#287;ildir. Tedaviye cevap �o&#287;unlukla k�t�d�r ve baz&#305;
di&#287;er epilepsi tiplerine �zellikle Lennox-Gastaut sendromuna ilerleme
g�r�lebilir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>d. Semptomatik Jeneralize Epilepsi Sendromlar&#305;</span></b><b><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Spesifik
Sendromlar <o:p></o:p></span></b></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Progresif miyoklonik epilepsiler (PME)</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Ba&#351;lang&#305;�
ya&#351;&#305; erken �ocukluktan eri&#351;kinli&#287;e dek olabilen bu tablodan
altta yatan �e&#351;itli, genellikle genetik ge�i&#351;li n�rodejeneratif
s�re�ler sorumludur (<b>Tablo 6 ve 7</b>). �ok say&#305;da etyolojik nedenlerin
t�m� seyrek g�r�l�r ve PME t�m epilepsilerin yakla&#351;&#305;k %1�ini
olu&#351;turur. Hepsinin ortak klinik �zellikleri genellikle post�r, aksiyon
veya d&#305;&#351; uyar&#305;lar (&#305;&#351;&#305;k, ses ve dokunma) ile
tetiklenen a&#287;&#305;r m<span style='mso-bidi-font-weight:bold'>iyoklonustur,
buna </span>JTKN ve di&#287;er n�betler eklenir. Tedaviye diren�li, giderek
&#351;iddeti artan ve mental a�&#305;dan da y&#305;k&#305;ma yol a�an
tablolard&#305;r. Demans d&#305;&#351;&#305;nda ba&#351;l&#305;ca serebellar
olmak �zere �e&#351;itli n�rolojik, oftalmolojik ve sistemik bulgular
g�r�lebilir. EEG�de tipik olarak temel aktivitede yava&#351;lama ve jeneralize
epileptiform de&#351;arjlar, &#305;&#351;&#305;k
duyarl&#305;l&#305;&#287;&#305; ve bazen fokal bulgular saptan&#305;r (<b>&#350;ekil
9</b>). Klinik olarak ba&#351;lang&#305;�ta j�venil miyoklonik epilepsi gibi
selim epilepsi sendromlar&#305;yla kar&#305;&#351;abilir ama EEG genelde bu
tablolara g�re belirgin yava&#351;t&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'><span style='mso-spacerun:yes'>�</span><span
style='mso-bidi-font-weight:bold'>En s&#305;k g�r�len PME nedenleri:<o:p></o:p></span></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Unverricht-Lundborg
hastal&#305;&#287;&#305; <o:p></o:p></span></p>

<p style='text-align:justify;tab-stops:135.75pt'><span lang=TR
style='font-family:Tahoma'>-Lafora cisimli hastal&#305;k <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Mitokondrial
ensefalopati ve �atlak k&#305;rm&#305;z&#305; lifler &quot;rugged red
fibers&quot; (MERRF) <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Sialidoz
(�cherry red spot�-miyoklonus sendromu) <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Seroid
Lipofuksinozlar olarak say&#305;labilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Di&#287;er
nadir nedenler; Gaucher tip III-a, ��lyak hastal&#305;&#287;&#305;,
��Ramsey-Hunt�� Sendromu, Gangliozidozis, Hallervorden-Spatz,
dentatorubropallidoluysian atrofi (DRPLA:CAG trin�kleotid tekrar&#305;-
Japonya�da s&#305;kt&#305;r) olarak say&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><b style='mso-bidi-font-weight:
normal'><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil9.jpg">&#350;ekil 9<span style='font-weight:normal'>.</span></a></span></u></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Progresif miyoklonik
epilepsi i�in tipik EEG bulgular&#305; olan temel aktivitede yayg&#305;n
yava&#351;lama, &#305;&#351;&#305;&#287;a duyarl&#305;l&#305;k ve jeneralize
d�zensiz �ok dikenli dalga de&#351;arjlar&#305; g�r�lmektedir. Lafora olgusu
olan bu hastada ayr&#305;ca oksipital b�lgede dikenler de dikkati �ekmektedir.<b
style='mso-bidi-font-weight:normal'><span style='color:blue'> <o:p></o:p></span></b></span></p>

<p class=MsoNormal style='margin-left:35.4pt'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:35.4pt'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><o:p>&nbsp;</o:p></span></b></p>

</div>

<b style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:14.0pt;
font-family:Tahoma;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
TR;mso-fareast-language:TR;mso-bidi-language:AR-SA'><br clear=all
style='page-break-before:always;mso-break-type:section-break'>
</span></b>

<div class=Section2>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
style='font-family:Tahoma'>Tablo 6. Miyoklonus, n�betler, ataksi ve demansla
giden klinik sendromlar&#305;n ili&#351;kisi ve kesi&#351;mesi<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=TR
style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0'>
  <td width=236 valign=top style='width:177.2pt;border-top:solid windowtext 1.0pt;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='tab-stops:2.0cm'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-top:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�betlerle
  giden progresif ensefalopatiler<o:p></o:p></span></b></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-top:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Progresif
  miyoklonik epilepsiler<o:p></o:p></span></b></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Progresif miyoklonik ataksiler<o:p></o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=236 valign=top style='width:177.2pt;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Erken klinik bulgular<o:p></o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Demans<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Miyoklonik
  n�betler <o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>tonik-klonik
  n�betler<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ataksi<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>miyoklonus<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=236 valign=top style='width:177.2pt;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Eklenen klinik bulgular<o:p></o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�betler
  veya miyoklonus (g�rece seyrek ve hafif)<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ataksi
  veya demans, progresyon<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Demans,
  tonik-klonik n�betler hafif veya yok<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=236 valign=top style='width:177.2pt;border:none;border-left:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Ba&#351;lang&#305;� ya&#351;&#305;<o:p></o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Genelde
  erken �ocukluk<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ge�
  �ocukluk veya <o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>ergenlik
  d�nemi<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-right:solid windowtext 1.0pt;
  mso-border-right-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tipik
  olarak eri&#351;kin<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Ana nedenler<o:p></o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal style='tab-stops:2.0cm'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bir
  �ok kal&#305;t&#305;msal metabolik hastal&#305;k<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Unverricht-Lundborg<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>MERRF<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Lafora
  Hastal&#305;&#287;&#305;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�ronal
  Seroid Lipofuksinozlar<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Sialidozlar<o:p></o:p></span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>MERRF<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Spinoserebellar
  dejenerasyon<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>��lyak
  hastal&#305;&#287;&#305;<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<b style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:20.0pt;
mso-bidi-font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:TR;mso-fareast-language:TR;mso-bidi-language:AR-SA'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:35.4pt'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-family:Tahoma'>Tablo 7. Progresif Miyoklonus
Epilepsileri<o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=854
 style='width:640.35pt;margin-left:19.5pt;border-collapse:collapse;border:none;
 mso-border-alt:solid windowtext 1.5pt;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
 mso-border-insideh:.75pt solid windowtext;mso-border-insidev:.75pt solid windowtext'>
 <tr style='mso-yfti-irow:0;height:11.9pt'>
  <td width=88 valign=top style='width:65.95pt;border-top:1.5pt;border-left:
  1.5pt;border-bottom:1.0pt;border-right:1.0pt;border-color:windowtext;
  border-style:solid;mso-border-top-alt:1.5pt;mso-border-left-alt:1.5pt;
  mso-border-bottom-alt:.75pt;mso-border-right-alt:.75pt;mso-border-color-alt:
  windowtext;mso-border-style-alt:solid;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt;
  height:11.9pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Hastal&#305;k<o:p></o:p></span></b></p>
  </td>
  <td width=74 valign=top style='width:55.8pt;border-top:solid windowtext 1.5pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-top-alt:solid windowtext 1.5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt;
  height:11.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Ba&#351;lang&#305;�<o:p></o:p></span></b></p>
  </td>
  <td width=202 valign=top style='width:151.85pt;border-top:solid windowtext 1.5pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-top-alt:solid windowtext 1.5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt;
  height:11.9pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Klinik
  �zellikler<o:p></o:p></span></b></p>
  </td>
  <td width=191 valign=top style='width:143.3pt;border-top:solid windowtext 1.5pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-top-alt:solid windowtext 1.5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt;
  height:11.9pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tipik
  laboratuvar �zelli&#287;i<o:p></o:p></span></b></p>
  </td>
  <td width=148 valign=top style='width:111.25pt;border-top:solid windowtext 1.5pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-left-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-top-alt:solid windowtext 1.5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt;
  height:11.9pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Genetik
  tan&#305;<o:p></o:p></span></b></p>
  </td>
  <td width=150 valign=top style='width:112.2pt;border-top:solid windowtext 1.5pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-left-alt:solid windowtext .75pt;mso-border-top-alt:1.5pt;
  mso-border-left-alt:.75pt;mso-border-bottom-alt:.75pt;mso-border-right-alt:
  1.5pt;mso-border-color-alt:windowtext;mso-border-style-alt:solid;background:
  #DBE5F1;padding:0cm 5.4pt 0cm 5.4pt;height:11.9pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tedavi<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:83.3pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:83.3pt'>
  <p class=MsoNormal style='margin-right:-17.25pt'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Unverricht-<o:p></o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Lundborg
  <o:p></o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Hastal&#305;&#287;&#305;<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>6-18
  ya&#351;<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Uyarana
  duyarl&#305; (&#305;&#351;&#305;k, ses, dokunma)
  k&#305;s&#305;tl&#305;l&#305;k yaratan a&#287;&#305;r miyokloniler; ataksi
  hafif, JTK kontrol� g�rece kolay, demans hafif/ yok<o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Yok<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>T�m
  PME lerde g�r�lebilen EEG, dev SEP ve di&#287;er bulgular&#305; var<o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Otozomal resesif<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>21q22.3; EPM1<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Sistatin
  B geninde mutasyon (Dodekamer ekspansiyonu veya nokta mutasyonlar&#305;)<o:p></o:p></span></p>
  </td>
  <td width=150 style='width:112.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Palyatif,
  semptomatik (valproik asit, +klonazepam, y�ksek doz pirasetam, levetirasetam,
  zonisamid, topiramat).<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Karbamazepin,
  fenitoin gibi ila�lardan ka�&#305;n&#305;lmal&#305;!<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:83.3pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:83.3pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Lafora
  Hastal&#305;&#287;&#305;<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:83.3pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>10-19<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Miyokloni,
  oksipital n�betler, atipik absanslar, atonik, kompleks parsiyel n�betler,
  a&#287;&#305;r demans<o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Deri, karaci&#287;er veya
  beyin biyopsisinde &#305;&#351;&#305;k mikroskopisiyle Lafora cisimleri<o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Otozomal resesif<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>EPM2; Laforin ve malin
  genlerinde mutasyonlar <o:p></o:p></span></p>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>-Delesyonlar<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>-Nokta
  mutasyonlar&#305; <o:p></o:p></span></p>
  </td>
  <td width=150 style='width:112.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Palyatif,
  semptomatik (valproik asit, +klonazepam, y�ksek doz pirasetam, levetirasetam,
  zonisamid, topiramat)<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Karbamazepin,
  fenitoin gibi ila�lardan ka�&#305;n&#305;lmal&#305;!<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:59.5pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:59.5pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>MERRF<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:59.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Her ya&#351;<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  59.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  color:black'>Serebellar ataksi, miyokloni,</span><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'> miyopati, n�ropati, i&#351;itme
  kayb&#305;, demans geri planda, k&#305;sa boy, optik atrofi, i&#351;itme
  kayb&#305; <o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  59.5pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Kan veya BOS laktat </span><span
  lang=TR style='font-size:10.0pt;font-family:Wingdings;mso-ascii-font-family:
  Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:Tahoma;mso-char-type:
  symbol;mso-symbol-font-family:Wingdings'><span style='mso-char-type:symbol;
  mso-symbol-font-family:Wingdings'>�</span></span><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>, anormal kas MR spektroskopisi <o:p></o:p></span></p>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Kas biyopsisinde
  k&#305;rm&#305;z&#305; �atlak lifler (%90)<span style='mso-spacerun:yes'>�
  </span><o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  59.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Maternal
  kal&#305;t&#305;m, mitokondrial DNA�da tRNA da nokta mutasyonlar&#305;<o:p></o:p></span></p>
  </td>
  <td width=150 style='width:112.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:59.5pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ampirik
  ; antioksidan vitamin kombinasyonlar&#305; ve koenzimQ ve L-karnitin<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�bet
  tedavisi i�in VPA�dan ka�&#305;n&#305;lmal&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:71.4pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:71.4pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>NSL
  Ge� infantil<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:71.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>2,5-4<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  71.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  color:black'>Miyoklonik, tonik-klonik, atonik, atipik absans n�betleri</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  71.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Deri,
  rektal/beyin biopsisinde elektron mikroskopisiyle kurvilinear profiller<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>-F<span
  style='color:black'>ibroblast/l�kositlerde azalm&#305;&#351;/ saptanamayan
  TPP1 enzim akt.</span><o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  71.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>11p15
  Lizozomal proteaz nokta mutasyonlar&#305;,<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=150 valign=top style='width:112.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:71.4pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semptomatik,
  palyatif </span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:35.7pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:35.7pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>NSL
  J�venil<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:35.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>4-10<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  35.7pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  color:black'>G�rme bozuklu&#287;u, demans, dizartri, ataksi, ekstrapiramidal
  �zellikler</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  35.7pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Kanda
  vakuoll� lenfositler, deri biyopsisinde/lenfositlerde <span style='color:
  black'>parmak izi profilleri</span><o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  35.7pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>16p12 Membran protein 1
  kb delesyonu<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>-Nokta mutasyonlar&#305;<o:p></o:p></span></p>
  </td>
  <td width=150 valign=top style='width:112.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:35.7pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semptomatik,
  palyatif </span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:23.8pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:23.8pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>NSL Eri&#351;kin<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:23.8pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>11-50<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  23.8pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  color:black'>Demans, ataksi, ekstrapiramidal bulgular, Miyokloni<span
  style='mso-spacerun:yes'>� </span></span><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  23.8pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Garan�ler
  osmiofilik depositler/ Parmak izi profilleri<o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  23.8pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>?<o:p></o:p></span></p>
  </td>
  <td width=150 valign=top style='width:112.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:23.8pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semptomatik,
  palyatif </span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:83.3pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-alt:solid windowtext .75pt;
  mso-border-left-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:83.3pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Sialidozlar<o:p></o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tip
  I<o:p></o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tip
  II<o:p></o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:83.3pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>8-20<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>10-30<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>a&#287;&#305;r
  miyokloni, fundusta cherry-red spot, tonik-klonik n�bet, ataksi <o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>dismorfizm,
  korneada bulutlanma, hepatomegali,<span style='color:black'> iskelet
  displazisi, �&#287;renme bozuklu&#287;u</span><o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  color:black'>&#304;drar kromatografide artm&#305;&#351; siyali���l-oligosakkaritler,
  <o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  color:black'>-l�kosit/ fibroblast k�lt�rlerinde lizozomal enzim defekti (</span><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>a&#287;&#305;r
  n�roaminidaz eksikli&#287;i (tip I ve II) ve parsiyel </span><span lang=TR
  style='font-size:10.0pt;font-family:Symbol;mso-ascii-font-family:Tahoma;
  mso-hansi-font-family:Tahoma;mso-bidi-font-family:Tahoma;mso-char-type:symbol;
  mso-symbol-font-family:Symbol'><span style='mso-char-type:symbol;mso-symbol-font-family:
  Symbol'>b</span></span><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'>-galaktosidaz eksikli&#287;i (tipII)<o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;padding:0cm 5.4pt 0cm 5.4pt;height:
  83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Otozomal
  resesif;<o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>6p21.3
  nokta mutasyonlar&#305;<o:p></o:p></span></p>
  </td>
  <td width=150 style='width:112.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-right-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:83.3pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semptomatik,
  palyatif <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-yfti-lastrow:yes;height:47.6pt'>
  <td width=88 style='width:65.95pt;border-top:none;border-left:solid windowtext 1.5pt;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-top-alt:.75pt;
  mso-border-left-alt:1.5pt;mso-border-bottom-alt:1.5pt;mso-border-right-alt:
  .75pt;mso-border-color-alt:windowtext;mso-border-style-alt:solid;padding:
  0cm 5.4pt 0cm 5.4pt;height:47.6pt'>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>DRPLA<o:p></o:p></span></b></p>
  </td>
  <td width=74 style='width:55.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;mso-border-alt:
  solid windowtext .75pt;mso-border-bottom-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.6pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Her ya&#351;<o:p></o:p></span></p>
  </td>
  <td width=202 style='width:151.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-bottom-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Serebellar
  atrofi, ataksi, koreatetoz, miyokloni, epilepsi, demans, psikiyatrik
  semptomlar<o:p></o:p></span></p>
  </td>
  <td width=191 style='width:143.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-bottom-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>MRG
  bulgular&#305; destekleyici<o:p></o:p></span></p>
  </td>
  <td width=148 style='width:111.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  mso-border-alt:solid windowtext .75pt;mso-border-bottom-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>12p13
  <o:p></o:p></span></p>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>-CAG
  ekspansiyon Anormal CAG tekrar&#305;n&#305;n g�sterilmesi<o:p></o:p></span></p>
  </td>
  <td width=150 style='width:112.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext .75pt;mso-border-left-alt:solid windowtext .75pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.6pt'>
  <p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Semptomatik<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoFooter><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>NSL: N�ronal seroid lipofuksinoz<o:p></o:p></span></p>

</div>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:TR;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always;mso-break-type:section-break'>
</span>

<div class=Section3>

<p style='text-align:justify'><a name="d._Fokal_veya_jeneralize_oldu&#287;u_belirlen"></a><b><span
lang=TR style='font-family:Tahoma'>e. Fokal veya Jeneralize Oldu&#287;u
Belirlenemeyen Baz&#305; Epilepsi Sendromlar&#305;</span></b><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>S�t �ocu&#287;unun a&#287;&#305;r miyoklonik
epilepsisi</span></i></b><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Genellikle
ilk aylarda veya ilk y&#305;l i�inde normal bir bebekte jeneralize veya fokal
miyoklonik n�betler geli&#351;ir. Febril bir status epileptikus olarak
ba&#351;layabilir. Psikomotor geli&#351;im ikinci y&#305;l i�inde geriler.
Tablo ila�lara diren�lidir. EEG�de jeneralize diken-dalga, fokal bulgular ve
fotosensitivite g�r�l�r. Ailesel olgular s&#305;kt&#305;r. Bu tablonun Ohtahara
sendromu (EEG'de burst-s�presyonlarla giden erken infantil epileptik
ensefalopati) ve erken miyoklonik ensefalopati ile kesi&#351;en y�nleri
oldu&#287;u d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Landau-Kleffner sendromu</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>�ok
nadir olan bu tablo konu&#351;may&#305; normal olarak �&#287;renmi&#351; olan
3-10 ya&#351; aras&#305; bir �ocukta konu&#351;man&#305;n kaybolmas&#305; (<i
style='mso-bidi-font-style:normal'>edinsel epileptik afazi</i>) ve bunu genellikle
izleyen parsiyel motor ve JTK tipte epileptik n�betlerle ortaya �&#305;kar. EEG
bulgular&#305; tan&#305; koydurur (<b>&#350;ekil 10</b>). Patofizyolojisi
ayd&#305;nlat&#305;lamam&#305;&#351; olan bu tabloda ilerleyen ya&#351;la
birlikte genellikle remisyon g�r�l�r. Ancak hastalarda baz&#305;
davran&#305;&#351; problemleri ve ileti&#351;im g��l�&#287;� kal&#305;c&#305;
olabilmektedir. Tedavisinde klinik deneyimlerimize g�re en etkili ila�
steroidin yan&#305; s&#305;ra klonazepamd&#305;r. Baz&#305; olgularda CSWSS
(continiuous spike and waves during slow wave sleep) tablosu g�r�lebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><b
style='mso-bidi-font-weight:normal'><u><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:blue'>&#350;ekil 10.</span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> Landau-Kleffner Sendromu
tan&#305;s&#305; ile izlenen <span style='mso-bidi-font-weight:bold'>9
ya&#351;&#305;ndaki erkek </span>hasta; <span style='mso-bidi-font-weight:bold'>7
ya&#351;&#305;nda ba&#351;layan jeneralize tonik klonik n�betlerine 7 ay sonra
eklenen edinsel afazi nedeniyle �ocuk n�rolojisi birimine
ba&#351;vurmu&#351;tur. EEG incelemesinde uykuyla aktive olan, frontotemporal b�lgelerde
birbirinden ba&#287;&#305;ms&#305;z diken-dalga de&#351;arjlar&#305; ile <b><u><span
style='color:blue'><a href="sekil10a.bmp">&#350;ekil10a.</a></span></u></b>
yava&#351; uyku s&#305;ras&#305;nda devaml&#305; diken-dalga aktivitesi
izlenmektedir <b><u><span style='color:blue'><a href="sekil10b.bmp">&#350;ekil10b.</a></span></u></b><o:p></o:p></span></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:#0070C0'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>f.
�zel (�zg�n) Sendromlar</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Duruma
Ba&#287;l&#305; N�betler</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Febril n�bet (febril konv�lz�yon,
ate&#351;li havale)</span></i></b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Merkezi
sinir sistemi infeksiyonu veya kronik bir beyin hastal&#305;&#287;&#305;
olmaks&#305;z&#305;n, 6 ay-5 ya&#351; (3ay-6 ya&#351;) aras&#305; normal
�ocuklarda ate&#351;li d�nemlerde ortaya �&#305;kan n�betlerdir ve g�r�lme
s&#305;kl&#305;&#287;&#305; toplumlara g�re de&#287;i&#351;mekle birlikte % 3-5
aras&#305;d&#305;r. Febril n�bet (FN) ge�iren bir olguda n�rolojik durum ve
geli&#351;im, koinsidental olabilecek baz&#305; bulgular d&#305;&#351;&#305;nda
t�m�yle normal olmal&#305;d&#305;r. FN�lerin yakla&#351;&#305;k � '� basit FN
olarak gruplanabilir. Bu grupta konv�lz�yon 15 dakikadan k&#305;sa s�rer,
kas&#305;lmalar jeneralizedir ve n�rolojik bulgu yoktur. Komplike FN olarak
s&#305;n&#305;flanan grubun ise n�beti uzundur (ya da status epileptikus
&#351;eklindedir), fokal kas&#305;lma g�r�l�r ve Todd parezisi gibi baz&#305;
n�rolojik bulgular e&#351;lik edebilir. Olgular&#305;n %30�unda FN tekrarlar ve
bunlar&#305;nda yine 1/3'�nde 3. bir n�bet daha g�r�l�r. FN ge�iren olgularda
epilepsi geli&#351;me riski %2-5 olarak bildirilmi&#351;tir. Bu bu oran normal
pop�lasyonun riskinden �ok da y�ksek de&#287;ildir. Ancak komplike FN �yk�s�
ile diren�li bir mezyal temporal lob epilepsisi geli&#351;tirme
a�&#305;s&#305;ndan anlaml&#305; bir ba&#287;lant&#305; oldu&#287;u
g�sterilmi&#351;tir. Bu ili&#351;kide neden-sonu� ba&#287;lant&#305;s&#305;
&#351;u anda tam olarak ayd&#305;nlat&#305;lamam&#305;&#351;t&#305;r. FN'de
profilaktik tedavi verilmesi tart&#305;&#351;mal&#305;d&#305;r. Profilaksinin
n�bet tekrar&#305;n&#305; ve epilepsi geli&#351;imini engelledi&#287;ini
g�steren somut bir kan&#305;t g�sterilememi&#351;tir. Tekrarlayan ve uzun
FN'leri olan olgularda n�beti durdurmak i�in rektal diazepam uygulamas&#305;
kolay ve etkili bir y�ntem olarak kabul edilmektedir. Aileler ate&#351;
kontrol� a�&#305;s&#305;ndan e&#287;itilmelidir.<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Refleks N�betler ve Epilepsi <o:p></o:p></span></i></b></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>Refleks epilepsi</span></i><span
lang=TR style='font-family:Tahoma'> herhangi bir duysal d&#305;&#351; uyarana
ba&#287;l&#305; olarak geli&#351;en ve tekrarlayan epileptik n�betler
durumudur. <i style='mso-bidi-font-style:normal'>Refleks n�betler</i> ise �zg�n
bir uyarana kar&#351;&#305; daima veya hemen daima ortaya �&#305;kan
n�betlerdir. Duysal alg&#305;lar&#305;n refleks n�betleri tetikledi&#287;i
19.y�zy&#305;ldan �nce de bilinmektedir. Y&#305;llar i�inde �e&#351;itli
refleks epilepsi sendromlar&#305; tan&#305;mlanm&#305;&#351;t&#305;r, en
s&#305;k g�r�leni %75-80 oran&#305;yla &#305;&#351;&#305;&#287;a duyarl&#305;
gruptur.<span style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>&#304;lk kez 1989 ILAE sendrom s&#305;n&#305;flamas&#305;nda, �zel
uyaranlarla ortaya �&#305;kan epilepsi tan&#305;m&#305; konulmu&#351;tur. 2001
y&#305;l&#305;ndaki s&#305;n&#305;flamada <span style='mso-bidi-font-weight:
bold'>refleks n�betleri ortaya �&#305;karan uyaranlar; g�rsel uyaranlar
(yan&#305;p s�nen &#305;&#351;&#305;klar, </span>paternler, di&#287;er g�rsel
uyaranlar), d�&#351;�nme, m�zik, yemek yeme, praksi, somatik duysal, propriyoseptif,
okuma, s&#305;cak su, �startle� olarak belirtilmi&#351;tir.<span
style='mso-bidi-font-weight:bold'> Refleks epilepsiler; idyopatik fotosensitif
oksipital lob</span> epilepsisi, di&#287;er g�rsel sensitif epilepsiler, primer
okuma epilepsisi ve �startle� epilepsisi olarak 2001 s&#305;n&#305;flama
�nerisinde yer almaktad&#305;r. <span style='mso-bidi-font-weight:bold'>Refleks
epilepsi sendromlar&#305;nda g�r�len epileptik n�betler fokal veya jeneralize;
erken veya ge� latansl&#305;; basit uyarana ba&#287;l&#305; veya
karma&#351;&#305;k uyaranlara ba&#287;l&#305; olabilir. Spontan n�betler de
e&#351;lik edebilir. &#304;zole refleks n�bet g�r�ld�&#287;�nde bu ki&#351;inin
epilepsi tan&#305;s&#305; almas&#305;n&#305; gerektirmez. Alkol�n
b&#305;rak&#305;lmas&#305; veya ate&#351; gibi �zel durumlarda ortaya
�&#305;km&#305;&#351; olan n�betler refleks n�bet de&#287;ildir. </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>Fotosensitivite:</span></i><b
style='mso-bidi-font-weight:normal'><span lang=TR style='font-family:Tahoma'> </span></b><span
lang=TR style='font-family:Tahoma'>Klinik olarak &#305;&#351;&#305;k
uyaranlarla tetiklenen n�betler refleks fotosensitif n�betlerdir. Epileptik
hastalar&#305;n yakla&#351;&#305;k %5�inde EEG�de &#305;&#351;&#305;k
duyarl&#305;l&#305;&#287;&#305; g�r�l�r Bu oran idyopatik jeneralize
epilepsilerde %21� e kadar y�kselir. &#304;JE sendromlar&#305; i�inde �zellikle
JME ve sabah uyan&#305;rken olan jeneralize tonik-klonik n�betlerde; �AE ve
di&#287;er &#304;JE sendromlar&#305;na g�re daha fazlad&#305;r.
Fotosensitivitenin ya&#351; ve cinsiyete ba&#287;l&#305; penetrans g�steren,
otozomal dominant bir kal&#305;t&#305;m paterni vard&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>Aral&#305;kl&#305; &#305;&#351;&#305;k uyaran&#305;na kar&#351;&#305;
olu&#351;an yan&#305;ta g�re &#305;&#351;&#305;&#287;a duyarl&#305;l&#305;k 3
alt grupta incelenebilir:<o:p></o:p></span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l60 level1 lfo19;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma'>Sadece
     &#305;&#351;&#305;k uyaranla n�bet ge�irenler<o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l60 level1 lfo19;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma'>I&#351;&#305;k
     uyaranla ya da uyaran olmadan n�bet ge�irenler<o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l60 level1 lfo19;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma'>EEG�de
     &#305;&#351;&#305;&#287;a duyarl&#305;l&#305;&#287;&#305; saptanan
     asemptomatik ki&#351;iler<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>I&#351;&#305;&#287;a duyarl&#305;l&#305;k belirgin olarak ya&#351;a
ba&#287;&#305;ml&#305;l&#305;k g�sterir ve en fazla g�r�lme ya&#351;lar&#305;
10-15 ya&#351; aras&#305;ndad&#305;r. Kad&#305;nlarda 10-25
ya&#351;lar&#305;nda g�rsel uyaran ile ortaya �&#305;kan n�bet ve EEG�de
fotoparoksismal yan&#305;t s&#305;k g�r�l�r. Kad&#305;n/Erkek oran&#305; 1.5-2
civar&#305;ndad&#305;r. Fotosensitif epilepsinin t�m d�nyada
tan&#305;nmas&#305; Pokemon isimli �izgi film ile olmu&#351;tur. Bu y�ksek kontrastl&#305;
g��l� &#305;&#351;&#305;k uyaran i�eren �izgi filmi 16 Aral&#305;k 1997
y&#305;l&#305;nda Japonya�da seyreden yakla&#351;&#305;k 685 �ocuk n�bet
ge�irme nedeniyle acillere ba&#351;vurmu&#351;tur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-right:3.5pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-right:3.5pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>I&#351;&#305;&#287;a duyarl&#305; refleks epilepsili
olgularda �e&#351;itli &#305;&#351;&#305;k kaynaklar&#305; rol oynayabilir. En
s&#305;k bildirilen &#305;&#351;&#305;k kayna&#287;&#305; TV�dir. TV ile
birlikte veya ayr&#305; olarak bilgisayar ekran&#305;, video oyunlar&#305; da
uyaran olarak rol oynamaktad&#305;r. G�ne&#351;
&#305;&#351;&#305;&#287;&#305;n&#305;n direkt &#351;ekilde veya
a&#287;a�l&#305; bir yolda aral&#305;kl&#305; yans&#305;mas&#305;, lamba
&#305;&#351;&#305;&#287;&#305;, e&#287;lence yerlerinde yan&#305;p s�nen renkli
ve parlak &#305;&#351;&#305;klar, paternler, fotosensitif olgularda di&#287;er
uyaranlard&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-right:3.5pt;text-align:justify'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'>Patern
duyarl&#305;l&#305;&#287;&#305;:</span></i><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'> </span></b><span lang=TR style='font-family:
Tahoma'>Aral&#305;kl&#305; &#305;&#351;&#305;k uyaran&#305;n&#305;n
ard&#305;ndan en s&#305;k g�r�len g�rsel tetikleyicidir. Patern
duyarl&#305;l&#305;&#287;&#305;n&#305;n fotosensitivite ile yak&#305;n
ili&#351;kisi bilinmekte ve patern-fotosensitif birlikteli&#287;i %70�e varan
oranda bildirilmektedir. Hastalar �izgili duvar ka&#287;&#305;tlar&#305;,
d�&#351;emeler, �niformalar, y�r�yen merdiven, &#305;zgaralar, radyat�rler, �st
�ste duran tabaklar&#305; uyaran olarak bildirmektedir. Paterne duyarl&#305;
hastalar ile &#305;&#351;&#305;&#287;a duyarl&#305; hastalar aras&#305;nda
demografik farkl&#305;l&#305;k, klinik farkl&#305;l&#305;k bildirilmemi&#351;tir.
Ailesel �zellik s&#305;kt&#305;r.<span style='background:aqua;mso-highlight:
aqua'><o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;background:aqua;mso-highlight:aqua'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>�Startle� Epilepsi:</span></i><b
style='mso-bidi-font-weight:normal'><span lang=TR style='font-family:Tahoma'> </span></b><span
lang=TR style='font-family:Tahoma'>Startle epilepsi ani, beklenmedik ses veya
somatosensoryel uyar&#305; ile tetiklenen n�betlerle karakterizedir. N�betler
genellikle jeneralize toniktir, fakat parsiyel olabilir ve genellikle
semptomatik k�kenlidir. Startle n�betlerinin epileptojenik bir fokusun
proprioseptif uyaran ile aktivasyonuna ba&#287;l&#305; oldu&#287;u
d�&#351;�n�lmektedir. Startle epilepsi epileptik k�kenli olmayan startle
(irkilme) reaksiyonlar&#305;ndan ay&#305;rt edilmelidir.<span
style='mso-spacerun:yes'>��� </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>S&#305;cak Su Epilepsisi:</span></i><b
style='mso-bidi-font-weight:normal'><span lang=TR style='font-family:Tahoma'> </span></b><span
lang=TR style='font-family:Tahoma'>Banyo s&#305;ras&#305;nda s&#305;cak suyun
etkisiyle olu&#351;an epilepsi, s&#305;cak su epilepsisi veya banyo epilepsisi
olarak adland&#305;r&#305;lmaktad&#305;r. Avustralya, Japonya, &#304;ngiltere
gibi �lkelerden izole olgular bildirilmektedir. Buna kar&#351;&#305;l&#305;k
Satichandra ve ark. 4 y&#305;l i�inde saptanan 279 vaka ile G�ney Hindistan�dan
geni&#351; bir seri bildirmi&#351;lerdir. Bu b�lgenin iklim
ko&#351;ullar&#305;, banyo s&#305;ras&#305;nda a&#351;&#305;r&#305; s&#305;cak
su ile ba&#351;&#305;n �st�ne d�k�n�lerek y&#305;kan&#305;lmas&#305; ve genetik
�zelliklerin etkisi vurgulanmaktad&#305;r. Bu nedenle toplumlar aras&#305;
k�lt�rel farkl&#305;l&#305;klar, co&#287;rafi �zellikler, genetik fakt�rler ve
sosyal al&#305;&#351;kanl&#305;klar&#305;n rol�
tart&#305;&#351;&#305;lmaktad&#305;r. S&#305;cak su epilepsisi, �zg�n bir
d&#305;&#351; uyaran olan �s&#305;cak su ile y&#305;kanma� s&#305;ras&#305;nda
ortaya �&#305;kan kompleks parsiyel n�betlerle karakterize refleks epilepsi
t�r�d�r. En s&#305;k erkek �ocuklarda rastlan&#305;r, iyi seyirlidir, aylar ya
da y&#305;llar i�inde remisyon beklenir. Ancak 40 ya&#351;&#305;ndan sonra dahi
ortaya �&#305;kabilir. Di&#287;er taraftan spontan n�betler de
geli&#351;ebilir. N�betten yo&#287;un haz duyma ve bilin� kayb&#305;
olu&#351;uncaya kadar kompulsif bir &#351;ekilde su d�k�nmeyi s�rd�rme yani
self-ind�ksiyon �o&#287;u olgular i�in en dikkat �ekici �zelliklerinden
biridir. N�rolojik muayene normaldir, str�kt�rel lezyon genellikle
bulunmamaktad&#305;r. Yurdumuzda Avrupa �lkelerine g�re s&#305;k rastland&#305;&#287;&#305;
g�r�len bu tabloda genelde temporal b�lgede epilepsi oda&#287;&#305; dikkati
�ekmektedir ve genetik �zellik oldu&#287;unu d�&#351;�nd�ren ailesel olgular
vard&#305;r. En s&#305;k banyo s&#305;ras&#305;nda s&#305;cak suyun ba&#351;tan
a&#351;a&#287;&#305; d�k�lmesiyle ortaya �&#305;kar. �ok defa fokal belirtilere
yol a�an n�betlerdir. Uyaran&#305;n �zellikleri ki&#351;iden ki&#351;iye
de&#287;i&#351;kenlik g�sterebilir; so&#287;uk su ile veya k�vette
y&#305;kanma, du&#351; alma, hatta elini so&#287;uk su dolu kovaya sokma,
ya&#287;mur damlas&#305;n&#305;n v�cuda de&#287;mesi vb. n�bet i�in
uyar&#305;c&#305; olabilir. Doktora az ba&#351;vurulmas&#305; ve banyodaki
self-ind�ksiyonla tetiklenen n�betlerin gizlenmesi s�z konusu olabilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>Okuma Epilepsisi: </span></i><span
lang=TR style='font-family:Tahoma'>Okuma epilepsisi, idyopatik (primer) ve daha
az oranda semptomatik epilepsi olarak alt gruplara ayr&#305;l&#305;r. Primer
okuma epilepsisinde spontan n�betler olmaks&#305;z&#305;n sadece okuma ile
ortaya �&#305;kan �enede atma kas&#305;lma &#351;eklinde n�betler g�r�l�r.
Genellikle ba&#351;lang&#305;� ya&#351;&#305; ergenlik d�nemidir. %40-50�sinde
herediter �zellik g�r�lm�&#351;t�r ve JME�li baz&#305; olgularda
g�r�lebildi&#287;ine dikkat �ekilmi&#351;tir. Erkek/Kad&#305;n
oran&#305;:1.8�dir. Geli&#351;im �yk�s�, n�rolojik muayene, interiktal EEG ve
g�r�nt�leme tetkikleri (BT; MRG) normaldir. N�betlerin sessiz veya y�ksek sesle
okuma ile ortaya �&#305;kmas&#305;n&#305;n d&#305;&#351;&#305;nda; 1/4�inde
heyecanl&#305; veya tart&#305;&#351;mal&#305; bir konu&#351;ma
s&#305;ras&#305;nda da n�bet g�r�lebilir. Olgular&#305;n bir k&#305;sm&#305;nda
yaz&#305; yazma s&#305;ras&#305;nda kulland&#305;&#287;&#305; kolda ya
s&#305;�rama ya da kas&#305;lma olur (grafojenik epilepsi). Sekonder okuma
epilepsisi olanlarda ise spontan n�betler ile birlikte okuma ve
&#305;&#351;&#305;k uyaran ile ind�klenen n�betler g�r�l�r. Oral miyoklonik
atmalar yoktur ve interiktal EEG anormaldir. G�r�nt�lemelerde lezyon
g�r�lebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Yemek yeme
epilepsisi:</span></i><b style='mso-bidi-font-weight:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Epilepsi
s&#305;n&#305;flamalar&#305;nda hen�z ayr&#305; bir epilepsi sendromu olarak
yerini alamam&#305;&#351;t&#305;r. �ok nadir g�r�l�r. Epilepsisi olanlarda
prevalans&#305; 1/1000-2000 olarak bulunmu&#351;tur, ancak Sri Lanka�dan hayli
y�ksek de&#287;erler bildirilmi&#351;tir. Daha k&#305;sa latansl&#305; yutma
ile tetiklenen ve uzun latansl&#305; kompleks tetik gerektiren tipleri
bildirilmi&#351;tir. Genelde sol temporal b�lgede aktif epileptiform anomali
saptan&#305;r ve �zge�mi&#351;te bir tetikleyici olay �yk�s� vard&#305;r,
erkeklerde s&#305;kt&#305;r. Yemek yeme epilepsisi olan hastalarda spontan
n�betler de g�r�lebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>M�zikojenik
Epilepsi:</span></i><b style='mso-bidi-font-weight:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>M�zik ile tetiklenen n�betlerdir,
ilk kez 1936 y&#305;l&#305;nda tan&#305;mlanm&#305;&#351;t&#305;r. M�zikojenik
epilepsi �ok nadirdir, prevalans&#305; 1/10.000.000 olarak tahmin edilmektedir
ve tan&#305;da g��l�k nedeniyle az tan&#305; kondu&#287;u d�&#351;�n�lmektedir.
Erkeklerde (%76) daha s&#305;k g�r�lmektedir. Ba&#351;lang&#305;�
ya&#351;&#305; 11-39 aras&#305;nda, ortalama ya&#351; 14 d�r. Farkl&#305; m�zik
�e&#351;itlerinde (caz, klasik m�zik, folk par�alar&#305; vb) ki&#351;iye g�re
de&#287;i&#351;en, sesin y�ksekli&#287;i, ortamdan etkilenme, afektif
i�eri&#287;i de olabilen farkl&#305; uyaranlar bildirilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>D�&#351;�nme
ve belli uzaysal g�revlerle ortaya �&#305;kan n�betler:</span></i><b
style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Uyaranlar; matematik, yaz&#305; yazmak, resim yapmak, karar
vermek, ka&#287;&#305;t oyunu oynamak, satran� vb oyunlar&#305; oynamak ve
d�&#351;�nmektir. �ok ender rastlanan tablolard&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma'>EP&#304;LEPS&#304;L&#304; HASTANIN
DE&#286;ERLEND&#304;R&#304;LMES&#304; <o:p></o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>ANAMNEZ
VE MUAYENE</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi
n�beti bir semptomdur. Altta yatan �ok say&#305;da sebepten hangisinin sorumlu
oldu&#287;unu bulmak kimi zaman sadece iyi al&#305;nm&#305;&#351;
ayr&#305;nt&#305;l&#305; bir anamnezle (�rne&#287;in tipik genetik ge�i&#351;li
idyopatik jeneralize ve parsiyel epilepsi sendromlar&#305;nda oldu&#287;u gibi)
m�mk�nd�r. Bazen en ayr&#305;nt&#305;l&#305; MRG gibi yap&#305;sal g�r�nt�leme
y�ntemleri uygulanm&#305;&#351; bir hastada kan kalsiyum d�zeyi
bak&#305;lmad&#305;&#287;&#305; i�in ger�ek etyoloji
anla&#351;&#305;lamayabilir. Epilepsi tan&#305;s&#305; ve
de&#287;erlendirmesinde anamnezde hastan&#305;n perinatal �yk�s�, geli&#351;me
basamaklar&#305;, kafa travmas&#305;, MSS infeksiyonu, ailede epilepsi ve
di&#287;er s&#305;k g�r�len hastal&#305;klar&#305;n defalarca ve
ayr&#305;nt&#305;l&#305; bir &#351;ekilde sorgulanmas&#305; �ok �nem
ta&#351;&#305;maktad&#305;r. Hastal&#305;&#287;&#305;n ba&#351;lang&#305;�
ya&#351;&#305; da etyolojik a�&#305;dan �nem ta&#351;&#305;r. Epilepsi n�beti
beynin hemen her hastal&#305;&#287;&#305;n&#305;n sonucu olabilece&#287;i gibi
sistemik bir�ok hastal&#305;kta ve iyatrojenik �e&#351;itli nedenlerle de
epileptik n�bet olu&#351;abilece&#287;i (intoksikasyonlar, postoperatif
metabolik anoksik nedenler, �e&#351;itli ila�lar&#305;n terap�tik dozda bile
epilepsi e&#351;i&#287;ini d�&#351;�rmesine ba&#287;l&#305; olarak vb.)
unutulmamal&#305;d&#305;r. Bu nedenle �ok ayr&#305;nt&#305;l&#305; anamnez
al&#305;nmas&#305;n&#305; izleyerek detayl&#305; bir n�rolojik ve sistemik
muayene mutlaka yap&#305;lmal&#305;d&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>ETYOLOJ&#304;<o:p></o:p></span></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsiye
yol a�an ba&#351;l&#305;ca nedenler: <o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Bilinmeyen
(muhtemelen genetik)<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Bilinen
genetik-kromozomal anormallikler<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Perinatal
hasarlar<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>MSS
infeksiyonlar&#305;<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>T�m�rler<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Serebrovask�ler
hastal&#305;klar<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Kafa
travmas&#305;<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Dejeneratif
beyin hastal&#305;klar&#305;<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Metabolik
ve hormonal hastal&#305;klar<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>&#304;la�lar
ve<span style='mso-spacerun:yes'>� </span>alkol yoksunlu&#287;u <o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l22 level1 lfo21;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:"Comic Sans MS";mso-fareast-font-family:"Comic Sans MS";
mso-bidi-font-family:"Comic Sans MS"'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Di&#287;erleri
(porfiri, eklampsi vb)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='text-align:justify'><a name="Epileptik_Hastan&#305;n_De&#287;erlendirilmesinde"></a><b><span
lang=TR style='font-family:Tahoma'>LABORATUAR &#304;NCELEMELER&#304;</span></b><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epileptik
hastan&#305;n tan&#305;s&#305;nda ve takibinde klinik de&#287;erlendirmenin
�nceli&#287;i ve vazge�ilmez oldu&#287;u yads&#305;namaz bir ger�ektir. Bununla
birlikte g�n�m�zde �e&#351;itli laboratuvar y�ntemleri bu konuda hekime �ok
yararl&#305; bilgiler sunacak duruma gelmi&#351;tir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Elektroensefalografi (EEG) <o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;lk
olarak 1940'larda kullan&#305;lmaya ba&#351;layan bu y�ntem bug�n i�in de
epilepsi biliminin temel dire&#287;ini olu&#351;turmaktad&#305;r. EEG beyindeki
geni&#351; bir n�ron grubunun elektriksel aktivitesindeki dalgalanman&#305;n
kay&#305;tlanmas&#305; ilkesine dayanmaktad&#305;r. Sa�l&#305; deriden
kay&#305;tlanan potansiyellerin �o&#287;u piramidal h�crelerdeki toplam
sinaptik potansiyellerin ekstrasell�ler ak&#305;mlarla ili&#351;kisinin
sonucudur (ayr&#305;ca bak&#305;n&#305;z: Sinir Sistemi Semiyolojisi, <u><span
style='color:#0070C0'><a href="../semi2/eeg.htm">Elektroensefalografi</a>)</span></u>.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Rutin
EEG ilk n�betle gelen hastada en �nemli testtir. Zemin aktivitesinde belirgin
asimetri veya yava&#351;lama, epileptiform de&#351;arjlar (diken, keskin ve
diken-dalga de&#351;arjlar&#305;) elektroklinik sendromlar hakk&#305;nda bilgi
verir. Her EEG anomalisinin epilepsi ile e&#351;de&#287;er
olmad&#305;&#287;&#305; ve normal bir EEG�nin epilepsiyi d&#305;&#351;lamayaca&#287;&#305;
unutulmamal&#305;d&#305;r. &#304;lk EEG�de % 50 oran&#305;nda tipik
epileptiform anomali saptan&#305;rken tekrarlanan EEG�lerde ise bu oran
y�kselmekte ve %80-90�a ula&#351;maktad&#305;r. Aktivasyon y�ntemlerinin iyi
uygulanmas&#305; esast&#305;r, gerekirse uyku kay&#305;tlar&#305;, n�betler
s&#305;ksa video-EEG monit�rizasyonu yap&#305;lmal&#305;d&#305;r. EEG zemin
aktivitesi postiktal d�nem d&#305;&#351;&#305;nda idyopatik epilepsilerde
normaldir, yava&#351;lama semptomatik epilepsiyi d�&#351;�nd�r�r. Epileptiform
de&#351;arjlar fokal, lateralize ve jeneralize olabilir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>EEG'nin
epileptik olgunun de&#287;erlendirilmesine ba&#351;l&#305;ca
katk&#305;lar&#305;n&#305; 3 ana maddede �zetlemek olas&#305;d&#305;r: <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:71.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l30 level1 lfo23;tab-stops:list 71.4pt'><![if !supportLists]><span
lang=TR style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Klinik
olarak konulmu&#351; olan tan&#305;n&#305;n desteklenmesi ve do&#287;ru
tan&#305; konmas&#305;na yard&#305;m <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:71.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l30 level1 lfo23;tab-stops:list 71.4pt'><![if !supportLists]><span
lang=TR style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>N�bet
kayd&#305; yap&#305;labilirse veya dolayl&#305; baz&#305; bulgularla n�bet tipi
ve buradan hareketle epilepsi sendromunu belirlemesi <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:71.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l30 level1 lfo23;tab-stops:list 71.4pt'><![if !supportLists]><span
lang=TR style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Oda&#287;&#305;n
lateralizasyon-lokalizasyonu hakk&#305;nda bilgi verebilmesi <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>Giderek geli&#351;tirilen ve bilgisayarlarla ba&#287;lant&#305;l&#305;
hale getirilen klasik EEG cihazlar&#305;n&#305;n yan&#305; s&#305;ra telemetrik
incelemeler ve video-EEG cihazlar&#305; ile epilepsi elektrofizyolojisi
konusundaki bilgilerimiz giderek artm&#305;&#351;t&#305;r. Bu incelemeler
ayn&#305; zamanda n�bet semiyolojisinin de �ok ayr&#305;nt&#305;l&#305;
analizine olanak sa&#287;lamaktad&#305;r (<b style='mso-bidi-font-weight:normal'>&#350;ekil
11</b>). Epilepsi cerrahisindeki ilerlemelere paralel olarak invazif ve
yar&#305;-invazif y�ntemlerle de&#287;i&#351;ik derin/intrakranyal elektrod
yerle&#351;imleri de epilepsi cerrahisi yap&#305;lan merkezlerde rutin
kullan&#305;ma girmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><b
style='mso-bidi-font-weight:normal'><u><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:blue'><a href="sekil11.jpg">&#350;ekil 11.</a></span></u></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'> </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>�e&#351;itli epilepsili
olgular&#305;n&#305;n, tan&#305;sal veya preoperatif haz&#305;rl&#305;k
ama�l&#305; video-EEG incelemeleri s&#305;ras&#305;nda kaydedilen n�bet
semiyolojisi a�&#305;s&#305;ndan tipik video kesitleri: �st s&#305;rada en
solda: Sa&#287; mezyal temporal lob epilepsisi (MTLE) olan hastada tipik
ba&#351;ta sa&#287;a do&#287;ru ipsiversiyon ve sa&#287; elde ipsilateral
otomatizmaya e&#351;lik eden kontralateral distoni; �st s&#305;ra ve ortada:
Startle epilepsisi olan bir hastada kaydedilen asimetrik tonik n�bet g�r�n�m�;
�stte en sa&#287;da: Frontal lob epilepsili bir hastada uyku
s&#305;ras&#305;nda ortaya �&#305;kan hipermotor tipte bacak
otomatizmalar&#305;; Altta en sa&#287;da: Lennox-Gastaut sendromlu bir olgunun
uykuda ortaya �&#305;kan tonik n�beti; altta ortada: MTLE�li bir olguda
sekonder jeneralize tonik-klonik bir n�betin ilk asimetrik ba&#351;lang&#305;�
an&#305;; altta en solda nadir g�r�len bir absans n�beti tipi olan miyoklonik
absans n�beti ge�iren bir olgunun omuzlar&#305;ndaki miyoklonik hareket<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>N�ropsikolojik De&#287;erlendirme <o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epileptik
hastalar&#305;n normallere oranla kognitif defektler g�sterebildikleri
bilinmektedir. Bu defektler yap&#305;sal lezyonlarla bir �l��de
a�&#305;klanmakla birlikte, g�sterilebilen bir yap&#305;sal lezyonu bulunmayan
olgularda da kognitif defektlerin varl&#305;&#287;&#305;na dikkat
�ekilmi&#351;tir. Antiepileptik tedavi, �zellikle difenilhidantoin,
barbit�ratlar, yeni ila�lardan �zellikle topiramat bu kognitif fonksiyon
bozuklu&#287;unun sorumlusu olarak su�lanm&#305;&#351;; ancak baz&#305; �al&#305;&#351;mac&#305;lar
bu g�r�&#351;e kar&#351;&#305; �&#305;km&#305;&#351;lar ve hen�z ilaca
ba&#351;lanmam&#305;&#351; epileptik olgularda da normallerle
k&#305;yasland&#305;&#287;&#305;nda belirli davran&#305;&#351; ve kognitif
parametrelerde bozukluk oldu&#287;unu g�stermi&#351;lerdir. Bu nedenle epilepsi
hastalar&#305;n&#305;n unutkanl&#305;k gibi yak&#305;nmalar&#305;
oldu&#287;unda ayr&#305;nt&#305;l&#305; n�ropsikolojik testlerle de&#287;erlendirilmesi,
takip ve tedaviyi y�nlendirmek a�&#305;lar&#305;ndan �ok yararl&#305;d&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epileptik
olgularda kognitif fonksiyonu etkileyen fakt�rleri 7 noktada toplamak
m�mk�nd�r: <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-family:
Tahoma'>1. Etyolojiye ili&#351;kin fakt�rler <br>
2. N�bet aktivitesi <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;text-indent:-18.0pt;mso-list:
l67 level3 lfo25'><![if !supportLists]><span lang=TR style='font-family:Wingdings;
mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>n�betlerin
ba&#351;lang&#305;� ya&#351;&#305; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;text-indent:-18.0pt;mso-list:
l67 level3 lfo25'><![if !supportLists]><span lang=TR style='font-family:Wingdings;
mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>n�bet
s&#305;kl&#305;&#287;&#305; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;text-indent:-18.0pt;mso-list:
l67 level3 lfo25'><![if !supportLists]><span lang=TR style='font-family:Wingdings;
mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>n�bet
s�resi <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;text-indent:-18.0pt;mso-list:
l67 level3 lfo25'><![if !supportLists]><span lang=TR style='font-family:Wingdings;
mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>n�bet
tipi <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;text-indent:-18.0pt;mso-list:
l67 level3 lfo25'><![if !supportLists]><span lang=TR style='font-family:Wingdings;
mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>EEG
anomalisinin tipi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-family:
Tahoma'>3. Antiepileptik tedavinin yan etkileri <br>
4. Beyin fonksiyon bozuklu&#287;unun taraf&#305; <br>
5. Di&#287;er yeti kay&#305;plar&#305; ve n�ropsikolojik bozukluklar <br>
6. �evresel fakt�rler, aile yap&#305;s&#305; <br>
7. Emosyonel fakt�rler ve ki&#351;ilik geli&#351;imi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>Bilgisayarl&#305; Tomografi
(BT) ve Magnetik Rezonans G�r�nt�leme (MRG) <o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>X
&#305;&#351;&#305;nlar&#305;n&#305; kullanan bilgisayarl&#305; tomografi
y�nteminin n�roloji prati&#287;inde yerini almas&#305; �zellikle semptomatik
parsiyel epilepsiler a�&#305;s&#305;ndan bir devrim niteli&#287;inde olmu&#351;tur.
G�n�m�zde ise beyin anatomisini �ok detayl&#305; bir &#351;ekilde g�steren MRG
epileptik hastalarda ilk tercih edilecek g�r�nt�leme y�ntemi olarak BT'nin
yerini alm&#305;&#351; durumdad&#305;r. Kranyal tomografi incelemesinde bulgu
saptanmayan %20-30 hastada MRG pozitiftir (ayr&#305;ca bak&#305;n&#305;z: Sinir
Sistemi Semiyolojisi, <u><span style='color:#0070C0'><a
href="../nororad/nororad.htm">N�roradyoloji</a></span></u>). <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Baz&#305;
glial t�m�rler, vask�ler malformasyonlar, kavernoma, hamartoma, lokalize atrofi
ve n�ronal migrasyon anomalileri gibi �e&#351;itli yap&#305;sal lezyonlar&#305;
g�stermede MRG'nin BT'den �st�n oldu&#287;u saptanm&#305;&#351;t&#305;r <b
style='mso-bidi-font-weight:normal'>(&#350;ekil 12 ve 13).</b> Buna
kar&#351;&#305;n serebral kalsifikasyonlar&#305; g�sterme a�&#305;s&#305;ndan
BT MRG'ye �st�n konumdad&#305;r. Kompleks parsiyel n�betlerin etyolojisinde
%70-80 civar&#305;nda g�r�len mezyal temporal sklerozun MRG ile tespitinin
m�mk�n olabildi&#287;i ortaya konmu&#351;tur. MRG'nin radyasyon i�ermemesi,
kontrast madde verilmesine �o&#287;u zaman gerek olmamas&#305;, BT'ye oranla
kemik artefaktlar&#305;n&#305;n olmamas&#305; nedeniyle mezyal temporal lobu ve
arka �ukur yap&#305;lar&#305;n&#305; daha iyi g�r�nt�lemesi ve rekonstr�ksiyonla
her planda g�r�nt�n�n kolayca elde edilebilmesi di&#287;er �st�n
yanlar&#305;d&#305;r. Ancak MRG�nin epilepsi protokol�ne uygun
yap&#305;lmas&#305; sa&#287;lanmal&#305;d&#305;r. Bu protokol
olabildi&#287;ince y�ksek Tesla g�c�nde bir cihazla, FLAIR
sekanslar&#305;n&#305; ve sagital kesitleri, gere&#287;inde vol�metrik g�r�nt�
elde edilebilecek &#351;ekilde ince kesitli, aral&#305;ks&#305;z T1A koronal
kesitleri de i�ermeli, temporal ve frontal loblar ayr&#305;nt&#305;l&#305;
incelenmelidir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;dyopatik
epilepsilerde bu yap&#305;sal g�r�nt�leme y�ntemlerinin yard&#305;m&#305;
olduk�a azd&#305;r. Baz&#305; �al&#305;&#351;malarda %10 gibi oranlarda
rastlant&#305;sal patolojik bulguya rastland&#305;&#287;&#305;
belirtilmektedir. MRG�de g�r�len lezyonun EEG ve klinikle korelasyonu
yap&#305;lmal&#305;d&#305;r. Bulgular&#305;n kolay g�zden ka�abilece&#287;i ve
tekrar tekrar incelenmesi gereklili&#287;i unutulmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>�nemli
bir nokta ise kimi zaman ge�ici BT veya MRG anomalilerine rastlanabilmesidir.
Bu g�r�nt�lerin fokal n�bet veya status aktivitesi s&#305;ras&#305;ndaki �deme,
l�ks perf�zyona veya b�lgesel kan beyin bariyeri y&#305;k&#305;m&#305;na
ba&#287;l&#305; olabilece&#287;i d�&#351;�n�lmektedir. <o:p></o:p></span></p>

<p style='margin-left:35.4pt;text-align:justify'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue'><a href="sekil12.jpg">&#350;ekil
12.</a></span></u></b><b><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;color:blue'> </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>N�rog�r�nt�leme y�ntemleri ile
�e&#351;itli epilepsi olgular&#305;nda g�sterilmi&#351; olan ve epilepsiye yol
a�t&#305;&#287;&#305; d�&#351;�n�len lezyonlar <b>A</b>: Mezyal temporal lob
epilepsisi tan&#305;s&#305;yla izlenen bir olguda ok ile i&#351;aretli olan mezyal
temporal sklerozu d�&#351;�nd�ren MRG�de T2 hiperintensitesi ve normal
hipokampal i�yap&#305;n&#305;n kayb&#305; (normal g�r�n�m
sa&#287;&#305;l&#305;kl&#305; olan kar&#351;&#305; hipokampusda
izlenebilmektedir), <b>B:</b> Semptomatik parsiyel epilepsili olguda kavernom
ile uyumlu heterojen lezyon, <b>C:</b> Tuberoz sklerozlu bir olguda izlenen
multifokal kortikal tuberler, <b>D:</b> Lipoid proteinoz tan&#305;l&#305;
hastada BT�de diagnostik bilateral meziyal temporal kalsifikasyonlar, <b>E</b>:
Sturge-Weber sendromu tan&#305;l&#305; olguda BTde tipik oksipital lob
yerle&#351;imli kalsifikasyon, <b>F:</b> Herpes simpleks ensefaliti olgusunda
tipik meziyal temporal yerle&#351;imli lezyon<o:p></o:p></span></p>

<p style='margin-left:35.4pt;text-align:justify'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:blue'><a href="sekil13.jpg">&#350;ekil
13.</a></span></u></b><b><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;color:blue'> </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Epilepsiye s&#305;k neden olan
n�ronal geli&#351;imsel bozukluk �rnekleri: <b>A</b>: Fokal kortikal displazi, <b>B:</b>
Nod�ler heterotopi, <b>C:</b> Bilateral (bir yanda a�&#305;k dudakl&#305;
di&#287;er yanda kapal&#305; dudakl&#305; tipte) &#351;izensefali, <b>D:</b>
Bilateral perisilviyen displaz,i <b>E:</b> Hemimegalensefali, <b>F:</b> �ift
korteks sendromu.<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Fonksiyonel G�r�nt�leme <o:p></o:p></span></i></b></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>SPECT</span></i><span
lang=TR style='font-family:Tahoma'> <i style='mso-bidi-font-style:normal'>(Single
Photon Emission Computed Tomography):</i> PET olana&#287;&#305; bulunmayan
yerlerde fonksiyonel g�r�nt�leme amac&#305;yla ba&#351;vurulabilecek yegane
y�ntemdir. Geni&#351; klinik kullan&#305;m olanaklar&#305;yla epileptik
hastalar&#305;n incelenmesinde BT, MRG, EEG ile birlikte klinik bilgilere
katk&#305;s&#305; olabilece&#287;i d�&#351;�n�lmektedir. Epileptojenik
oda&#287;&#305;n lokalizasyonu a�&#305;s&#305;ndan kullan&#305;lan hi� bir
y�ntem tek ba&#351;&#305;na tam g�venilir de&#287;ildir ve bu �e&#351;itli
y�ntemlerin kombinasyonunu gerektirmektedir. SPECT bu multidisipliner yelpaze
i�inde epileptik odak belirlenmesinde, invazif tan&#305; y�ntemlerine ge�meden
�nce katk&#305; sa&#287;layabilecek tamamlay&#305;c&#305; bir y�ntemdir.
�zellikle iktal SPECT ile saptanan hiperperf�zyon ile odak lokalizasyonu
a�&#305;s&#305;ndan �ok yararl&#305; bilgiler elde edilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>SPECT, beyin kan ak&#305;m&#305;n&#305;n Tc-hexamethylpropylenamine
oxime (HMPAO) veya ba&#351;ka i&#351;aretleyiciler ile g�r�nt�lenmesidir. Bu
maddenin 1 dakikada %70�i tutulur, 6 saat boyunca stabil kal&#305;r.
&#304;ntrasel�ler glutatyon ile etkile&#351;ir, hidrofilik hale ge�er ve
kan-beyin bariyerini ge�emez. Bu nedenle iktal kay&#305;t yapmak daha
kolayd&#305;r, bu noktada PET'e �st�nd�r. % 65-90 oran&#305;nda EEG
oda&#287;&#305;yla uyumlu beyin kan ak&#305;m&#305;
art&#305;&#351;&#305;n&#305; g�sterir, interiktal d�nemde ise ayn&#305; b�lgede
hipoperf�zyon (azalm&#305;&#351; kan ak&#305;m&#305;) g�zlenir.</span><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>PET </span></i><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'>(
Positron Emission Tomography): </span></i><span lang=TR style='font-family:
Tahoma'>Beyin kan ak&#305;m&#305;n&#305;n haritalamas&#305;nda 15 O�e
ba&#287;l&#305; su, b�lgesel serebral glikoz metabolizmas&#305; i�in 18
Florodeoksiglikoz FDG kullan&#305;l&#305;r. Flumazenil�in santral
benzodiazepin-GABA-A resept�r kompleksine ba&#287;lan&#305;&#351;&#305; gibi
spesifik ligandlar&#305;n ba&#287;lan&#305;&#351;&#305;n&#305; da g�sterir.
SPECT'e g�re daha iyi rezol�syon sa&#287;lar. MRG-PET aras&#305;nda
yap&#305;sal-fonksiyonel korelasyonu kurmak her zaman kolay olmaz.
&#304;nteriktal olarak epileptojenik oda&#287;&#305;n i&#351;areti,
azalm&#305;&#351; glikoz metabolizmas&#305; ve azalm&#305;&#351; kan
ak&#305;m&#305; olmas&#305;d&#305;r ve genellikle patolojik b�lgeden daha
geni&#351; g�r�nmektedir. Bunun nedeni epileptojenik odak �evresindeki
n�ronlar&#305;n inhibisyonudur. Parsiyel n�bet s&#305;ras&#305;nda ise;
epileptojenik odakta b�lgesel glikoz metabolizmas&#305; ve kan
ak&#305;m&#305;nda art&#305;&#351; ile karakterizedir, ancak iktal kay&#305;t
sa&#287;lanmas&#305; �ok g��t�r. 15 O'in yar&#305;lanma �mr� 2 dk, FDG'nin
al&#305;n&#305;m&#305; ise 40 dakikad&#305;r. �zellikle temporal ve frontal lob
epilepsilerinde cerrahi tedavi d�&#351;�n�len vakalarda kullan&#305;m&#305;
�nemlidir. Jeneralize epilepsilerde kullan&#305;m&#305; a�&#305;s&#305;ndan
interiktal �al&#305;&#351;malar dikkat �ekici de&#287;ildir. S&#305;k
absanslar&#305;n varl&#305;&#287;&#305;nda serebral glikoz
metabolizmas&#305;nda yayg&#305;n art&#305;&#351; g�r�l�r, bu art&#305;&#351;
daha �ok �ocuklarda olur. Absans statusta ise beyin glikoz
metabolizmas&#305;nda azalma olur. Fokal anomali yoktur ve metabolizma
h&#305;z&#305; ile diken dalga aktivitesi aras&#305;nda ba&#287;lant&#305;
kurulamaz. Absans s&#305;ras&#305;nda beyin kan ak&#305;m&#305;nda global %15
ve talamusta %4-8 art&#305;&#351; vard&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Sonu�
olarak PET de odak konusunda genel bir bilgi verir, spesifik de&#287;ildir ve
ger�ek patolojik alandan daha geni&#351; g�r�n�r. Diren�li epilepsiler ve
malinite taramalar&#305;nda indike olan bir incelemedir (<b style='mso-bidi-font-weight:
normal'>&#350;ekil 14</b>).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt'><b style='mso-bidi-font-weight:
normal'><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil14.jpg">&#350;ekil 14.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> Epileptik bir hastan&#305;n PET
inceleme �rne&#287;i: 15 ya&#351;&#305;ndaki kad&#305;n hasta 3
ya&#351;&#305;ndan beri tedaviye diren�li kompleks parsiyel n�betler
ge�irmektedir. MRG�si tamamen normal olan hastan&#305;n sol temporofrontal
b�lgede hipometabolizma g�steren PET bulgular&#305; (oklar), EEG
bulgular&#305;na destek olu&#351;turmu&#351; ve invazif incelemenin
planlanmas&#305;n&#305; sa&#287;lamak a�&#305;s&#305;ndan �ok de&#287;erli
olmu&#351;tur<b style='mso-bidi-font-weight:normal'><span style='color:#0070C0'>.</span></b></span><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><a name="Epilepsilerin_genetik"></a><b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma'>AYIRICI TANI</span></b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepside
tan&#305; �ncelikle klinik olarak konur ve dolay&#305;s&#305;yla ge�irilen
ataklar&#305;n �ok ayr&#305;nt&#305;l&#305; olarak hasta ve g�renler
taraf&#305;ndan tarif edilmesine dayan&#305;r. E&#287;er olay &#351;�pheli
kal&#305;rsa yanl&#305;&#351; bir etiket yap&#305;&#351;t&#305;rmaktansa sadece
gerekli ara&#351;t&#305;rmalar&#305; yap&#305;p izlemek daha do&#287;ru bir
yakla&#351;&#305;md&#305;r. Yanl&#305;&#351; konan epilepsi tan&#305;s&#305;
hastay&#305; ciddi bi�imde �ok boyutlu (�m�r boyu epilepsi hastas&#305;
say&#305;lmak, do&#287;ru tedavinin gecikmesi, uzun s�re antiepileptik
ila�lar&#305;n maddi y�k� ve yan etki olas&#305;l&#305;klar&#305; vb.)
s&#305;k&#305;nt&#305;larla kar&#351;&#305; kar&#351;&#305;ya b&#305;rakmak
demektir. Bu nedenle epilepsi tan&#305;s&#305; koyarken ay&#305;r&#305;c&#305;
tan&#305;ya �ok �nem vermek gerekmektedir (<b style='mso-bidi-font-weight:normal'>Tablo
8</b>). Epilepside n�bet tiplerinin ne kadar �ok �e&#351;itli ve
de&#287;i&#351;ken oldu&#287;u d�&#351;�n�ld�&#287;�nde ay&#305;r&#305;c&#305;
tan&#305; yelpazesinde yer alan hastal&#305;klar&#305;n da ne kadar �ok ve
�e&#351;itli olaca&#287;&#305; a�&#305;kt&#305;r. (Ayr&#305;ca
bak&#305;n&#305;z:<span style='color:blue'> </span>Sinir Sistemi Semiyolojisi<span
style='color:blue'>, <u><a href="../epizodik/epizodik.htm">Epizodik Bilin�
Bozukluklar&#305;</a></u></span>) En s&#305;k kar&#351;&#305;la&#351;&#305;lan
ve sorun yaratan di&#287;er olas&#305;l&#305;klar <i style='mso-bidi-font-style:
normal'>senkop</i> ve <i style='mso-bidi-font-style:normal'>yalanc&#305;
n�betler</i>dir (<b style='mso-bidi-font-weight:normal'>Tablo 9</b>). EEG
tan&#305;da �ok yard&#305;mc&#305; olabilir ama bazen yeterli bilgi sahibi olmayanlar
taraf&#305;ndan yorumland&#305;&#287;&#305;nda ciddi yan&#305;lg&#305;lara da
yol a�ar. �rne&#287;in yava&#351; dalgalar gibi spesifik olmayan
bozukluklar&#305;n epilepsi lehine yorumlanmas&#305; s&#305;k rastlanan bir
yan&#305;lg&#305;d&#305;r. Bunun d&#305;&#351;&#305;nda epilepsisi olmayan
normal ki&#351;ilerde de %5'e varan oranda epileptiform anomalilerin
g�r�lebildi&#287;i ve epilepsi olgular&#305;nda ilk EEG' nin 1/3'lere varan
oranda normal bulunabildi&#287;i unutulmamal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><br>
<b><span style='color:black'>Tablo 8. Epilepside Ay&#305;r&#305;c&#305;
Tan&#305;</span></b> <o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-language:EN-US'>

<hr size=2 width="100%" align=center>

</span></div>

<p style='text-align:justify'><u><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>A) �ocukluk �a&#287;&#305;</span></u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Senkop <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Siyanotik nefes tutma
     ataklar&#305; <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Gece korkular&#305;
     (Pavor nocturnus)<o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Metabolik nedenlere
     ba&#287;l&#305; &#351;uur kayb&#305; <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Migren (konf�zyonel
     durum, baziler migren) <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Kardiyak ritim
     bozukluklar&#305; (�zellikle supraventrik�ler ta&#351;ikardi) <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tikler <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Titreme ataklar&#305;
     (yenido&#287;an d�neminde) <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Psikiyatrik k�kenli n�betler
     ve M�nchausen sendromu <i>(ebeveynler sorumlu alabilir)</i> <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Hipnagojik
     miyokloniler <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Benign paroksizmal
     koreatetoz <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Yalanc&#305; n�betler <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Gastro�zofageal refl� <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l1 level1 lfo28;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>�ocuklu&#287;un benign
     miyoklonisi <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>B) Eri&#351;kin d�nem</span></u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='text-align:justify;mso-list:l13 level1 lfo31;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Senkop <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-left:72.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>-refleks: post�ral, valsalvaya
ba&#287;l&#305;, miksiyona ba&#287;l&#305; vb <o:p></o:p></span></p>

<p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;
margin-bottom:.0001pt;text-align:justify'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>-kardiyak: disritmi (kalp blo&#287;u, ta&#351;ikardi vb);
valv�ler (en s&#305;k aort stenozu); kardiyomiyopati; &#351;antl&#305;
hastal&#305;klar vb <o:p></o:p></span></p>

<p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;
margin-bottom:.0001pt;text-align:justify'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>-perf�zyon yetmezli&#287;i: hipovolemi, otonom yetmezlik<o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='text-align:justify;mso-list:l13 level1 lfo31;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Psikojenik ataklar <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-left:72.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>-yalanc&#305; n�bet <o:p></o:p></span></p>

<p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;
margin-bottom:.0001pt;text-align:justify'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>-panik atak <o:p></o:p></span></p>

<p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;
margin-bottom:.0001pt;text-align:justify'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>-hiperventilasyon<o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='text-align:justify;mso-list:l13 level1 lfo31;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Ge�ici iskemik atak <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l13 level1 lfo31;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Migren <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l13 level1 lfo31;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Narkolepsi/katapleksi<o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l13 level1 lfo31;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>REM uyku
     davran&#305;&#351; bozuklu&#287;u<o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l13 level1 lfo31;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Huzursuz bacak
     sendromu<o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l13 level1 lfo31;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ge�ici global amnezi <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l13 level1 lfo31;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Akut konf�zyonel
     durumlar<o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l13 level1 lfo31;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Hipoglisemi ba&#351;ta olmak �zere metabolik nedenler <o:p></o:p></span></li>
</ul>

<div style='margin-left:36.0pt'>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'>Tablo 9. Epilepsinin
Ay&#305;r&#305;c&#305; Tan&#305;s&#305;nda �nemli Noktalar</span></b><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellpadding=0 width=594 style='width:445.5pt;
 mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:3.0pt 3.0pt 3.0pt 3.0pt'>
 <tr style='mso-yfti-irow:0'>
  <td width="20%" valign=top style='width:20.8%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
  Tahoma'>&nbsp;<o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Senkop</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Epilepsi</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>Yalanc&#305; n�bet</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Post�r</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Ayakta</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Her post�r</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Her post�r</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Terleme</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek&nbsp;</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>De&#287;i&#351;ken</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Renk</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Beyaz</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Morarma</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>De&#287;i&#351;ken</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Ba&#351;lang&#305;�</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yava&#351; (presenkop belirtileri)</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Ani/aura</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>De&#287;i&#351;ken</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yaralanma</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k�a</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>�ok seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Konv�lz�yon</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Tipik</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Atipik kas&#305;lmalar</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>&#304;drar inkontinans&#305;</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>�ok seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Bilin�siz s�re</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Saniyeler</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Dakikalar</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Genelde yok veya uzun</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>D�zelme</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>H&#305;zl&#305;</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yava&#351;�a</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>De&#287;i&#351;ken</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Postiktal konf�zyon</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>�ok seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok/seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;kl&#305;k</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>De&#287;i&#351;ken</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Genelde s&#305;k</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Artt&#305;ran fakt�rler</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>A�l&#305;k, heyecan, s&#305;k&#305;nt&#305;</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Uykusuzluk, stres, tipik refleks uyaranlar</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Stresli olay, kalabal&#305;k</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Pelvik hareket&nbsp;</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Asenkron hareket</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yuvarlanma</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Stereotipik atak</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k ve tipik</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>G�z a�maya diren�</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>&#304;nd�klenebilme</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:19'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>EEG iktal bulgu</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Hemen her zaman var</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:20;mso-yfti-lastrow:yes'>
  <td width="20%" valign=top style='width:20.8%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>&#304;nteriktal bulgu</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="28%" valign=top style='width:28.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Spesifik olmayan</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.56%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>S&#305;k</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.6%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Yok/seyrek</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>EP&#304;LEPS&#304;LER&#304;N
GENET&#304;&#286;&#304;</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepside
genetik e&#287;ilimin �nem ta&#351;&#305;d&#305;&#287;&#305; Hipokrat
d�neminden beri bilinmektedir. T�m epilepsilerin %40-60'&#305;n&#305;n etyolojisinde
genetik fakt�rler rol oynamaktad&#305;r. �zellikle idyopatik epilepsi
sendromlar&#305;nda aile �yk�s�n�n pozitifli&#287;i semptomatik epilepsilere
oranla daha belirgindir. Genel olarak toplumdaki epilepsi prevalans&#305; %0.5
iken �rnek olarak idyopatik absans n�betleri olan anne veya baban&#305;n
�ocu&#287;unda epilepsi olas&#305;l&#305;&#287;&#305; % 9 oran&#305;nda
bildirilmi&#351;tir. Epileptik olgular&#305;n akrabalar&#305;nda epilepsi
olas&#305;l&#305;&#287;&#305;n&#305;n artmas&#305;n&#305;n yan&#305;s&#305;ra,
% 50'ye varan oranlarda EEG anomalisi varl&#305;&#287;&#305; da
bildirilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>�zellikle
son y&#305;llarda genetikte kaydedilen b�y�k ilerlemeler sonucunda epilepsi
geneti&#287;i ile ilgili bilgiler giderek artmaktad&#305;r. 1980�lerin
ortalar&#305;ndan bu yana devam eden &#304;nsan Genom Projesi ile insan
DNA�s&#305;n&#305;n yap&#305;s&#305;, d�zeni ve i&#351;levleri konusunda bir�ok
bilgi haz&#305;r hale gelmi&#351;tir<span style='color:blue'>. </span>(Ayr&#305;ca
Bak&#305;n&#305;z: Sinir Sistemi Semiyolojisi, <u><span style='color:#0070C0'><a
href="../norogenetik/norogenetik.htm">Klinik N�rogenetik</a></span></u>).
Epilepsiler bir �ok di&#287;er s&#305;k rastlanan sistemik (hipertansiyon) ve
n�rolojik (Alzheimer, Parkinson Hastal&#305;&#287;&#305;, migren) hastal&#305;k
gibi kompleks bir kal&#305;t&#305;m g�sterirler ve molek�ler genetik
�al&#305;&#351;malar bu durumda g��t�r. Ancak �zelllikle otomozomal dominant
ge�i&#351; g�steren baz&#305; epilepsilerin genetik temelleri son y&#305;llarda
bulunmu&#351;tur (<b style='mso-bidi-font-weight:normal'>Tablo 10</b>). <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;dyopatik
epilepsi sendromlar&#305;n&#305;n �o&#287;unlu&#287;u poligenik �kompleks�
kal&#305;t&#305;m paterni�� g�sterir. Ayn&#305; ailede fenotipik varyasyonlar
g�r�lebilir: Bir olgu �ocukluk �a&#287;&#305; absans epilepsili (�AE),
di&#287;eri j�venil miyoklonik epilepsili (JME) olabilir. Ayn&#305; aile
a&#287;ac&#305;nda farkl&#305; &#304;JE formlar&#305;n&#305;n bir arada bulunmas&#305;,
ortak bir genetik temel oldu&#287;unu d�&#351;�nd�rmektedir. Baz&#305; genlerin
n�bet tipine, baz&#305; genlerin di&#287;er fenotip �zelliklerine yol
a�t&#305;&#287;&#305; d�&#351;�n�lebilir. &#350;u anda bilinen ondan fazla
epilepsi geninin �o&#287;u iyon kanal sub�nitelerini kodlamaktad&#305;rlar. Bu
iyon kanallar&#305; ligand kap&#305;l&#305; ya da voltaj
kap&#305;l&#305;d&#305;rlar. Yani idyopatik epilepsileri bug�n i�in ailesel
kanalopatiler olarak d�&#351;�nmek olas&#305; g�r�nmektedir. &#304;yon
kanallar&#305; n�ronal eksitabilitede maj�r rol oynamakta ve genetik
epileptojenik de&#287;i&#351;ikliklerin ana nedeni olarak g�r�nmektedir.
Ayr&#305;ca idyopatik parsiyel epilepsiler, kortikal malformasyonlar, PME gibi
hastal&#305;klarda kanal d&#305;&#351;&#305;ndaki genlerde mutasyonlar yer
almaktad&#305;r. Bir�o&#287;unun tam olarak etkisi bilinmemekle birlikte n�ronal
uyar&#305;labilirlik art&#305;&#351;&#305;na yol a�an veya inhibisyonu azaltan
mutasyonlar olduklar&#305; d�&#351;�n�lmektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Epilepside genetik ara&#351;t&#305;rmalar son y&#305;llarda bilim
adamlar&#305;n&#305;n g�zde u&#287;ra&#351;&#305; olmu&#351;tur. Fare deneyleri
ve insanda yap&#305;lan �al&#305;&#351;malar ile epilepsilerin molek�ler
geneti&#287;i konusunda ilerlemeler kaydedilmektedir. Avrupa Birli&#287;i 6.
�er�eve projesi kapsam&#305;nda �lkemizin de i�inde yer ald&#305;&#287;&#305;
EPICURE (Fonksiyonel Genomik ve Epilepsi N�robiyolojisi<span style='mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'>) projesi buna �nemli bir �rnek
olu&#351;turmaktad&#305;r (www.epicure.eu). </span>Epilepside
hastal&#305;&#287;a neden olan molek�ler mekanizmalar&#305;n ve genetik
fakt�rlerin belirlenmesi, tan&#305;mlanan veriler
&#305;&#351;&#305;&#287;&#305;nda yeni tedavi
yakla&#351;&#305;mlar&#305;n&#305;n geli&#351;tirilmesi �zellikle ilaca
diren�li epilepsilerde, ilaca diren� mekanizmalar&#305;n&#305;n a�&#305;&#287;a
kavu&#351;turulmas&#305; a�&#305;s&#305;ndan �nemlidir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Genetik �al&#305;&#351;malar; hastal&#305;klar&#305;n kesin
tan&#305;s&#305; (bazen klinik ve laboratuvar bulgular&#305; yetersiz
kalabilir), prenatal tan&#305; ve ta&#351;&#305;y&#305;c&#305;lar&#305;n
tan&#305;nmas&#305;, sa&#287;l&#305;k ve hastal&#305;kta genetik fakt�rlerin
rol�, di&#287;er fakt�rler ile etkile&#351;imi, kal&#305;tsal hastal&#305;klara
yatk&#305;nl&#305;klar&#305;n ortaya konulmas&#305;, ila�lara diren� ve cevap,
epilepsilerin s&#305;n&#305;fland&#305;r&#305;lmas&#305;, fizyopatolojinin
anla&#351;&#305;lmas&#305;, farkl&#305; tan&#305; y�ntemleri ve yeni tedavi
�nerilerine &#305;&#351;&#305;k tutmaktad&#305;r.<span
style='mso-spacerun:yes'>� </span>�rnek olarak yeni geli&#351;tirilen bir
antiepileptik ila� olan Retigabine, potasyum kanal mutasyonlar&#305;n&#305;n
epilepsi ile ili&#351;kisinin g�sterilmesi �zerine, n�ronal potasyum (KCNQ)
kanallar&#305;n&#305;n etkisini artt&#305;rarak spesifik etkinlik g�stermek
�zere geli&#351;tirilmi&#351; olmas&#305; nedeniyle �nemlidir. Gendeki mutasyona
ba&#287;l&#305; patolojinin fonksiyonel incelemesi, hedefe y�nelik tedaviyi
olu&#351;turmak i�in zorunludur. &#304;la� metabolizmas&#305;ndan sorumlu
genler toplumlararas&#305;, hatta bireysel farkl&#305;l&#305;klar
g�sterebilmekte, baz&#305; olgularda ilaca dirence yol a�abilmekte ve
hastan&#305;n tedavi se�eneklerini de&#287;i&#351;tirebilmektedir. Bu alanda
yap&#305;lan ara&#351;t&#305;rmalar farmakogenetik �al&#305;&#351;malar&#305;
olu&#351;turmaktad&#305;r. Sonu� olarak genetik alan&#305;ndaki geli&#351;meler
epileptogenez mekanizmas&#305; hakk&#305;nda ciddi bilgi
sa&#287;lam&#305;&#351; olmakla birlikte, bunlar&#305;n klinik prati&#287;e
yans&#305;malar&#305; hen�z &#351;ekillenme a&#351;amas&#305;ndad&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>&#304;nsan epilepsilerinin genetik temellerinin
ara&#351;t&#305;r&#305;lmas&#305;nda &#351;u basamaklar s�z konusudur: <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l47 level1 lfo36;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;lk �nce
     ara&#351;t&#305;r&#305;lan klinik sendromun net olarak belirlenmesi ve
     uygun ailelerden DNA �rneklerinin toplanmas&#305; gerekmektedir.
     Ba&#351;ar&#305;l&#305; sonu� elde edebilmek i�in �ok say&#305;da
     etkilenmi&#351; bireyi i�eren b�y�k birka� aile ya da k���k ama homojen,
     �ok say&#305;da ailelerin aile a&#287;a�lar&#305; (pedigri)
     belirlenmelidir. Bu klinik �al&#305;&#351;malarla kal&#305;t&#305;m tipi
     belirlenmeye �al&#305;&#351;&#305;l&#305;r. Genetik incelemelerin
     yap&#305;laca&#287;&#305; materyal olarak genellikle kandaki l�kositlerden
     elde edilen DNA kullan&#305;lmaktad&#305;r. Bu ama�la her bireyden 10 ml
     EDTA�l&#305; t�pe (genellikle mor kapakl&#305;) al&#305;nan kan oda
     &#305;s&#305;s&#305; veya +4 C�de en k&#305;sa s�rede DNA izolasyonunun
     yap&#305;laca&#287;&#305; laboratuvara ula&#351;t&#305;r&#305;l&#305;r. <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l47 level1 lfo36;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bu materyal �zerinde
     &quot;linkage� ba&#287;lant&#305; analizi denen y�ntemle
     ara&#351;t&#305;rma yap&#305;l&#305;r. Bu �al&#305;&#351;man&#305;n
     sonucunda ara&#351;t&#305;r&#305;lan genin yakla&#351;&#305;k
     yerle&#351;imi belirlenmeye �al&#305;&#351;&#305;l&#305;r. Haploid insan
     genomunda yakla&#351;&#305;k 3000 megabaz DNA yer al&#305;r ve
     ba&#287;lant&#305; analizi �al&#305;&#351;mas&#305;n&#305;n sonucunda ilgi
     alan&#305; yakla&#351;&#305;k 10-15 megabaza indirgenir. Buna ra&#287;men
     bu b�lgede hala y�zlerce gen yer almaktad&#305;r. <o:p></o:p></span></li>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l47 level1 lfo36;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>&quot;Positional
     cloning&quot; ya da &quot;candidate gene&quot; y�ntemleriyle ilgili b�lge
     i�indeki hatal&#305; gen saptan&#305;r, mutasyonlar belirlenir. <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>Epileptik n�betlerin fenotipin yaln&#305;zca bir
par�as&#305;n&#305; olu&#351;turdu&#287;u, ek olarak bir�ok n�rolojik bulgu
saptanan ve seyrek g�r�len �ok say&#305;da klinik tablo i�inden
baz&#305;lar&#305;n&#305;n basit (Mendeliyen ) ge�i&#351; g�sterdi&#287;i ve
genleri saptanabilmi&#351;tir. Bunlar&#305;n ba&#351;l&#305;ca �rnekleri
progressif miyoklonik epilepsilerin ana nedenleri aras&#305;nda yer alan
Unverricht-Lundborg hastal&#305;&#287;&#305; (sistatin B geninde mutasyonlar)
ve Lafora cismi hastal&#305;&#287;&#305; (tirozinfosfataz mutasyonlar&#305;)
olarak verilebilir (<b style='mso-bidi-font-weight:normal'>Tablo 7</b>). Bir
di&#287;er ilgin� grup da; ailesel subkortikal band heterotopisi (doublecortin
mutasyonlar&#305;) ve ailesel periventrik�ler heterotopi (filamin 1
mutasyonlar&#305;) gibi �e&#351;itli geli&#351;imsel kortikal malformasyonun
yer ald&#305;&#287;&#305; gruptur (<b style='mso-bidi-font-weight:normal'>Tablo
11</b>) . <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Kromozomal anomali ve nonkonv�lzif status epileptikus ile seyreden
ilgin� bir tablo Inoue ve arkada&#351;lar&#305; taraf&#305;ndan 1997 de
tan&#305;mlanm&#305;&#351; halka kromozom 20�dir. Ana klinik �zelli&#287;i
epilepsi olan nadir bir kromozomal anomalidir. Kromozomun 2 kolunun f�zyonu s�z
konusudur. Translokasyon veya distal par�alar&#305;n delesyonu olabilir.
K&#305;sa kolun delesyonu epilepsiye yol a�mazken, uzun kolun terminal
delesyonu epilepsiye yol a�ar. Epilepsiyle olan ili&#351;kisi </span><st1:metricconverter
ProductID="1972�"><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>1972�</span></st1:metricconverter><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>de bildirilmi&#351;ken,
epileptik tablonun �zellikleri yeni belirlenmi&#351; ve 26 epileptik olguda bu
tablonun ayr&#305; bir epilepsi sendromu olu&#351;turdu&#287;u
g�zlenmi&#351;tir. Uzam&#305;&#351; bir konf�zyonel durumdan olu&#351;an
s&#305;k epileptik n�betler bir saati nadiren a&#351;ar, her g�n ya da en
az&#305;ndan her hafta ataklar tekrarlar. Ek motor n�betler olabilir.
&#304;ktal EEG�de uzun s�reli, bilateral paroksizmal y�ksek amplit�dl�
yava&#351; dalgalar ve seyrek dikenler g�r�l�r. N�rolojik muayene t�m�yle
normaldir. N�ro-g�r�nt�lemede normal sonu�lar&#305;n yan&#305; s&#305;ra
baz&#305; olgularda ili&#351;kisinden emin olunamayan MRG bulgular&#305;
g�r�lm�&#351;t�r. Tedaviye diren�li seyir s&#305;kt&#305;r. Mosaisizme dikkat
�ekilmi&#351;tir. (Lenfositlerdeki halka 20 oran&#305; 10-100%
aras&#305;ndad&#305;r). Bu tablonun da n�ronal nikotinik asetilkolin resept�r
alfa 4 sub�niti ile ili&#351;kili olabilece&#287;i d�&#351;�n�lmektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Basit (Mendeliyen) kal&#305;t&#305;m paterninin rol oynad&#305;&#287;&#305;
idiyopatik epilepsilerden olan otozomal nokt�rnal frontal lob epilepsisi (ilk
bulunan gen, 1995), benign ailesel yenido&#287;an konv�lziyonlar&#305; (ilk
ba&#351;ar&#305;l&#305; &quot;linkage&quot;, 1989) ve febril n�bet art&#305;
jeneralize epilepsinin gen mutasyonlar&#305; saptanm&#305;&#351;t&#305;r.
Otozomal dominant nokt�rnal frontal lob epilepsisi yeni genetik
ara&#351;t&#305;rmalarla ortaya konan kal&#305;tsal parsiyel epilepsi
sendromlar&#305; i�in prototipik bir �rnektir. Erken �ocukluktan
eri&#351;kinli&#287;e dek hemen her d�nemde g�r�lebilir, en s&#305;k 10
ya&#351; civar&#305;nda ba&#351;lar. N�betler hemen t�m�yle uykuda g�r�l�r.
Avustralya�da yap&#305;lan bir �al&#305;&#351;ma ile sorumlu genin n�ronal
asetilkolin resept�r�n�n alfa-4 sub�nitesini kodlad&#305;&#287;&#305;
anla&#351;&#305;lm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Bu geli&#351;melere kar&#351;&#305;n kompleks kal&#305;t&#305;m
paterninin rol oynad&#305;&#287;&#305; d�&#351;�n�len ve geni&#351; bir grubu
olu&#351;turan idyopatik jeneralize epilepsilerin ancak baz&#305;lar&#305;nda
gen lokalizasyonlar&#305; saptanabilmi&#351;tir. Bununla birlikte ayn&#305;
hastal&#305;k i�in farkl&#305; gen lokalizasyonlar&#305;n&#305;n bildirilmesi
tart&#305;&#351;malara yol a�maktad&#305;r. Ayn&#305; aile bireylerinde
farkl&#305; idyopatik epileptik sendromun birlikte bulundu&#287;u g�zlenmekte,
bu nedenle ortak etyopatogenezde iyon kanal patolojilerinin rol
oynad&#305;&#287;&#305; d�&#351;�n�lmektedir. &#304;dyopatik jeneralize
epilepsili hastalarda hastal&#305;&#287;&#305;n ba&#351;lang&#305;c&#305;,
seyri, tedaviye yan&#305;t&#305;, s�resi gibi �zellikler sendromun tek bir alt
tipinde dahi �nemli farkl&#305;l&#305;klar g�sterebilmektedir. �rne&#287;in
j�venil miyoklonik epilepside hastalar&#305;n belli bir k&#305;sm&#305;n&#305;n
(1/3) &#305;&#351;&#305;&#287;a duyarl&#305; oldu&#287;u bilinmektedir.
Fotosensitiviteden bir endofenotip olarak yararlanmaya y�nelik
�al&#305;&#351;malar da yap&#305;lmaktad&#305;r. �yleyse ayn&#305; alt gruptaki
klinik de&#287;i&#351;kenlikleri a�&#305;klayabilecek genetik
farkl&#305;l&#305;klar oldu&#287;unu d�&#351;�nmek gerekecektir. Bug�n i�in
saptanm&#305;&#351; bulunan epilepsi genlerinin lokalizasyonlar&#305; <b
style='mso-bidi-font-weight:normal'>Tablo 10�</b>da g�r�lmektedir. Soru
i&#351;aretlerinin ve tek bir �al&#305;&#351;man&#305;n sonucu olanlar&#305;n
�oklu&#287;u dikkati �ekmektedir. Bug�n i�in oligogenik model �zerinde
durulmaktad&#305;r. Son y&#305;llarda �e&#351;itli lokalizasyonlarda
mikrodelesyonlar ve kopya say&#305;s&#305; de&#287;i&#351;imleri
saptanm&#305;&#351; ve epilepsi ile ili&#351;kisinin �st�nde durulmaya
ba&#351;lanm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Hayvan modellerinden yola �&#305;k&#305;larak gen tedavisinin insanda
uygulanabilece&#287;i d�&#351;�n�lmektedir. N�ropeptid-Y ve Galamin ile ilgili
�nemli ipu�lar&#305; vard&#305;r ve bunlar n�bet bask&#305;lanmas&#305;
sa&#287;lamaktad&#305;rlar. Ancak daha bir�ok teknik a&#351;aman&#305;n
sa&#287;lanmas&#305; gerekmektedir. Ba&#351;ar&#305;l&#305; gen tedavisi i�in
hedef n�rona transgenin ta&#351;&#305;nabilmesi gerekir. Yeni geli&#351;tirilen
vekt�rler n�rona �ekim, toksisitenin olmamas&#305;, n�ronda persiste etmesi
sonucunda transgenin uzun s�reli dayan&#305;kl&#305;l&#305;&#287;&#305;n&#305;
sa&#287;layarak bir�ok basama&#287;&#305;n ba&#351;ar&#305;ya
ula&#351;mas&#305;n&#305; sa&#287;lam&#305;&#351;t&#305;r. Ancak bu alanda faz
1 �al&#305;&#351;malar&#305;n ba&#351;lamas&#305;na epilepside hen�z �ok zaman
vard&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify;text-indent:35.4pt'><b style='mso-bidi-font-weight:
normal'><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil15.jpg">&#350;ekil 15.</a></span></u></b><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Epilepsi geneti&#287;ine
ili&#351;kin bilinenlerin &#351;ematik anlat&#305;m&#305;<o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>Tablo 10. &#304;dyopatik Epilepsilerin Molek�ler Geneti&#287;ine
&#304;li&#351;kin �rnekler</span></b><span lang=TR style='font-family:Tahoma'>
&nbsp; <o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=522
 style='width:391.35pt;mso-cellspacing:0cm;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border-top:1.5pt;border-left:
  1.5pt;border-bottom:1.0pt;border-right:1.0pt;border-color:black;border-style:
  solid;mso-border-top-alt:1.5pt;mso-border-left-alt:1.5pt;mso-border-bottom-alt:
  .75pt;mso-border-right-alt:.75pt;mso-border-color-alt:black;mso-border-style-alt:
  solid;background:#DBE5F1;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sendrom<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  border-top:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-top-alt:
  solid black 1.5pt;background:#DBE5F1;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Gen<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:1.5pt;border-left:
  1.0pt;border-bottom:1.0pt;border-right:1.5pt;border-color:black;border-style:
  solid;mso-border-top-alt:1.5pt;mso-border-left-alt:.75pt;mso-border-bottom-alt:
  .75pt;mso-border-right-alt:1.5pt;mso-border-color-alt:black;mso-border-style-alt:
  solid;background:#DBE5F1;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Gen fonksiyonu<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Otozomal dominant nokt�rnal frontal lob epilepsisi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>CHRNA4<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Asetil kolin resept�r� sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Otozomal dominant nokt�rnal frontal lob epilepsisi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>CHRNB2<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Asetil kolin resept�r� sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Otozomal dominant nokt�rnal frontal lob epilepsisi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>CHRNA2<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Asetil kolin resept�r� sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Jeneralize epilepsi febril n�bet plus<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>SCN1B<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sodyum kanal&#305; sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Jeneralize epilepsi febril n�bet plus 2<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>SCN1A<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sodyum kanal&#305; sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Jeneralize epilepsi febril n�bet plus 3<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABRG2<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABA resept�r sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Benign
  neonatal/infantil<span style='mso-spacerun:yes'>� </span>ailesel
  konv�lziyonlar<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>SCN2A<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sodyum kanal&#305; sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Benign ailesel neonatal n�betler<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>SCN1A<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sodyum kanal&#305; sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:21.0pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Dravet Sendromu (SMEI)<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>SCN1A<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:21.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sodyum kanal&#305; sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>�ocukluk �a&#287;&#305; absans epilepsisi ve febril n�bet<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABRG2<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABAA resept�r� sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>�ocukluk �a&#287;&#305; absans epilepsisi ve febril n�bet<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>CLCN2<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Klor kanal&#305; sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:35.25pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:35.25pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Febril n�bet ve temporal lob epilepsisi <o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:35.25pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABRA1<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:35.25pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABAA resept�r� sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Lateral temporal lob epilepsisi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>LGI1<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Fonksiyonu bilinmiyor<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Otozomal dominant juvenil miyoklonik epilepsi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABRA1<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GABA resept�r sub�nitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>J�venil miyoklonik epilepsi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>EFHC1<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>R tip Ca ak&#305;m&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>J�venil miyoklonik epilepsi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Ser 1Aresept�r� <o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;mso-yfti-lastrow:yes;height:18.75pt'>
  <td width=229 valign=top style='width:171.6pt;border:solid black 1.0pt;
  border-left:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-left-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Erken ba&#351;lang&#305;�l&#305; absans epilepsisi<o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>GLUT1<o:p></o:p></span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border:solid black 1.0pt;
  border-right:solid black 1.5pt;mso-border-alt:solid black .75pt;mso-border-right-alt:
  solid black 1.5pt;padding:0cm 0cm 0cm 0cm;height:18.75pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Glikoz transport geni<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tablo 11. Kortikal Geli&#351;im Anomalileri
ile &#304;lgili Baz&#305; Gen Lokalizasyon ve Mutasyonlar&#305; <o:p></o:p></span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=398
 style='width:298.5pt;mso-cellspacing:0cm;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:#BBE0E3;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Sendrom</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:#BBE0E3;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Lokus</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:#BBE0E3;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Gen</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;zole
  lisensefali sekans&#305;<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Xq22.3-q23<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>DCX
  (doublecortin)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:30.75pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:30.75pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:30.75pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>17p13.3<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:30.75pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>LIS1<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:24.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:24.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Subkortikal band
  heterotopisi (SBH)<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:24.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Xq22.3-q23<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:24.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>DCX
  (doublecortin)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:30.75pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:30.75pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>&nbsp;<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:30.75pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>17p13.3<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:30.75pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>LIS1<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Miller-Dieker
  sendromu (MDS)<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>17p13.3<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>�Contigious� gen
  defektleri<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Serebral
  hipoplazi ile lisensefali<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>7q22<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>RELN<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Kas-g�z-beyin
  hastal&#305;&#287;&#305; (MEB)<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>1p32<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bilinmiyor<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:24.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:24.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bilateral
  periventrik�ler nod�ler heterotopi <o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:24.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Xq28<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:24.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>FLN1 (filamin 1)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tuberoskleroz 1
  (TSC1)<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>9q32<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>TSC1 (hamartin)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;mso-yfti-lastrow:yes;height:15.0pt'>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tuberoskleroz 2
  (TSC2)<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>16p13.3<o:p></o:p></span></p>
  </td>
  <td width=133 valign=top style='width:99.75pt;border:solid black 1.0pt;
  mso-border-alt:solid black .75pt;background:white;padding:0cm 0cm 0cm 0cm;
  height:15.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>TSC2 (tuberin)<o:p></o:p></span></p>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
</table>

<p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><a name="Epilepsi_tedavi"></a><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma'>EP&#304;LEPS&#304;
TEDAV&#304;S&#304;</span></b><span lang=TR style='font-size:14.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi
tedavisinde ilk basamak, tan&#305;n&#305;n do&#287;ru konmas&#305; ve ila�la
tedaviye gerek olup olmad&#305;&#287;&#305;n&#305;n belirlenmesidir. Tedaviye
gerek g�r�ld�&#287;�nde n�bet &#351;ekli, sendrom �zellikleri, k&#305;smen de
etyolojisine g�re hangi ilac&#305;n verilmesi gerekti&#287;i belirlenir.
Tan&#305; do&#287;ru da olsa verilen ilac&#305;n uygun olmamas&#305;, takiplerde
olgunun yanl&#305;&#351; olarak diren�li epilepsisi oldu&#287;unu
d�&#351;�nd�rebilir. Epilepside genel olarak verilen uygun ilk antiepileptik
ila�la (AE&#304;) n�bet kontrol� % 65-75 civar&#305;ndad&#305;r. Tedavi
alanlarda 2 y&#305;l n�betsiz kalma oran&#305; % 74.7 olarak
bildirilmi&#351;tir.<span style='mso-spacerun:yes'>� </span>&#304;la�
tedavisine cevaps&#305;z oldu&#287;u s�ylenerek epilepsi cerrahisi uygulanan
merkezlere g�nderilen olgular&#305;n aras&#305;nda dahi %15 kadar&#305;n&#305;n
video-monitorizasyon incelemeleri sonunda �yalanc&#305; n�bet� tan&#305;s&#305;
ald&#305;&#287;&#305;n&#305; an&#305;msamak ay&#305;r&#305;c&#305; tan&#305; ve
do&#287;ru tan&#305;n&#305;n �nemini vurgulamak a�&#305;s&#305;ndan
anlaml&#305;d&#305;r.<span style='mso-spacerun:yes'>�� </span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>AE&#304; tedavisi
en az 4-5 y&#305;l s�ren, erken veya ge� d�nemde �&#305;kabilecek,olas&#305;
hafif veya a&#287;&#305;r yan etkilerin g�r�lebilece&#287;i bir tedavidir.
Hastan&#305;n bireysel �zellikleri iyi belirlenmelidir. Hastan&#305;n tedaviye
g�sterece&#287;i bireysel farkl&#305;l&#305;klar, tedaviye uyumu, uzun s�reli
takip gereklili&#287;i konunun �nemini g�stermektedir. Ayr&#305;ca komorbid
hastal&#305;klar&#305; ve bu hastal&#305;klar&#305; i�in kullanmas&#305;
gereken ila�lar&#305;n da rol� unutulmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;yi bir
antiepileptik tedaviden beklenen �zellikler yan etkisinin olmamas&#305;, iyi
bir biyoyararlan&#305;m&#305;n&#305;n olmas&#305;, basit lineer kineti&#287;e
sahip olmas&#305;, ila� etkile&#351;imlerinin olmamas&#305;, proteinlere az
veya hi� ba&#287;lanmamas&#305;, ilac&#305; metabolize eden sistemleri
etkilememesi, g�nde 1 veya en fazla 2 kerede kullan&#305;labilmesi ve
maliyetinin d�&#351;�k olmas&#305;d&#305;r. Teratojen olmamas&#305; ve
farkl&#305; form�llerde al&#305;nabilmesi de �nemlidir (&#351;urup, kaps�l,
tablet vb).<span style='mso-spacerun:yes'>� </span>Karaci&#287;erde metabolize
olan ve enzim ind�kleyicisi olan AE&#304;�lar, birbirleriyle ve di&#287;er
ila�larla etkile&#351;mektedir. Bu �zellikler eski ku&#351;ak ila�larda daha
belirgindir. Genel olarak yeni ku&#351;ak ila�lar bu ama�la
geli&#351;tirilmi&#351;tir ve daha az etkile&#351;im g�steririler. Gabapentin,
pregabalin ve levetirasetam hemen hemen hi� etkile&#351;ime girmeyen ila�lar
olarak �ne �&#305;kmaktad&#305;r. 1993�ten sonra lamotrijin, okskarbazepin,
levetirasetam, vigabatrin, klobazam, topiramat, felbamat, gabapentin, tiagabin,
zonisamid, pregabalin, lakozamid gibi pek �ok ila� d�nyada ve �lkemizde
kullan&#305;ma sunulmu&#351;tur. Yeni ku&#351;aktan ba&#351;l&#305;ca beklenti
y�ksek etkinlik, yani daha az yan etki ve daha �ok etkili olmalar&#305; iken,
yeni AE&#304;�larla da bir�ok sorunun varoldu&#287;u ve devam etti&#287;i
g�r�lmektedir. Yak&#305;n ge�mi&#351;e kadar k&#305;s&#305;tl&#305; say&#305;da
ila�larla zorlu bir tedavinin �stesinden gelinmeye
�al&#305;&#351;&#305;lmaktayd&#305;. Son y&#305;llarda bu yeni molek�ller
tedavi se�eneklerini artt&#305;rmakta, �zellikle tedaviye diren�li epilepsi
olgular&#305;nda ba&#351;l&#305;ca ba&#351;vuru ila�lar&#305; olmaktad&#305;r.
Ayr&#305;ca, yan etkilerin varl&#305;&#287;&#305;nda yerine konabilecek
di&#287;er tedavi olas&#305;l&#305;klar&#305;n&#305;n olmas&#305; hekimi pratikte
rahatlat&#305;c&#305; bir unsurdur. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Bu
geli&#351;melere ra&#287;men yeni AE&#304;�lar epilepsinin zorlu tedavisinde,
arzu edildi&#287;i kadar etkin olmaktan hen�z uzakt&#305;r. Eski ku&#351;ak
AE&#304;�lar&#305;n eskileri kadar iyi tan&#305;nmamalar&#305; ve beklenmedik
yan etkilere rastlanma olas&#305;l&#305;&#287;&#305; bir di&#287;er sorunudur.
Ayr&#305;ca �lkemiz ko&#351;ullar&#305;nda etkin ve ucuz tedavilerin yerini
almadan �nce, titizlikle de&#287;erlendirilmeleri gerekmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>Epilepside hedef
farmakolojik tedavi 3 basamakta d�&#351;�n�lebilir:<o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>N�betleri
bask&#305;lamak,</span><span lang=TR style='font-size:24.0pt;font-family:Tahoma;
color:#FFFFCC'> </span><span lang=TR style='font-size:11.0pt;font-family:Tahoma;
text-transform:uppercase'>ANT&#304;EP&#304;LEPT&#304;K</span><span lang=TR
style='font-family:Tahoma'> tedavi (&#351;u an i�in kullan&#305;lan ila�lar)<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsiyi
tedavi etmek,</span><span lang=TR style='font-size:24.0pt;font-family:Tahoma;
color:#000099'> </span><span lang=TR style='font-size:11.0pt;font-family:Tahoma'>ANT&#304;EP&#304;LEPTOJEN&#304;K</span><span
lang=TR style='font-family:Tahoma'> tedavi<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>H�cre
�l�m�n� engellemek,</span><span lang=TR style='font-size:24.0pt;font-family:
Tahoma;color:#FFFFCC'> </span><span lang=TR style='font-size:11.0pt;font-family:
Tahoma'>N�ROPROTEKT&#304;F</span><span lang=TR style='font-family:Tahoma'>
tedavi<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Antiepileptojenik
bir ila� epilepsili hastalarda kal&#305;c&#305; remisyon sa&#287;lamal&#305;,
epilepsinin progresyonunu ve farmakorezistans<span style='mso-spacerun:yes'>�
</span>(ilaca diren�) geli&#351;imini<span style='mso-spacerun:yes'>�
</span>durdurmal&#305;,<span style='mso-spacerun:yes'>� </span>risk grubundaki
hastalarda epilepsinin ba&#351;lamas&#305;n&#305; �nlemelidir (profilaktik
etki). Antiepileptik ila�lar&#305;n epileptogenezi yani epilepsiyi
olu&#351;turan temel mekanizmalar&#305; engelleyemedi&#287;i, sadece
kullan&#305;ld&#305;klar&#305; s�re i�in n�betleri azaltabildi&#287;i veya
ortadan kald&#305;rabildi&#287;ini bilmek tedaviyi belirlemek
a�&#305;s&#305;ndan �nemlidir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;laca
diren� mekanizmas&#305;n&#305;n, n�betlerin n�robiyolojik
sonu�lar&#305;n&#305;n ne oldu&#287;u halen belirsizli&#287;ini
korumaktad&#305;r. Ancak n�betlerin �nlenmesiyle n�ronal �l�m�n �nlenme
s�recine katk&#305; da potansiyel antiepileptojenik etki olarak kabul edilebilir.
<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Benzer
olarak n�roprotektif etkiler de tart&#305;&#351;mal&#305;d&#305;r.
N�roproteksiyonun amac&#305; n�ronal fonksiyon bozuklu&#287;u/�l�m�
s&#305;n&#305;rlayarak beyinde m�mk�n olan en y�ksek h�cre interaksiyonunu
sa&#287;lamak ve n�ral fonksiyonun bozulmas&#305;n&#305; �nlemektir. Ancak
epileptogenez mekanizmas&#305;n&#305;n halen bilinmemesi, ba&#351;lang&#305;�
hasar&#305; ve s�recin zamanlamas&#305;n&#305;n yap&#305;lamamas&#305;
n�roprotektif stratejileri de yetersiz k&#305;lmaktad&#305;r. Klinikte genelde
kronik epilepsi olu&#351;tuktan sonra hastalarla kar&#351;&#305;
kar&#351;&#305;ya kal&#305;nmaktad&#305;r. <span style='mso-bidi-font-weight:
bold'>&#304;nsanda yap&#305;lan n�roproteksiyon �al&#305;&#351;malar&#305;
yetersiz ve dolayl&#305; bilgi sa&#287;lamaktad&#305;r.<o:p></o:p></span></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>AE&#304;
tedavisinde baz&#305; tart&#305;&#351;mal&#305; klinik durumlar &#351;�yle
s&#305;ralanabilir:<o:p></o:p></span></i></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>&#304;lk
n�bet <o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>�ok
seyrek n�betler (5-10 y&#305;lda bir n�bet gibi)<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>�ok
hafif n�bet (sadece deja vu vb.)<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Profilaksi
ama�l&#305; kullan&#305;m (post-travmatik, postoperatif d�nemlerde)<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>�zel
durumlara ba&#287;l&#305; n�betler (uykusuzluk, alkol al&#305;m&#305;,
a&#351;&#305;r&#305; yorgunluk, ate&#351; ile tetiklenen n�betler)<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Akut
semptomatik, toksik/metabolik n�betler (genellikle 3-6 ay tedavi yeterli
say&#305;labilir)<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Yaln&#305;zca
uykuda olan n�betler<o:p></o:p></span></p>

<p style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l52 level1 lfo39;tab-stops:list 36.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>D&#305;&#351;
uyaranlara ba&#287;l&#305; refleks n�betler<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;lk
epileptik n�bet ile ba&#351;vuran bir hastada tedaviye ba&#351;lama konusu
bug�n i�in halen tart&#305;&#351;mal&#305; bir konudur. &#304;lk n�bet kronik
bir epilepsi hastal&#305;&#287;&#305;na ba&#287;l&#305; ortaya �&#305;kan ilk
atak m&#305;d&#305;r? Akut semptomatik bir n�bet midir? Altta yatan bir neden
var m&#305;d&#305;r? sorular&#305;na yan&#305;t aranmas&#305; gerekir. Bu
sorulara yap&#305;lm&#305;&#351; az say&#305;da olan klinik
�al&#305;&#351;madan dolayl&#305; olarak �&#287;rendiklerimiz ile
yakla&#351;maktay&#305;z. Hemen tedavi ba&#351;lanan hasta grubunda, tedavi
ba&#351;lanmayan gruba g�re yeni n�bet riski ilk 1-2 y&#305;l i�in daha az
olmas&#305;na ra&#287;men, uzun s�reli remisyon a�&#305;s&#305;ndan 3-5
y&#305;l sonra belirgin bir fark g�r�lmemektedir. MESS
�al&#305;&#351;mas&#305;nda n�bet tekrar&#305; a�&#305;s&#305;ndan belirlenmi&#351;
olan en �nemli risk fakt�rleri hastan&#305;n ba&#351;vuru s&#305;ras&#305;ndaki
n�bet say&#305;s&#305;n&#305;n birden fazla olmas&#305;, n�rolojik bir
hastal&#305;&#287;&#305;n e&#351;lik etmesi ve anormal bir EEG bulgusunun
olmas&#305;d&#305;r.<span style='mso-spacerun:yes'>� </span>Ayr&#305;ca fokal
ba&#351;lang&#305;� varsa, belirgin bir neden (g�r�nt�lemede lezyon
varl&#305;&#287;&#305;), fokal n�rolojik bulgu, ailede epilepsi �yk�s�, anormal
EEG bulgusu olarak jeneralize diken dalga, fokal yava&#351; veya epileptiform
aktivitenin varl&#305;&#287;&#305; rek�rens riskini artt&#305;rmakta, buna
kar&#351;&#305;n belirli bir neden yok, EEG ve g�r�nt�leme normal ise risk
d�&#351;mektedir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>N�bet
tekrar&#305;n&#305;n getirece&#287;i fiziksel (yaralanma, kaza-sakatl&#305;k
vs) ve psikososyal (i&#351; kayb&#305;,<span style='mso-spacerun:yes'>�
</span>mahcubiyet duygusu, d&#305;&#351;lanma vs) zararlar ile tedavinin
olumsuz etkileri (sistemik ve/veya psikiyatrik yan etkiler, ila�
etkile&#351;imleri, doz ayarlama, uyum g��l�kleri) iyi de&#287;erlendirilmeli
ve denge iyi olu&#351;turulmal&#305;d&#305;r. Burada hastan&#305;n meslek ve
ya&#351;am ko&#351;ullar&#305; da belirleyici rol oynamaktad&#305;r.
�rne&#287;in yaln&#305;zca gece uykusunda n�bet ge�iren bir ev han&#305;m&#305;
ile &#305;&#351;&#305;kl&#305; ortamlarda n�bet ge�iren bir televizyon
spikerinin epilepsi tedavisi ayn&#305; ba&#287;lamda ele al&#305;namaz. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Baz&#305;
olgular �m�rleri boyunca tek bir n�bet veya uzun y&#305;llar arayla seyrek
olarak n�bet ge�irmektedirler. Bir epileptik n�betin tekrarlama riski ilk 3 ay
i�inde en y�ksektir. &#304;lk y&#305;l i�inde tekrarlamad&#305;&#287;&#305;nda
bir n�betin tekrarlama riski d�&#351;mektedir. Bu nedenle baz&#305; durumlarda
uzun s�recek, yan etkileri olabilecek ve belki de gereksiz olan bir tedaviye
ba&#351;lamadan �nce epilepsinin do&#287;al seyrini izlemek ak&#305;lc&#305;
olabilir. Ancak bu durumda da hasta ayr&#305;nt&#305;l&#305; olarak etyolojik
a�&#305;dan ara&#351;t&#305;r&#305;lmal&#305; ve mutlaka izlemeye al&#305;nmal&#305;d&#305;r.
�nemli bir di&#287;er nokta da hastaya durumun anlat&#305;lmas&#305; ve
verilecek karara kat&#305;l&#305;m&#305;n&#305;n sa&#287;lanmas&#305;d&#305;r.
Baz&#305; �ok iyi seyirli, hafif ve ya&#351;am&#305; etkilemeyen ve n�betleri
sadece uyku s&#305;ras&#305;nda olan sendromlarda (�rne&#287;in �ocukluk
�a&#287;&#305;n&#305;n selim santrotemporal dikenli epilepsisi) hastan&#305;n
ve ailesinin g�r�&#351;� de al&#305;narak tedavi yap&#305;lmayabilir. Burada
�nemli noktalardan biri de d�zenli, y&#305;llar s�ren bir tedaviye uyum
sa&#287;lamak a�&#305;s&#305;ndan hastan&#305;n i&#351; birli&#287;inin mutlaka
sa&#287;lanmas&#305;d&#305;r. �zel durumlara ba&#287;l&#305; n�betler e&#287;er
tekse tedavi verilmeyebilir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bug�n
i�in post-travmatik ya da postoperatif d�nem gibi riskli zamanlarda AE&#304;
verilmesini destekleyen veri yoktur, ancak �zellikle n�ro&#351;ir�rjiyenler
taraf&#305;ndan erken d�nem risklerini �nlemek i�in verilmektedir.
Ba&#351;lanm&#305;&#351; profilaktik ama�l&#305; tedavinin de mutlaka dikkatle
izlenmesi ve rasyonel bir &#351;emas&#305; olmas&#305; gerekti&#287;ini
unutmamak gerekir. Benzer &#351;ekilde saptanm&#305;&#351; toksik/metabolik
nedene ba&#287;l&#305; n�betler tedavi gerektirmez, e&#287;er
tekrarlam&#305;&#351; ve AE&#304; ba&#351;lanm&#305;&#351;sa da genellikle 3-6
ay tedavi yeterli say&#305;labilir. Saf refleks n�betlerde uyar&#305;dan uzak
durarak kontrol yoluna gidilebilir. Spontan n�betler eklenirse ya da
uyar&#305;y&#305; kontrol etmek yeterli de&#287;ilse n�bet tipine g�re tedavi
ba&#351;lan&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'>Epilepside ila�
tedavisinin temel ilkeleri</span></i><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'> &#351;u sekilde �zetlenebilir:<o:p></o:p></span></i></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Hasta
ile tedavinin gereklili&#287;i ve riskleri konusunda konu&#351;ularak uzun
s�reli bir izleme plan&#305; yap&#305;lmal&#305; <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Altta
yatan bir neden varsa (�rne&#287;in, intrakranyal t�m�r/arteryoven�z
malformasyon) veya komorbid ba&#351;ka bir hastal&#305;&#287;&#305; varsa
epilepsi ile birlikte tedavi edilmeli<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Sendroma
ve n�bet tipine uygun se�ilen tek ila� ile tedavi uygulanmal&#305; (monoterapi
ilkesi) <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>En
d�&#351;�k etkili dozla ba&#351;lanmal&#305; ve ilac&#305;n yan etkisi en az
veya hi� olmamal&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Doz tam
n�bet kontrolu sa&#287;lanana ya da yan etkiler g�r�lene dek
artt&#305;r&#305;lmal&#305; <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>&#304;la�
kan d�zeyi toksik etki veya tedaviye uyumsuzluk &#351;�phesi olursa kontrol
edilmeli ve bunun d&#305;&#351;&#305;nda n�bet kontrol�
sa&#287;lanm&#305;&#351; hastada sadece kan d�zeyine bak&#305;larak doz
de&#287;i&#351;ikli&#287;i yap&#305;lmamal&#305; <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Kullan&#305;lacak
di&#287;er ila�larla (�rne&#287;in antibiyotikler, oral kontraseptifler vd.)
ilac&#305;n etkisinin kaybolabilece&#287;i ya da toksik d�zeye
ula&#351;abilece&#287;i hastaya mutlaka belirtilmeli <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>&#304;lac&#305;n
aniden kesilmesi, unutulmas&#305;n&#305;n riskleri ve ila� al&#305;m&#305;ndaki
uyumsuzluk nedeniyle do&#287;abilecek riskler hakk&#305;nda bilgilendirilmeli <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>&#304;lk
ilaca yan&#305;t al&#305;nmazsa ikinci uygun se�im ile monoterapi; buna da
yan&#305;t al&#305;nmazsa uygun ila� kombinasyonuna gidilmesi veya di&#287;er
tedavi se�enekleri (epilepsi cerrahisi, vagal sinir stimulasyonu, vb)
d�&#351;�n�lece&#287;i konusunda hasta bilgilendirilmeli<span
style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Sadece
ila� al&#305;m&#305;n&#305;n yetmeyebilece&#287;i, n�beti tetikleyecek
durumlardan uzak durulmas&#305; konusunda bilgilendirilmeli (uykusuzluk, alkol
al&#305;m&#305; vb)<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Epilepsi
n�betlerinin tedavisi ile �zellikle psikiyatrik hastal&#305;klar&#305;n
(depresyon, anksiyete vb) gerileyip kaybolabilece&#287;i ve sosyal
integrasyonun tekrar sa&#287;lanaca&#287;&#305; anlat&#305;lmal&#305; <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l50 level2 lfo41;
tab-stops:list 18.0pt 72.0pt'><![if !supportLists]><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";
mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Tedavi
&#351;artlar&#305;n&#305;n hastan&#305;n ya&#351;am kalitesini y�kseltmeye
y�nelik oldu&#287;u unutulmamal&#305; (�rne&#287;in n�bet kontrol�
sa&#287;lanmas&#305;na ra&#287;men yan etkilerin hastay&#305; k�t� durumda
b&#305;rakmas&#305;n&#305;n engellenmesi gibi)<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma'>&#304;LA� SE�&#304;M&#304;</span></b><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Antiepileptik
ila� se�imi i�in ilk �nce hastan&#305;n n�betlerinin ve epilepsi tipinin
s&#305;n&#305;flanmas&#305; gerekir. &#304;la� se�iminde rol oynayan en �nemli
fakt�rler etkinlik, toksik etkilerin olmamas&#305; veya daha ger�ek�i
yakla&#351;&#305;mla en az yan etki ve ucuzluk olarak �zetlenebilir.
Bunlar&#305;n yan&#305; s&#305;ra kullan&#305;m kolayl&#305;&#287;&#305;
(�rne&#287;in g�nde tek doz kullanma vb) �nemli bir fakt�rd�r. En ucuz
antiepileptikler fenitoin ve barbit�rat grubu ila�lard&#305;r. Yeni
antiepileptikler diye adland&#305;rd&#305;&#287;&#305;m&#305;z grubun �ok daha
pahal&#305; olmas&#305; kullan&#305;mlar&#305;n&#305;
k&#305;s&#305;tlay&#305;c&#305; en �nemli fakt�rd�r. Yan etki profilleri de g�z
�n�ne al&#305;nd&#305;&#287;&#305;nda bug�n i�in ilk basamakta se�ilecek
antiepileptikler idyopatik jeneralize epilepside valproik asid ve izleyerek
lamotrijin, levetirasetam, topiramat veya zonisamiddir. Sadece absans n�beti
olan hastalarda etos�ksimid ye&#287;lenebilir. Parsiyel epilepside ise ilk
se�enek karbamazepin veya okskarbazepindir. Lamotrijin ve levetirasetam
di&#287;er s&#305;k kullan&#305;lan ve parsiyel epilepsilerde monoterapi endikasyonu
alm&#305;&#351; olan ila�lara �rnek olarak verilebilir. Yeni antiepileptiklerin
�o&#287;u parsiyel epilepside ek tedavide kullan&#305;lmaktad&#305;r. Fenitoin
ve valproat h&#305;zl&#305; y�kleme avantaj&#305; nedeniyle status epileptikus
ve statusa e&#287;ilim durumlar&#305;nda ba&#351;vurulabilecek se�eneklerdir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;la�
se�iminde monoterapiler denenip ilaca yan&#305;t g�r�lmezse bu ila�lar&#305;n
kombinasyonlar&#305; hastaya verilebilir. Ancak diren�li epilepsilerde en �ok
yap&#305;lan hata monoterapi denenmeden gereksiz polifarmasi veya y�ksek doz
ila� kullan&#305;m&#305;d&#305;r. &#304;la� �ok �abuk titre edilerek
y�kseltilmemelidir. Ayr&#305;ca daha �nce y�ksek doz denenmi&#351; ila�lar veya
ayn&#305; kombinasyondaki ila�larda &#305;srarc&#305; olmamak, farkl&#305;
kombinasyonda d�&#351;�k dozda ila� vermek yan etkilerin ortaya �&#305;kmas&#305;n&#305;
�nler. Y�ksek dozda ortaya �&#305;kabilecek n�betlerin de �n�ne ge�ilmi&#351;
olur.<o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'>Yerle&#351;mi&#351;
antiepileptik ila�lar</span></i></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bu
grupla ilgili ana �zellikler <b style='mso-bidi-font-weight:normal'>Tablo 12 ve
13</b>�te k&#305;saca �zetlenmi&#351;tir. Miyokloni ve absans n�betleriyle
seyreden sendromlarda valproat&#305;n ilk se�enek oldu&#287;u ve
yanl&#305;&#351; tedaviyle �rne&#287;in karbamazepin veya fenitoin
kullan&#305;ld&#305;&#287;&#305;nda bu n�betlerin artabilece&#287;i
bilinmektedir. Bu durum tedavi se�iminde do&#287;ru s&#305;n&#305;flaman&#305;n
�nemini a�&#305;k�a ortaya koymaktad&#305;r. <br>
&nbsp;<o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>Tablo 12. Yerle&#351;mi&#351; Antiepileptik &#304;la�lar&#305;n
Farmakokinetikleri</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width=660 style='width:495.0pt;
 mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:3.0pt 3.0pt 3.0pt 3.0pt'>
 <tr style='mso-yfti-irow:0'>
  <td width="13%" valign=top style='width:13.28%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'>&#304;la�</span></b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'>Emilim (Bioyararlan&#305;m)</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'>Proteine ba&#287;lanma</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'>Yar&#305;lanma s�resi (saat)</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'>At&#305;lma yolu</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:9.0pt;font-family:Tahoma'>�zellikler</span></b><span
  lang=TR style='font-size:9.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="13%" valign=top style='width:13.28%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Karbamazepin<o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>yava&#351;&nbsp; <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>(%75-85)<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>%70-80<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>24-45(tek doz) <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>8-24 (kronik)<o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>hepatik (%95) metabolizma <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>aktif metabolit<o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>enzim ind�ksiyonu <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>otoind�ksiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="13%" valign=top style='width:13.28%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Na-Valproat<o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>h&#305;zl&#305; <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>(%100)<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>%88-92<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>7-17&nbsp; <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>(chrono formu d&#305;&#351;&#305;nda)<o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Hepatik metabolizma <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>aktif metabolit<o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>enzim
  inhibisyonu <o:p></o:p></span></p>
  <p><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>konsantrasyona
  ba&#287;l&#305; protein ba&#287;lanmas&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width="13%" valign=top style='width:13.28%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Fenitoin<o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Yava&#351;<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>%90-93<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>9-40<o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Doyurulabilen hepatik metabolizma<o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>enzim
  ind�ksiyonu <o:p></o:p></span></p>
  <p><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>konsantrasyona
  ba&#287;l&#305; yar&#305;lanma&nbsp;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width="13%" valign=top style='width:13.28%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Fenobarbital<o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Yava&#351;<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>%48-54<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>72-144<o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Hepatik (%75) metabolizma <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>��� de&#287;i&#351;meden at&#305;l&#305;r<o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>enzim
  ind�ksiyonu, sedasyon, tolerans ve rebound<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width="13%" valign=top style='width:13.28%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Klonazepam<o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>h&#305;zl&#305; <o:p></o:p></span></p>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>(%80-90)<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>%80-90<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>30-40<o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Hepatik metabolizma<o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>sedasyon,
  tolerans ve rebound<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width="13%" valign=top style='width:13.28%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>Etos�ksimid<o:p></o:p></span></p>
  </td>
  <td width="18%" valign=top style='width:18.36%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>h&#305;zl&#305; (%90-95)<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.76%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>0<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  9.0pt;font-family:Tahoma'>20-60<o:p></o:p></span></p>
  </td>
  <td width="16%" valign=top style='width:16.74%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:9.0pt;
  font-family:Tahoma'>%80 hepatik, %20 renal,<span style='mso-spacerun:yes'>�
  </span><o:p></o:p></span></p>
  </td>
  <td width="25%" valign=top style='width:25.02%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal><span lang=TR style='font-size:9.0pt;font-family:Tahoma'>�
  de&#287;i&#351;meden at&#305;l&#305;r �ocuklarda daha h&#305;zl&#305; klirens<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;color:black'>Tablo 13. Yerle&#351;mi&#351;
Antiepileptik &#304;la�lar&#305;n Endikasyonlar&#305; ve Dozlar&#305;</span></b><span
lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width=648 style='width:486.0pt;
 mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:3.0pt 3.0pt 3.0pt 3.0pt'>
 <tr style='mso-yfti-irow:0'>
  <td width="13%" valign=top style='width:13.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>&#304;la�</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>Endikasyonlar&#305;</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>Ba&#351;lama dozu</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>Ortalama doz (g�n)</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>Kullan&#305;ld&#305;&#287;&#305; devam
  dozlar&#305;</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>Doz aral&#305;&#287;&#305;</span></b><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-family:Tahoma'>Hedef d�zey&nbsp;</span></b><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Karbamazepin</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>parsiyel epilepside 1. se�enek</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>200mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>600-800mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>400-1600mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>G�nde 2/1(?)*</span><span lang=TR
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>4-10mg/L</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Na-Valproat</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>jeneralize epi.de 1. se�enek +parsiyel ep.</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>500mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>1000mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>500-3000mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>g�nde 2/1*</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>50-100mg/L</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Fenitoin</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>parsiyel epi. +status epileptikus</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>200mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>300mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>100-400mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>g�nde 2</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>10-20mg/L</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Fenobarbital</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>parsiyel + jeneralize epi + status epi. (2.)</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>60mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>120mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>60-240mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>g�nde 2/1</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>10-40mg/L</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Klonazepam</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Jeneralize epi (miyokloni) + status epileptikus</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>1mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>4mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>2-8mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>g�nde 2/1</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>yok</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Etos�ksimid</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="20%" valign=top style='width:20.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>absans n�betleri i�in spesifik</span><span
  lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>500mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>750mg</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="17%" valign=top style='width:17.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>500-1000mg</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>g�nde 2/1</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>40-100mg/L</span><span lang=TR style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>*od-bd sadece kontroll�
sal&#305;n&#305;m formlar&#305; ile</span><span lang=TR style='font-family:
Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:9.0pt;
font-family:Tahoma;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Yeni antiepileptik ila�lar</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'> <b
style='mso-bidi-font-weight:normal'>(Tablo 14)<o:p></o:p></b></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>G�n�m�zde
kullan&#305;lmakta olan yerle&#351;mi&#351; antiepileptik ila�lar&#305;n t�m
olgularda tam n�bet kontrol� sa&#287;lamamas&#305; ve yan etkilerin olmas&#305;
yeni antiepileptik ila�lar&#305;n geli&#351;tirilmesine neden olmaktad&#305;r.
Epileptik hastalar&#305;n yakla&#351;&#305;k %15-25 kadar&#305;nda t�m ila�
tedavisi se�eneklerine ra&#287;men etkili n�bet kontrol� sa&#287;lanamamaktad&#305;r.
Yeni AE&#304;lar&#305;n etki mekanizmalar&#305; (iyon kanallar&#305;n&#305;n
blokaj&#305;, GABAerjik transmisyonu art&#305;rmalar&#305;, eksitat�r
transmisyonun antagonizmas&#305;) temelde, daha �nceki baz&#305; ila�lar&#305;n
mekanizmalar&#305;yla b�y�k �l��de �ak&#305;&#351;maktad&#305;r <b
style='mso-bidi-font-weight:normal'>(Tablo 15)</b>. Bununla birlikte, molek�ler
d�zeyde meydana getirdikleri etkiler kesin olarak bilinmemektedir. Bu
ila�lar&#305;n baz&#305;lar&#305;, metabolik transformasyon ve d�&#351;�k
etkile&#351;im potansiyeli (levetirasetem, vigabatrin ve gabapentin) gibi
�zelliklerle eskilerden ayr&#305;lmaktad&#305;r; baz&#305;lar&#305; ise yo&#287;un
bir &#351;ekilde metabolize olmakta ve ila� etkile&#351;imlerinde yayg&#305;n
bir rol oynamaktad&#305;r (felbamat, lamotrijin) Baz&#305; yeni
antiepileptikler aktivite spektrumu a�&#305;s&#305;ndan, sadece parsiyel
n�betlerin tedavisinde kullan&#305;l&#305;rken (okskarbazepin, vigabatrin,
pregabalin, gabapentin gibi); baz&#305;lar&#305; ise hem parsiyel hem de
jeneralize n�bet tipleri �zerinde etkinlik g�stermektedir (levetirasetam,
lamotrijin, topiramat, zonisamid, ve felbamat). Ayr&#305;ca, bu ila�lar&#305;n
infantil spazmlar (�zellikle vigabatrin) ve ilaca diren�li epilepsilerin
tedavisinde ve n�bet s&#305;kl&#305;&#287;&#305;n&#305;n d�&#351;�r�lmesinde de
etkili olduklar&#305; g�r�lmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Yeni
antiepileptik ila�lar&#305;n yerle&#351;mi&#351; di&#287;er antiepileptiklere
oranla en b�y�k &#351;anss&#305;zl&#305;klar&#305; yo&#287;un
ara&#351;t&#305;rmalar sonucu geli&#351;tirilmelerine ba&#287;l&#305; olan �ok
y�ksek maliyetleridir. Bunun d&#305;&#351;&#305;nda eskiden beri kullan&#305;lan
ila�lar&#305;n olas&#305; tehlikeli yan etkilerinin zaten biliniyor olmas&#305;
oysa yeni antiepileptiklerle bilinmeyen tehlikeli yan etkilere rastlama
olas&#305;l&#305;&#287;&#305; da yerle&#351;mi&#351; antiepileptiklere tercih
edilmelerini engellemektedir. Bug�n i�in yeni ila�lar&#305;n (karbamazepin
benzeri okskarbazepin hari�) ilk basamak tedavide net yeri
bulunmamaktad&#305;r. Yerle&#351;mi&#351; antiepileptiklere diren�li veya yan
etki g�r�len hastalarda yeni antiepileptikler kullan&#305;labilir. T�rkiye�de
yeni antiepileptiklerden lamotrijin, vigabatrin, okskarbazepin, topiramat,
gabapentin, pregabalin, levetirasetam, zonisamid, lakozamid piyasada
bulunmaktad&#305;r. Klobazam, tiagabin, progabid, brivarasetam, karisbamat
yak&#305;n gelecekte piyasaya verilecektir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:9.0pt;
font-family:Tahoma;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:9.0pt;
font-family:Tahoma;color:black'>Ta</span></b><b><span lang=TR style='font-family:
Tahoma;color:black'>blo 14. Yeni antiepileptik ila�lar&#305;n farmakokinetikleri</span></b><span
lang=TR style='font-family:Tahoma'> <b><o:p></o:p></b></span></p>

<table class=MsoNormalTable border=1 cellpadding=0 width=739 style='width:554.25pt;
 mso-cellspacing:1.5pt;background:#FFFFCC;mso-padding-alt:3.0pt 3.0pt 3.0pt 3.0pt'>
 <tr style='mso-yfti-irow:0'>
  <td width="12%" valign=top style='width:12.18%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>&#304;la�</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'>At&#305;lma yolu</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><b><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'>Proteine ba&#287;lanma</span></b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><b><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'>Yar&#305;lanma s�resi (saat)</span></b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><b><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'>Kullan&#305;m s&#305;kl&#305;&#287;&#305;</span></b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><b><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'>Kararl&#305; d�zeye ula&#351;ma</span></b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:#DBE5F1;padding:
  3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><b><span lang=TR style='font-size:10.0pt;font-family:
  Tahoma'>Not<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Felbamat<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>%50 hepatik, %50 renal<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>%25<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>20-23 saat<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>2 veya 3<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>5-10 g�nde<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>VPA ve DFH klirensini azalt&#305;r<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Gabapentin<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>%100 b�brek<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>%0<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>5-7&nbsp; <o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>En az 3 <o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>1-2<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Doza ba&#287;l&#305; emilim g�sterir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Lamotrijin<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>% 90 karaci&#287;er<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>%50-55<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>10-15, Enzim ind�kleyici ila�la 40-60 <o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>2<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>15&nbsp;<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Glik�ronidasyon
  ile temizlenir. &#304;nd�kleyicilerle artar, VPA ile azal&#305;r. Metaboliti
  inaktif<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Levetirasetam<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>%66
  b�brek, % 34 asetamid gruplar&#305;na hidroliz<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>%10&gt;<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>7-8<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>2<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>3-4<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Karaci&#287;er d&#305;&#351;&#305;nda metabolize
  olur. Metaboliti inaktif<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Okskarbazepin<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>%60-70 karaci&#287;er, kalan&#305; renal<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>%40<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>8-10<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>2
  veya 3<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
  text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>3-4<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Maj�r metaboliti 10 hidroksi karbazepin<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Pregabalin<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>B�brek %95<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>0<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>6<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>2 veya 3<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>2<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Etkile&#351;im yok<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Tiagabin<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>%90 karaci&#287;er<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>96<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>5-9<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>2-3-4<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>3<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Oksidatif metabolizma ile inaktif metabolitlere
  d�n�&#351;�r<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Topiramat<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>%40-70 b�brek<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>9-17<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>20-24<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>2<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>5-7<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Karaci&#287;erden de metabolize, enzim
  ind�kleyicilerle artar. &#304;naktif metabolit<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;mso-yfti-lastrow:yes'>
  <td width="12%" valign=top style='width:12.18%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Zonisamid<o:p></o:p></span></p>
  </td>
  <td width="14%" valign=top style='width:14.9%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>%70 karaci&#287;er<o:p></o:p></span></p>
  </td>
  <td width="10%" valign=top style='width:10.5%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>40-60<o:p></o:p></span></p>
  </td>
  <td width="11%" valign=top style='width:11.34%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>50-68<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.24%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>G�nde 1 veya 2<o:p></o:p></span></p>
  </td>
  <td width="12%" valign=top style='width:12.7%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>12-14<o:p></o:p></span></p>
  </td>
  <td width="23%" valign=top style='width:23.96%;background:transparent;
  padding:3.0pt 3.0pt 3.0pt 3.0pt'>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>Enzim ind�kleyici ile klirens artar<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Tablo
15. Antiepileptik &#304;la�lar&#305;n Etki Mekanizmalar&#305; ve Etkili
Olduklar&#305; N�bet Tipleri <o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=671
 style='width:503.25pt;margin-left:-1.7pt;border-collapse:collapse;border:none;
 mso-border-alt:solid #4BACC6 1.0pt;mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
 mso-border-insideh:1.0pt solid #4BACC6;mso-border-insidev:1.0pt solid #4BACC6'>
 <tr style='mso-yfti-irow:0'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;la�<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Na
  kanal&#305;<span style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ca
  kanal&#305;<span style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA
  sistemi<span style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Glutamat
  resept�r� <span style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Fokal
  ba&#351;l. n�bet<span style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Primer
  jener. n�bet<span style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Absans<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Miyokloni<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Fenitoin<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Karbamazepin*<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Lamotrijin <span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>HVA<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+ NMDA AMPA<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+/-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Zonisamid<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>T tipi<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>?<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Fenobarbital ve primidon<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>HVA<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA<sub>A</sub>
  res*<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>AMPA<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+/-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Benzodiazepin<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA<sub>A</sub>
  res<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Vigabatrin<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABAT<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tiagabin **<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA geri
  al&#305;m inh.<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Etos�ksimid <span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+?<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>T tipi<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>?<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>?<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Valproik asit<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+?<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>T tipi?<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA
  art&#305;m&#305;<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Topiramat*<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>HVA<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA<sub>A</sub><o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>KA / AMPA<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Gabapentin<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>N tipi
  HAV&#945;2&#948;<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA
  art&#305;m&#305;<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+?<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Pregabalin<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>HAV&#945;2&#948;<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA
  art&#305;m&#305;<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Levetirasetam*<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>HAV<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ters etki<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Felbamat **<span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+ (mod)<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>HVA<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>GABA<sub>A</sub>
  res<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>NMDA<o:p></o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>(+)<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;mso-yfti-lastrow:yes'>
  <td width=117 valign=top style='width:88.1pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Okskarbazepin <span
  style='mso-bidi-font-weight:bold'><o:p></o:p></span></span></b></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=68 valign=top style='width:51.2pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>?<o:p></o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>
  </td>
  <td width=57 valign=top style='width:42.5pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b style='mso-bidi-font-weight:
  normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>+<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;border-top:none;border-left:none;
  border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p align=center style='text-align:center'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma'>-<o:p></o:p></span></b></p>
  </td>
 </tr>
</table>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>GABA<sub>A</sub>
res*: GABA<sub>A</sub> resept�rlerin negatif allosterik mod�lat�r�, HVA: high
voltage activated (y�ksek voltaj aktivasyonlu), GABAT:GABA transaminaz inhibisyonu,
NMDA: N-metil D-aspartat, KA: kainik asit, AMPA:
&#945;Amino-3-hidroksi-5-metil-4-izoksazol-proprionik asit, <o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>Ek
mekanizmalar: Levetirasetam: sinaptik vezik�l protein 2A (SV2A)ya y�ksek oranda
ba&#287;lanarak etki eder. Topiramat: </span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>karbonik anhidraz inhibisyonu; Karbamazepin:
monoamin, asetil kolin resept�rleri �zerinden etkili ve en yenilerden
lakozamid: <span style='mso-bidi-font-weight:bold'>Sodyum kanal&#305;
yava&#351; inaktivasyonu, kollapsin cevap mediat�r protein- 2 fonksiyon
mod�lasyonu sa&#287;lar<o:p></o:p></span></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>Parentez
i�indekiler: etkinliklerinin daha az olmas&#305;n&#305; g�steriyor; -: hi�
etkisi yok veya n�beti k�t�le&#351;tirdi&#287;ini g�steriyor <o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>**�lkemizde
bulunmamaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Antiepileptik &#304;la�lar&#305;n Yan
Etkileri (Tablo 16-18)</span></b><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>AE&#304;
yan etkileri be&#351; alt ba&#351;l&#305;k alt&#305;nda g�zden ge�irilebilir. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tip A</span></b><span lang=TR
style='font-family:Tahoma'> reaksiyonlar, akut reaksiyonlar, ila� etki
mekanizmas&#305; ile ilgilidir. Burada en �ok MSS �zerine etkiler g�r�l�r. Bu
yan etkiler i�inde kognitif etkilenme ki&#351;inin sosyal ve i&#351;
ya&#351;am&#305;n&#305; en �ok etkileyen �nemli bir problemdir. B�t�n AE&#304;�lar
kognitif etkilenme yapabilir. Polifarmasi, y�ksek dozda kullan&#305;m veya
AE&#304; serum d�zeyinin y�ksek olmas&#305; riski artt&#305;r&#305;r.
Yerle&#351;mi&#351; AE&#304; aras&#305;nda pirimidon ve fenobarbital ve yeni
AE&#304;�lardan topiramat kognitif etkilenmeyi en fazla yapan ila�lard&#305;r.
A<span style='mso-bidi-font-weight:bold'>kut doza veya konsantrasyona
ba&#287;l&#305;</span><i> </i>toksisite genellikle spesifik olmayan bir
ensefalopati &#351;eklinde seyreder, nistagmus, ataksi, dizartri, konf�zyon,
sersemlik dikkati �eker. Bu s&#305;rada genellikle ila� kan d�zeyi normal
s&#305;n&#305;rlar&#305;n �st�nde bulunur. Bu tabloya hemen t�m
yerle&#351;mi&#351; antiepileptikler yol a�abilir, en az vaproat ile
bildirilmi&#351;tir. Fenitoin istemsiz hareketlere yol a�abilir. �ocuklarda
fenobarbital ve benzodiazepinlere ba&#287;l&#305; olarak davran&#305;&#351;
bozukluklar&#305; olu&#351;abilmektedir. Bu tip yan etkilerin �zelli&#287;i doz
azalt&#305;lmas&#305; ile iz b&#305;rakmadan kaybolmas&#305;d&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tip B</span></b><span lang=TR
style='font-family:Tahoma'> idyosenkratik etki mekanizmalar&#305;yla
ili&#351;kilidir (imm�nolojik, genetik veya di&#287;er mekanizmalar). <span
style='mso-bidi-font-weight:bold'>Akut idyosenkratik</span> toksisite dozdan
ba&#287;&#305;ms&#305;z geli&#351;ir. Fenitoin ve karbamazepin ba&#351;ta olmak
�zere �o&#287;u ila� ile g�r�lebilen hafif mak�lopap�ler deri d�k�nt�leri bunun
en s&#305;k g�r�len �rne&#287;idir. �ok a&#287;&#305;r seyreden eksfolyatif
er�psiyonlar veya Stevens-Johnson sendromu nadir ancak �ok tehlikeli bir
dermatolojik yan etkidir, fenitoin, fenobarbital karbamazepin ve lamotrijinle g�r�lebilmektedir.
Bu tabloya ate&#351;, hepatotoksisite, lenfadenopati e&#351;lik edebilir.
Karbamazepine ba&#287;l&#305; bir di&#287;er ciddi ancak �ok seyrek
idyosenkratik yan etki aplastik anemidir. Yeni antiepileptiklerden
felbamat&#305;n 1/2000 oran&#305;nda aplastik anemiye yol
a�t&#305;&#287;&#305;n&#305;n sonradan anla&#351;&#305;lmas&#305; �zerine
kullan&#305;m&#305; s&#305;n&#305;rlanm&#305;&#351;t&#305;r. �zellikle k���k
�ocuklarda valprota ba&#287;l&#305; akut fatal karaci&#287;er yetmezli&#287;i
bildirilmi&#351;tir. <b style='mso-bidi-font-weight:normal'>Tablo 16</b>�da
baz&#305; idyosenkratik etkiler belirtilmi&#351;tir. Tedaviye
ba&#351;land&#305;ktan sonraki ilk haftalar veya aylarda g�r�l�r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tip C</span></b><span lang=TR
style='font-family:Tahoma'>, kronik veya gecikmi&#351; yan etkiler ise aylar ve
y&#305;llar i�inde g�r�lmektedir. Altta yatan mekanizmalar
anla&#351;&#305;lamam&#305;&#351;t&#305;r hemen her sistemi ilgilendirebilir.
Y�ksek doz kullan&#305;m&#305; ve ila� kombinasyonlar&#305; genellikle
k�m�latif olan bu tip yan etkiyi artt&#305;r&#305;c&#305; rol oynar
�rne&#287;in fenitoine ba&#287;l&#305; di&#351;eti hiperplazisi, barbit�rata
ba&#287;l&#305; omuz-el sendromu. Bilinen biyokimyasal veya metabolik
mekanizmalar sonucu vitamin D katabolizmas&#305;n&#305; h&#305;zland&#305;ran
enzim ind�kleyen AE&#304;�lar osteomalazi yapmaktad&#305;rlar. Endokrin ve
�reme organlar&#305;nda �rne&#287;in overlerde polikistik
de&#287;i&#351;iklikler, y�ksek testosteron d�zeyi ve menstr�el d�zensizlikler
g�r�lebilir. �nemli di&#287;er sorun ise AE&#304;�lar&#305;n kilo �zerine
etkisidir. Topiramat, felbamat ve zonisamid kilo kayb&#305;na neden olurken,
valproik asit, pregabalin, gabapentin, vigabatrin ve daha az oranda
karbamazepin kilo al&#305;m&#305; yapar. Kozmetik istenmeyen yan etkiler bir
yana, hastalar&#305;n kompliyans&#305;n&#305;n azalmas&#305;na veya ilac&#305;
bu nedenle tamamen b&#305;rakmas&#305;na neden olabilir. Kilo al&#305;m&#305;
�zellikle diabetus mellitusu ve kalp hastal&#305;&#287;&#305; olanlarda ciddi
riskler yaratabilir. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tip D</span></b><span lang=TR
style='font-family:Tahoma'> yan etki olarak ikinci jenerasyona etki (�r:
teratogenez) ve karsinojenik etki ele al&#305;n&#305;r. AE&#304; ile
karsinojenik etki bilinmemektedir ve teratogenez konusu son y&#305;llarda
geni&#351; �al&#305;&#351;malarda ele al&#305;nm&#305;&#351;t&#305;r.
A&#351;a&#287;&#305;da gebelik ve epilepsi b�l�m�nde ele al&#305;nacak olan bu
konuda bilinen, t�m AE&#304; lar&#305;n olas&#305; teratogenik etkileri
olmas&#305;na kar&#351;&#305;n bunun �zellikle d�&#351;�k doz kullan&#305;ld&#305;&#287;&#305;nda
ve monoterapi ile d�&#351;�k oldu&#287;udur. AE&#304;�lar&#305;n karsinojenik
ve/veya genotoksik etkileri �zerine �al&#305;&#351;malar s�rmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tip E</span></b><span lang=TR
style='font-family:Tahoma'> grubu ile ila� etkile&#351;imleri incelenir ve <b
style='mso-bidi-font-weight:normal'>Tablo 18</b>�de �zetlenmi&#351;tir.<b
style='mso-bidi-font-weight:normal'> </b><o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tablo 16. Antiepileptik &#304;la�lar&#305;n
Baz&#305; Yan Etkileri<o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid black;mso-border-insidev:.5pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  mso-border-alt:solid black .5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tip A (akut)<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tip B (idyosenkratik)<o:p></o:p></span></b></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tip C (kronik)<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Ataksi <o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Aplastik anemi<o:p></o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ba&#287; dokusu
  hastal&#305;klar&#305;: di&#351; eti hiperplazisi, y�z hatlar&#305;nda
  kabala&#351;ma, Dupuytren kontrakt�r�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>G�rme bulan&#305;kl&#305;&#287;&#305;, �ift g�rme<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Glokom<o:p></o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Endokrin
  hastal&#305;klar: Tiroksin d�zeyinde azalma, kortizol ve seks hormon
  metabolizmas&#305;nda artma<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Kognitif etkilenme<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Karaci&#287;er toksisitesi<o:p></o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Ig A eksikli&#287;i, ilaca ba&#287;l&#305; sistemik lupus
  eritematozus <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Duygudurum/davran&#305;&#351; bozulmas&#305;<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Cilt d�k�nt�s�<o:p></o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Sa� d�k�lmesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Ba&#351; d�nmesi<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Di&#287;er
  imm�n-arac&#305;l&#305; reaksiyonlar<o:p></o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Hirsutizm, akne <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Yorgunluk <o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Nefrolitiyazis<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Gastrointestinal semptomlar<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>G�rme alan&#305; defekti<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Ba&#351;a&#287;r&#305;s&#305;<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Vitamin D/folat eksikli&#287;i<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Hiponatremi <o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Kilo al&#305;m&#305; Kilo kayb&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>&#304;nsomni<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Osteomalazi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Somnolans<o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Bellek ba&#351;ta olmak �zere kognitif bozukluklar<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;mso-yfti-lastrow:yes'>
  <td width=175 valign=top style='width:131.4pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Tremor <o:p></o:p></span></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=247 valign=top style='width:185.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Davran&#305;&#351; problemleri<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma;
color:black'>Tablo 17. Yerle&#351;mi&#351; ve Yeni </span></b><b><span lang=TR
style='font-family:Tahoma'>Antiepileptik &#304;la�lar&#305;n Baz&#305; Ciddi ve
Di&#287;er Yan Etkileri<span style='color:black'><o:p></o:p></span></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='width:460.6pt;border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid black;mso-border-insidev:.5pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  mso-border-alt:solid black .5pt;background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><a name="Diren�li_epilepsiler_ve_cerrahi_yolla_te"></a><b><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;color:black'>&#304;la�<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Ciddi yan etki<span style='mso-tab-count:1'>���� </span><o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Di&#287;er yan etki<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Karbamazepin
  <o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Aplastik anemi, hepatotoksisite, Steven �Johnson sendromu,
  lupus benzeri tablo, ila� hipersensitivite sendromu<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Sersemlik, ataksi, diplopi, bulant&#305;,
  yorgunluk hissi, l�kopeni, d�k�nt�, trombositopeni, hiponatremi,
  davran&#305;&#351; bozuklu&#287;u, tikler<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Etos�ksimid<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Kemik ili&#287;i depresyonu, hepatotoksisite, lupus,
  psikoz, Steven-Johnson sendromu<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, gastrik iritasyon,
  ba&#351;a&#287;r&#305;s&#305;, d�k�nt�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Felbamat<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Aplastik anemi, hepatik yetersizlik,
  Steven-Johnson sendromu<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Anoreksi, kusma, insomni,
  ba&#351;a&#287;r&#305;s&#305;, somnolans<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Gabapentin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bilinmiyor<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Somnolans, sersemlik, ataksi, yorgunluk hissi,
  nistagmus, kilo art&#305;&#351;&#305;,<span style='mso-spacerun:yes'>�
  </span>�ocuklarda davran&#305;&#351; bozuklu&#287;u, �dem<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Lamotrijin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Steven-Johnson sendromu ya da toksik epidermal
  nekroz, akut hepatik yetmezlik /multiorgan yetmezli&#287;i<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Sersemlik, ataksi, insomni, ba&#351;a&#287;r&#305;s&#305;,
  diplopi, g�rme bulan&#305;kl&#305;&#287;&#305;, bulant&#305;, kusma, d�k�nt�,
  ajitasyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Levetirasetam<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bilinmiyor<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, ba&#351; a&#287;r&#305;s&#305;,
  sersemlik, yorgunluk, somnolans, davran&#305;&#351;
  de&#287;i&#351;ikli&#287;i<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Okskarbazepin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>D�k�nt�<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, ba&#351; a&#287;r&#305;s&#305;, sersemlik,
  yorgunluk, hiponatremi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Fenobarbital<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Hepatotoksisite,<span style='mso-spacerun:yes'>�
  </span>ba&#287; dokusu ve kemik ili&#287;i bozuklu&#287;u, Steven-Johnson
  sendromu, ila� hipersensitivite send.<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Sedasyon, ataksi, nistagmus, d�k�nt�, depresyon,
  �ocuklarda hiperaktivite, �&#287;renme g��l�&#287;�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Fenitoin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Aplastik anemi, hepatik yetersizlik,
  Steven-Johnson sendromu, lupus benzeri tablo, ps�dolenfoma, retroperitoneal
  fibroz, serebellar atrofi, ila� hipersensitivite sendromu<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Di&#351;eti hipertrofisi, hirsutizm, ataksi, nistagmus,
  diplopi, d�k�nt�, anoreksi, bulant&#305;, makrositoz, periferik n�ropati,
  osteoporoz<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Tiagabin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Stupor, nonkonv�lzif status<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, ba&#351;a&#287;r&#305;s&#305;,
  sersemlik, yorgunluk, g��s�zl�k<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Topiramat<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>B�brek ta&#351;&#305; , dar a�&#305;l&#305; glokom<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, ba&#351;a&#287;r&#305;s&#305;, sersemlik,
  yorgunluk, kognitif yava&#351;lama, kelime bulma g��l�&#287;�, parestezi,
  kilo kayb&#305;, terleme azalmas&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Valproat<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;color:black;mso-bidi-font-weight:bold'>Hepatotoksisite
  (&lt;2 ya&#351; �ocukta ve polifarmaside belirgin), hiperamonyemi, l�kopeni,
  trombositopeni, pankreatit<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, kusma, sa� d�k�lmesi, tremor,
  amenore, kilo art&#305;&#351;&#305;, konstipasyon, polikistik over sendromu<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Zonisamid<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>B�brek ta&#351;&#305;, aplastik anemi<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bulant&#305;, ba&#351;a&#287;r&#305;s&#305;,
  sersemlik, yorgunluk, parestezi, d�k�nt�, konu&#351;ma bozuklu&#287;u terleme
  azalmas&#305; (�zellikle �ocuklarda), zay&#305;flama<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Vigabatrin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'><span
  style='mso-spacerun:yes'>�</span>Kal&#305;c&#305; g�rme alan&#305; defekti<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Kilo art&#305;&#351;&#305;, �dem, halsizlik,
  psikoz<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Pregabalin<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bilinmiyor<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Karaci&#287;er enzimlerinde ge�ici hafif y�kselme
  uyuklama, yorgunluk hali, ba&#351; d�nmesi ve kilo art&#305;&#351;&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;mso-yfti-lastrow:yes'>
  <td width="33%" valign=top style='width:33.32%;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Lakosamid<o:p></o:p></span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Bilinmiyor<o:p></o:p></span></p>
  </td>
  <td width="33%" valign=top style='width:33.34%;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black;
  mso-bidi-font-weight:bold'>Uyuklama, hareketlerde yava&#351;lama<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&#304;la�
etkile&#351;imleri a�&#305;s&#305;ndan bak&#305;ld&#305;&#287;&#305;nda genelde
yeni AE&#304;�larla �nemli bir sorun olmaz iken yerle&#351;mi&#351;
AE&#304;�lar&#305;n bir�ok ila� ile etkile&#351;ime girdi&#287;i bilinmektedir.
Tablo 18�de bilinen baz&#305; ila� etkile&#351;imleri g�sterilmi&#351;tir.
�nemli ve s&#305;k etkile&#351;imlerden biri oral kontraseptiflerledir (OK).
Karbamazepin, fenitoin, fenobarbital, okskarbazepin, felbamat ve &gt;200mg/g
dozda topiramat bu ila�lar&#305;n metabolik temizlenmesini artt&#305;rmakta
yan&#305; do&#287;um kontrol�n� bozmaktad&#305;r. Lamotrijinin ikili etkisi
vard&#305;r. OK�lerin klerensini artt&#305;r&#305;rken di&#287;er yandan
OK�lerde lamotrijinin klirensini artt&#305;r&#305;r. Yeni AE&#304;�lardan
levetirasetam, gabapentin, tiagabin, pregabalin ve zonisamidin OK�lerle
etkile&#351;imleri yoktur. Hastaya anti-gribal ila�lar �rne&#287;inde
oldu&#287;u gibi gereksiz &#351;ekilde ve doktoruna dan&#305;&#351;madan ila�
kullanmamas&#305; �&#287;�tlenmelidir. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Tablo 18: Antiepileptik ila�lar&#305;n
di&#287;er ila�lar �zerine etkisi<o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid #4BACC6 1.0pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 1.0pt solid #4BACC6;mso-border-insidev:1.0pt solid #4BACC6'>
 <tr style='mso-yfti-irow:0'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  background:#DBE5F1;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>AE&#304;<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Etkisini azalt&#305;r<o:p></o:p></span></b></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Etkisini artt&#305;r&#305;r<o:p></o:p></span></b></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border:solid #4BACC6 1.0pt;
  border-left:none;mso-border-left-alt:solid #4BACC6 1.0pt;background:#DBE5F1;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>�neri <o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Benzodiazepin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����� </span><span
  style='mso-spacerun:yes'>���</span>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Sedatif
  ila�larla sedasyon etkisi artar<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Karbamazepin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Antikoagulan,
  kinidin, OK, kortikosteroid, siklosporin A, folat, dijital glikozidler,
  donezepil, doksisiklin, felodipin, mebendazol, metadon, kas
  gev&#351;eticiler, nifedipin, nimodipin, prasikuantel, teofilin, verapamil <o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Diltizem<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>AE&#304; ve MAO
  inhibit�rleri ile lityum n�rotoksisitesi artabilir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Felbamat<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Spesifik
  inhibit�r veya ind�kleyici etkile&#351;im olabilir.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Gabapentin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Di&#287;erila�larla
  etkile&#351;imi yoktur, oral kontraseptifleri etkilemez. Ancak antasitlerle
  birlikte al&#305;nd&#305;&#287;&#305;nda biyoyararlan&#305;m&#305; % 20
  oran&#305;nda d�&#351;er.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Lamotrijin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>OK <o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>OK kesilmesi<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>OK
  kullan&#305;m&#305;na dikkat edilmeli<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Levetirasetam<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>���������� </span><span
  style='mso-spacerun:yes'>�</span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Hepatik olmayan
  hidroliz ile k&#305;smen metabolize olur<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Okskarbazepin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Felodipin, OK,
  nifedipin, nimodipin<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>���������� </span>+<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>AE&#304; ve MAO
  inhibit�rleri ile lityum n�rotoksisitesi artabilir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Fenobarbital<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Antikoagulan, kinidin,
  OK kortikosteroid, siklosporin A, diltizem, dijital glikozidleri, donezepil,
  doksisiklin, felodipin, folat, griseofulvin, haloperidol, mebendazol,
  metadon, metoprolol, nifedipin, nimodipin, metronidazol, kas
  gev&#351;eticiler, prasikuantel, propanolol, takrolimus, tamoksifen,
  teofilin, verapamil <o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>AE&#304; ile
  metotreksat toksisitesi artabilir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Fenitoin <o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Antikoagulan,
  kinidin, OK kortikosteroid, siklosporin A,<span style='mso-spacerun:yes'>�
  </span>dijital glikozidleri, donezepil, doksisiklin, folat, mebendazol,
  metadon, kas gev&#351;eticiler,<span style='mso-spacerun:yes'>�
  </span>nifedipin, nimodipin, metronidazol,<span style='mso-spacerun:yes'>�
  </span>praksikuantel, teofilin, verapamil<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Diltizem,
  disulfiram<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>AE&#304; ve MAO
  inhibit�rleri ile lityum n�rotoksisitesi artabilir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Pregabalin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>�������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Periferik �deme neden
  olabilir, pregabalin ile antidiyabetik tiyazolidindiyon birlikte
  kullan&#305;ld&#305;&#287;&#305;nda egzersizlere dikkat edilmeli<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Pirimidon<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Antikoagulan,
  kinidin, OK kortikosteroid, siklosporin A, diltiazem, dijital glikozidleri,
  donezepil, doksisiklin, felodipin, folat, griseofulvin, haloperidol,
  mebendazol, metadon, metoprolol, nifedipin, nimodipin, metronidazol, kas
  gev&#351;eticiler, praksikuantel, propanolol, takrolimus, tamoksifen,
  teofilin, verapamil <o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>AE&#304; ile
  metotreksat toksisitesi artabilir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Tiagabin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>����������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>�������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>Di&#287;er
  AE&#304;�larla ve simetidin, digoksin,<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;color:black'>teofilin,
  varfarin veya OK ile etkile&#351;mez. PB, KBZ veya FT, TGB gibi sitokrom-P450
  izoenzimlerini ind�kleyen ila�larla al&#305;nd&#305;&#287;&#305;nda daha
  h&#305;zl&#305; metabolize olur.</span><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Topiramat<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>OK
  (TPM&gt;200mg/g)<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>�������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Vigabatrin<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>�������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;la�
  metabolize edici sistemleri etkilememekle birlikte AE&#304;�larla dinamik
  etkile&#351;imi vard&#305;r.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Valproik asit<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;trokonazol<o:p></o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>antikoagulan <o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Valproik asit
  antikoagulasyonu artt&#305;rabilir<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;mso-yfti-lastrow:yes'>
  <td width=115 valign=top style='width:86.4pt;border:solid #4BACC6 1.0pt;
  border-top:none;mso-border-top-alt:solid #4BACC6 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'>Zonisamid<o:p></o:p></span></b></p>
  </td>
  <td width=192 valign=top style='width:144.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='mso-layout-grid-align:none;text-autospace:none'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>KBZ, FB ve FT<span
  style='mso-spacerun:yes'>� </span>yar&#305;lanma �mr�n� azalt&#305;r.<span
  style='mso-spacerun:yes'>�������� </span><o:p></o:p></span></p>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=168 valign=top style='width:126.0pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><span
  style='mso-spacerun:yes'>�������������� </span>-<o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.2pt;border-top:none;border-left:
  none;border-bottom:solid #4BACC6 1.0pt;border-right:solid #4BACC6 1.0pt;
  mso-border-top-alt:solid #4BACC6 1.0pt;mso-border-left-alt:solid #4BACC6 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>Di&#287;er
  ila�larla ind�klenebilir veya inhibe olabilir, ancak Zonisamid�in di&#287;er
  AE&#304;�lar �zerine etkisi yoktur. <o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>OK: oral kontraseptifler<o:p></o:p></span></p>

<p style='margin:0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Tedavinin
Sonland&#305;r&#305;lmas&#305;</span></b><span lang=TR style='font-family:Tahoma'>
<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Antiepileptik
ila�lar&#305;n kronik kullan&#305;m&#305;nda yan etkileri olabilece&#287;inden
ve baz&#305; olgularda remisyonlar&#305;n g�r�lmesi m�mk�n oldu&#287;undan
�ocukluk �a&#287;&#305;nda son n�betten 2 y&#305;l, eri&#351;kinlikte ise 4-5
y&#305;l sonra ila� dozu yava&#351;�a azalat&#305;larak kesilebilir. Ancak
burada da, tedaviye ba&#351;lama konusunda oldu&#287;u gibi, �ncelikle riskleri
anlatarak hastan&#305;n g�r�&#351;�n� almak ve n�betlerin
s&#305;n&#305;flanmas&#305; <u>r</u>ol oynar. J�venil miyoklonik epilepsi gibi
baz&#305; sendromlarda n�ks�n neredeyse bir kural oldu&#287;u
unutulmamal&#305;d&#305;r. Yap&#305;lan �al&#305;&#351;malar, ila� kesiminin
hastalarda n�ks� 2 kat oran&#305;nda artt&#305;rd&#305;&#287;&#305;n&#305;
g�stermi&#351;tir. Bunun yan&#305; s&#305;ra n�kse etkili olan di&#287;er fakt�rler
aras&#305;nda epilepsinin s�resi, erken ya&#351;lardan beri n�betlerin
olmas&#305;, remisyon s�resi, remisyona kadar ge�en n�betli s�re, parsiyel
ba&#351;lang&#305;�l&#305; n�betleri, farkl&#305; n�bet tipleri, EEG�de fokal
anomalinin bulunmas&#305;, AE&#304; s&#305;ras&#305;nda veya kesilirken EEG
anomalisi/anomalilerinin artmas&#305;, jeneralize tonik-klonik n�bet
varl&#305;&#287;&#305;, miyokloni olmas&#305;, n�rolojik muayenenin anormal
olmas&#305;, IQ&lt;70 olmas&#305;, kranyal g�r�nt�lemede anormal bulgunun
olmas&#305; say&#305;labilir. &#304;la� kesimi s&#305;ras&#305;nda n�bet
tekrarlama riski az olan grup ise idyopatik epilepsisi olanlar, jeneralize
n�bet ge�irenler, aile �yk�s� olmayanlar, normal n�rolojik muayene ve normal
EEG�si olanlard&#305;r. En do&#287;ru yakla&#351;&#305;m genel ila� kesim
kriterleri yerine her hasta i�in �zg�n ko&#351;ullar&#305; de&#287;erlendirerek
hareket etmektir. &#304;la� kesimi sonras&#305; ilk bir y&#305;l i�inde,
�zellikle ilk 3 ayda n�bet olma riskinin y�ksek oldu&#287;unu bilinmeli ve
hi�bir zaman n�bet olma riskinin s&#305;f&#305;r olmad&#305;&#287;&#305;
hastaya anlat&#305;lmal&#305;d&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>D&#304;REN�L&#304;
EP&#304;LEPS&#304;LER VE CERRAH&#304; YOLLA TEDAV&#304;
ED&#304;LEB&#304;L&#304;R EP&#304;LEPS&#304;LER</span></b><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsili
hastalar&#305;n yakla&#351;&#305;k %25-30'&#305;nda uygun antiepileptik
ila�lar&#305;n (AE&#304;) kullan&#305;m&#305;na kar&#351;&#305;n n�betler
kontrol alt&#305;na al&#305;namamaktad&#305;r ve bu gruba �ila� tedavisine
diren�li epilepsi� denir. Kabul edilmi&#351; kesin bir diren�li epilepsi
tan&#305;m&#305; yoktur. Yap&#305;lm&#305;&#351; �ok say&#305;da tan&#305;mlardan
baz&#305;lar&#305; a&#351;a&#287;&#305;da �zetlenmi&#351;tir. Burada uygun ila�
ve maksimum dozda kullan&#305;m esast&#305;r. Yeni AE&#304; denenmesi kriterler
aras&#305;nda yer almamakla birlikte s&#305;kl&#305;kla denenmektedir.<o:p></o:p></span></p>

<p style='margin-left:54.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l17 level1 lfo43;tab-stops:list 54.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>En az 2
y&#305;l s�reyle,<span style='mso-spacerun:yes'>� </span>&gt;1/ay n�bet, en az
3 AE&#304; tek tek veya beraber kullan&#305;m <o:p></o:p></span></p>

<p style='margin-left:54.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l17 level1 lfo43;tab-stops:list 54.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Son 1
y&#305;l boyunca &gt;1/ay n�bet, 3 veya daha fazla AE&#304; kullan&#305;m&#305;
<o:p></o:p></span></p>

<p style='margin-left:54.0pt;text-align:justify;text-indent:-18.0pt;mso-list:
l17 level1 lfo43;tab-stops:list 54.0pt'><![if !supportLists]><span lang=TR
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma'>Son 1
y&#305;lda &gt;1/ay n�bet,<span style='mso-spacerun:yes'>� </span>2 veya daha
fazla AE&#304; kullan&#305;m&#305; (birisi DFH, KBZ, veya VPA olmal&#305;)<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bu
hastalar&#305;n aras&#305;nda son y&#305;llarda say&#305;lar&#305; giderek
artan epilepsi merkezlerinde yap&#305;lan ara&#351;t&#305;rmalar&#305;n ortaya
koydu&#287;u bir grup hasta epilepsi cerrahisi aday&#305; olarak
de&#287;erlendirilir. �lkemizde de epilepsi cerrahisi konusunda
�al&#305;&#351;malar epilepsi merkezlerinde s�rd�r�lmektedir. Tan&#305;mlar
aras&#305;nda baz&#305; de&#287;i&#351;meler olmakla birlikte, bu gruptaki
hastalar&#305; �diren�li epilepsi� olarak ele almak gereklidir. S&#305;k n�bet,
buna ba&#287;l&#305; ya&#351;am kalitesinin bozulmas&#305; �nemlidir. Rezektif
cerrahiye uygunluk a�&#305;s&#305;ndan kesin kriterlerin
tan&#305;mlanamamas&#305;n&#305;n nedeni her hastadaki fakt�rlerin farkl&#305;
olmas&#305;d&#305;r (epilepsinin tipi, epileptojenik lezyonun olup
olmamas&#305;, ya&#351; ve beraberindeki di&#287;er hastal&#305;klar vb).
Di&#287;er yandan incelemelerin sonu�lar&#305; da cerrahiye uygun aday olup
olamayaca&#287;&#305;n&#305; belirleyen �nemli bir etmendir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Mezyal
temporal lob epilepsisinde cerrahi tedavinin �st�n oldu&#287;unu g�steren
sadece bir randomize �al&#305;&#351;ma vard&#305;r, di&#287;er tablolar i�in b�yle
bir �al&#305;&#351;ma ise yoktur. Ancak yap&#305;lm&#305;&#351; bir�ok
randomize olmayan �al&#305;&#351;mada ekstratemporal veya kriptojenik olgular
i�in de epilepsi cerrahisinden sonra n�betsiz kalma oran&#305;n&#305;n
artt&#305;&#287;&#305; veya ya&#351;am kalitesinin y�kseldi&#287;i bilinmekte
ve tavsiye edilmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi
cerrahisi i�in uygun aday&#305;n belirlenmesinde �yk�n�n yeri �ok �nemlidir.
N�bet semiyolojisini ayr&#305;nt&#305;l&#305; soru&#351;turmak gereklidir.
Aday&#305;n idyopatik olmayan fokal n�betleri olmal&#305;d&#305;r.
Yukar&#305;da belirtilen ilaca diren� kriterlerinden en az birine uymal&#305;d&#305;r.
Epilepsinin yapt&#305;&#287;&#305; yeti kayb&#305; ki&#351;inin ge�irdi&#287;i
n�betlerin say&#305;s&#305; ve &#351;iddetiyle �l��l�r. Bunun
d&#305;&#351;&#305;nda altta yatan patoloji, e&#351;lik eden n�rolojik ve
n�ropsikolojik defektler, AE&#304; toksisitesi, sosyal ve aile ili&#351;kileri
de ki&#351;inin cerrahi aday&#305; olmas&#305;nda �nemli etkenlerdir. Ki&#351;i
ve ailesiyle ayr&#305;nt&#305;l&#305; &#351;ekilde konu&#351;arak cerrahi
tedavi konusunda bilgilendirme yap&#305;l&#305;r. Epilepsi cerrahisinde
deneyimli bir beyin cerrah&#305;n&#305;n elinde morbidite ve mortalite
oran&#305; d�&#351;�kt�r. Yarar ve risk oran&#305;na bakarken cerrahi riske
kar&#351;&#305;l&#305;k olarak kontrol alt&#305;na al&#305;namayan n�betlere
ba&#287;l&#305; yaralanma, bo&#287;ulma, intihar giri&#351;imi gibi risklerin
de oldu&#287;u bilinmelidir. Yarar ve risk oran&#305;n&#305;n her olgunun �zel
bulgular&#305;na g�re de&#287;erlendirilmesi en uygunudur. Ya&#351;
artt&#305;k�a dominant hemisfer cerrahisi yap&#305;lacak ki&#351;ilerde verbal
bellekte bozulma olmas&#305; daha y�ksek oranlara �&#305;kmaktad&#305;r.
Otuzbe&#351; ya&#351; sonras&#305; ameliyatlar cerrahi sonras&#305;
komplikasyonlar a�&#305;s&#305;ndan daha riskli olabilir. Psikiyatrik
a�&#305;dan postoperatif depresyon ve obsesif komp�lsif bozukluk g�r�lebilir.
Hastan&#305;n properatif de&#287;erlendirilmesi �ok �nem ta&#351;&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Di&#287;er
�nemli bir fakt�r de ba&#351;ka bir hastal&#305;&#287;&#305;n olmas&#305; ve o
hastal&#305;k ile ilgili ek ila� al&#305;nmas&#305;d&#305;r. �rne&#287;in
hematolojik ve kardiyak bir sorun cerrahi s&#305;ras&#305;nda risk olu&#351;turur
ve uyku apne sendromunun olmas&#305; n�betlerini tetikleyebilir. Cerrahi �ncesi
ayr&#305;nt&#305;l&#305; �yk�, y�ksek rezol�syonlu kranyal MR g�r�nt�lemesi
(epilepsi protokol�ne uygun), n�ropsikolojik testler mutlaka
yap&#305;lmal&#305;d&#305;r. T�m cerrahi adaylar&#305;na invazif olmayan video
EEG monitorizasyon yap&#305;lmal&#305;d&#305;r. Bu say&#305;lan tetkikler
birbiri ile oda&#287;&#305;n yerle&#351;imi a�&#305;s&#305;ndan uyum
g�steriyorsa ameliyat karar&#305; multidisipliner olarak epilepsi cerrahisi
ekibi (n�rolog, n�ro&#351;ir�rjiyen, n�roradyolog, n�ropsikolog, psikiyatrist,
epilepsi hem&#351;iresi) taraf&#305;ndan al&#305;n&#305;r. Ancak baz&#305;
olgularda tam bir uyum yoksa veya baz&#305; incelemeler normalse ba&#351;ka ek
incelemeler yap&#305;lmas&#305; gerekebilir; bunlar aras&#305;nda PET, SISCOM
(iktal SPECT MR g�r�nt�lerinin �st �ste kay&#305;t edilmesi ile elde edilir),
fonksiyonel MR<span style='mso-spacerun:yes'>� </span>ve magnetensefalografi
say&#305;labilir. Cerrahi inceleme sonu�lar&#305; aras&#305;nda uyum
olmad&#305;&#287;&#305; zaman invazif inceleme yap&#305;lmas&#305; gerekir.
&#304;nvazif incelemenin getirdi&#287;i riskler kanama, infeksiyon, bazen kitle
etkisi nedeniyle �dem olmas&#305;d&#305;r. &#304;nvazif elektrotlar olarak
grid, strip, derinlik elektrodu veya bunlar&#305;n kombinasyonlar&#305; her
hastaya g�re d�zenlenerek ve bir hipotez olu&#351;turularak
kullan&#305;l&#305;r. Cerrahi tedavinin kontrendike oldu&#287;u durumlar <b
style='mso-bidi-font-weight:normal'>Tablo 19</b>�da g�sterilmi&#351;tir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'><span
style='mso-spacerun:yes'>���� </span><b style='mso-bidi-font-weight:normal'>Tablo
19. Epilepsi Cerrahisi &#304;�in Tam ve Relatif Kontrendikasyonlar <o:p></o:p></b></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt;mso-border-insideh:
 .5pt solid black;mso-border-insidev:.5pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Tam kontrendikasyonlar<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>������������
  </span>&#304;dyopatik ya&#351;a ba&#287;l&#305; epilepsi sendromlar&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>������������
  </span>Epilepsiye neden olan sistemik bir hastal&#305;&#287;&#305;n
  olmas&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>������������
  </span>&#304;ncelemelere koopere olamayan ve i&#351;birli&#287;i kuramayan
  hasta<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma'>Relatif
  kontrendikasyonlar<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>�����������
  </span>Ger�ekle&#351;mesi m�mk�n olmayan y�ksek beklenti d�zeyi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>�����������
  </span>Psikopatoloji <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>����������� </span>Mental
  retardasyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>�����������
  </span>S&#305;rad&#305;&#351;&#305; (eloquent) kortekste odak (�rne&#287;in
  konu&#351;ma/ hareketle ili&#351;kili merkez)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>�����������
  </span>Bilateral, birbirinden ba&#287;&#305;ms&#305;z,<span
  style='mso-spacerun:yes'>� </span>interiktal ve/veya iktal EEG bulgular&#305;<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;mso-yfti-lastrow:yes'>
  <td width=614 valign=top style='width:460.6pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma'><span style='mso-spacerun:yes'>�����������
  </span>Progresif bir n�rolojik hastal&#305;&#287;&#305;n olmas&#305;<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'><span
style='mso-spacerun:yes'>�</span>Baz&#305; �zel epilepsi sendromlar&#305;nda
genel olarak ila� tedavisine yan&#305;t al&#305;namazken, cerrahi tedavi ile
iyi sonu�lar al&#305;nd&#305;&#287;&#305; son y&#305;llarda artan bilgi
birikimi ile kesinlik kazanm&#305;&#351;t&#305;r. Meziyal temporal lob
epilepsisi (MTLE) bu durum i�in en tipik ve s&#305;k rastlanan �rne&#287;i olu&#351;turmaktad&#305;r.
A&#351;a&#287;&#305;da konunun �nemine dikkat �ekmek amac&#305;yla k&#305;saca
cerrahi tedaviyle iyi sonu� al&#305;nan epilepsi ve sendromlar
anlat&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Mezyal temporal lob
epilepsisi (MTLE)</span></i></b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Bu tipik tablonun ana �zellikleri &#351;unlard&#305;r: <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l45 level1 lfo46;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>�yk�: <o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l61 level2 lfo49;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Hastalar&#305;n
      �o&#287;unun �zge�mi&#351;inde komplike olmu&#351; (yar&#305;m saatten
      uzun s�ren veya n�rolojik lateralizasyon bulgusu veren) <span
      style='mso-bidi-font-style:italic'>febril n�bet ge�irme �yk�s�
      vard&#305;r. Bu durumun MTLE tablosunun nedeni mi yoksa ayn&#305;
      patolojik s�recin erken d�nemdeki g�sterisi mi oldu&#287;u halen
      tart&#305;&#351;mal&#305;d&#305;r.</span> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l61 level2 lfo49;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>Ailede epilepsi �yk�s� de y�ksek oranda saptanmaktad&#305;r.</span><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l61 level2 lfo49;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>Ba&#351;lang&#305;� ya&#351;&#305; genellikle ilk dekad&#305;n
      son yar&#305;s&#305;nda olur.</span><span lang=TR style='font-size:10.0pt;
      font-family:Tahoma'> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l61 level2 lfo49;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>N�betlerin ergenlik ve gen� eri&#351;kinlik d�neminde remisyona
      girmesinin ard&#305;ndan tekrar ba&#351;lay&#305;p ila� tedavisine
      diren�li duruma gelmesi tipiktir.</span><span lang=TR style='font-size:
      10.0pt;font-family:Tahoma'> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l61 level2 lfo49;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>&#304;nteriktal davran&#305;&#351; de&#287;i&#351;iklikleri
      (s&#305;kl&#305;kla depresyon) g�r</span><span lang=TR style='font-size:
      10.0pt;font-family:Tahoma'>�l�r. <o:p></o:p></span></li>
 </ul>
</ol>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l65 level1 lfo52;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�bet �zellikleri <o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l5 level2 lfo55;tab-stops:list 72.0pt'><i><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Aura</span></i><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'> olarak da
      adland&#305;r&#305;lan hastan&#305;n n�bet �ncesinde farketti&#287;i �nc�
      belirti genellikle vard&#305;r. Bu aura MTLE�de en s&#305;k olarak
      mideden y�kselen tuhaf bir his (rising epigasric sensation)
      &#351;eklindedir. Bunun d&#305;&#351;&#305;nda di&#287;er otonom ve
      psi&#351;ik semptomlar (deja vu, jamais vu vb..) emosyonlar (en s&#305;k
      korku), koku ve tat duyular&#305;na ili&#351;kin duyumsamalar da aura
      olarak g�r�lebilir. Bazen aura dedi&#287;imiz bu basit parsiyel n�bet
      kabul edilebilecek durumu &#351;uur kayb&#305; ve di&#287;er n�bet
      belirtileri izlemeyebilir, yani izole aura g�r�lebilir. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l5 level2 lfo55;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Sekonder jeneralize
      olan n�bet g�rece nadir g�r�l�r. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l5 level2 lfo55;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>En tipik n�bet
      kompleks parsiyel (otomotor tipte) n�betlerdir. Genellikle temporal
      auray&#305; izleyerek, bazen de aniden durma ve donmay&#305; izleyen a&#287;&#305;z
      &#351;ap&#305;rdatma ve yutkunma, yalanma hareketleri gibi oroalimenter
      otomatizmler g�r�l�r. &#304;ktal de&#351;arj&#305;n kar&#351;&#305;
      taraf&#305;ndaki kolda tonik post�r ve ayn&#305; taraftaki kolda
      �e&#351;itli otomatizmler tipiktir (<b style='mso-bidi-font-weight:normal'>&#350;ekil
      11</b>). S�re genellikle 1-2 dakikad&#305;r. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l5 level2 lfo55;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Postiktal d�nemde
      genellikle oryantasyon bozuklu&#287;u, bellek bozuklu&#287;u, odak
      dominant hemisferdeyse konu&#351;ma bozuklu&#287;u g�r�l�r, postiktal
      d�nem genellikle dakikalar s�rer. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l5 level2 lfo55;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Di&#287;er epileptik
      n�bet tipleri ve �zel bir tetikleyici olmazsa genelde status epileptikus
      tablosu g�r�lmez. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l5 level2 lfo55;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Fokal motor veya
      spesifik duysal semptomlar ile (�rne&#287;in, g�rme kayb&#305; veya
      parestezi vb..) n�betin ba&#351;lamas&#305; MTLE�de g�r�lmez <o:p></o:p></span></li>
 </ul>
</ol>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l24 level1 lfo58;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�rolojik muayene <o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l66 level2 lfo61;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Genellikle normaldir.
      Fokal n�rolojik belirti tan&#305;da ku&#351;ku yaratmal&#305;d&#305;r. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l66 level2 lfo61;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bellek defektleri
      (odak soldaysa s�zel, sa&#287;daysa g�rsel modalitede) g�r�lebilir, ancak
      belirgin ve yayg&#305;n kognitif defektlerin varl&#305;&#287;&#305;
      MTLE'de g�r�lmez. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l66 level2 lfo61;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Oda&#287;&#305;n
      kar&#351;&#305; taraf&#305;ndaki nazolabial telemin silik oldu&#287;u
      baz&#305; olgularda g�zlenir (Emosyonel fasyal parezi).<o:p></o:p></span></li>
 </ul>
</ol>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l43 level1 lfo64;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>EEG <o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l20 level2 lfo67;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�betler aras&#305;
      d�nemde odak taraf&#305;nda veya bazen iki yanl&#305;
      ba&#287;&#305;ms&#305;z �n temporal b�lgede keskin dalga aktivitesi
      tipiktir. Ayr&#305;ca ayn&#305; b�lgede aral&#305;kl&#305; veya
      devaml&#305; ritmik ya da d�zensiz delta frekans&#305;nda yava&#351; dalga
      aktivitesi g�r�lebilir (<b style='mso-bidi-font-weight:normal'>&#350;ekil
      16A</b>).<o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l20 level2 lfo67;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ekstrakranyal n�bet
      aktivitesi fokal (�n temporal b�lgede) 5-7Hz ritmik aktivite
      &#351;eklinde ba&#351;lar ve genellikle yay&#305;l&#305;m ve frekans
      de&#287;i&#351;imleri g�sterir (<b style='mso-bidi-font-weight:normal'>&#350;ekil
      16B</b>).<o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l20 level2 lfo67;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>EEG�de jeneralize
      diken-dalga veya ba&#351;ka b�lgelerde fokal diken varl&#305;&#287;&#305;
      ile yayg&#305;n veya temporal d&#305;&#351;&#305; yava&#351; aktivite
      tan&#305; ve cerrahi tedavinin ba&#351;ar&#305;s&#305;
      a�&#305;s&#305;ndan ku&#351;ku yaratmal&#305;d&#305;r. <o:p></o:p></span></li>
 </ul>
</ol>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:54.0pt;text-align:justify'><b style='mso-bidi-font-weight:normal'><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'><a href="sekil16a.jpg">&#350;ekil
16a.</a></span></u></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>
MTLE sendromu tan&#305;s&#305;yla izlenen bir hastan&#305;n interiktal
EEG�sinde sol �n temporal b�lgede delta dalgalar&#305; ve F 7 elektrod
pozisyonunda faz d�nmesi g�steren keskin dalga aktivitesi g�r�lmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:54.0pt;text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'><a href="sekil16b.jpg">&#350;ekil
16b.</a> </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>MTLE
sendromlu ba&#351;ka bir hastan&#305;n preoperatif incelemesinde kaydedilen
sa&#287; frontotemporal b�lgedeki ritmik �build up� g�steren teta
dalgalar&#305; ve kas artefaktlar&#305;yla &#351;ekillenen tipik iktal
aktivitesi izlenmektedir. <o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l34 level1 lfo70;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>G�r�nt�leme <o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l2 level2 lfo73;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>MRG ile bir taraf
      hipokampusun daha k���k oldu&#287;u g�zle ya da �l��lerek (vol�metrik
      analiz) saptan&#305;r <a
      href="http://www.itfnoroloji.org/epilepsi/mts.jpg"><span
      style='color:windowtext;text-decoration:none;text-underline:none'>(<b
      style='mso-bidi-font-weight:normal'>&#350;ekil 17</b>).</span></a> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l2 level2 lfo73;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Ayr&#305;ca MRG ile ince
      kesitlerle incelendi&#287;inde hipokampus i� yap&#305;s&#305;n&#305;n
      bozulmu&#351; oldu&#287;u ve T2 ve FLAIR sekanslar&#305;nda
      artm&#305;&#351; sinyal �zelli&#287;i g�r�l�r <a
      href="http://www.itfnoroloji.org/epilepsi/mts.jpg"><span
      style='color:windowtext;text-decoration:none;text-underline:none'>(<b
      style='mso-bidi-font-weight:normal'>&#350;ekil 12 A</b> ).</span></a> <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l2 level2 lfo73;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bu durum bazen
      bilateral olabilir, normal insanlarla k&#305;yaslama gerekmektedir. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l2 level2 lfo73;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Bazen t�m temporal
      lobun daha k���k oldu&#287;u ve temporal boynuzun daha geni&#351;
      oldu&#287;u dikkati �eker. <o:p></o:p></span></li>
 </ul>
</ol>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:18.6pt;text-align:justify;text-indent:35.4pt'><b style='mso-bidi-font-weight:
normal'><u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil17.jpg">&#350;ekil 17.</a> </span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Sa&#287; mezyal temporal
yap&#305;larda sola k&#305;yasland&#305;&#287;&#305;nda belirgin atrofi dikkati
�ekmektedir.<o:p></o:p></span></p>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l23 level1 lfo76;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Fonksiyonel
     g�r�nt�leme<span style='mso-spacerun:yes'>� </span><o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l18 level2 lfo79;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>PET tekni&#287;i daha
      �st�n bir fonksiyonel inceleme y�ntemi olmakla birlikte
      pahal&#305;d&#305;r. PET ile mezyal temporal b�lgede g�rece geni&#351;
      bir hipometabolizma g�r�lmesi �nemli bir destekleyici lateralizan
      veridir.<o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l18 level2 lfo79;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;nteriktal SPECT
      ise daha d�&#351;�k g�r�nt� kalitesine ra&#287;men, ucuz ve kolay
      uygulanabilir oldu&#287;u i�in ve �zellikle iktal d�nemde inceleme
      yap&#305;labildi&#287;inden yard&#305;mc&#305; bir y�ntem olarak
      kullan&#305;lmaktad&#305;r. SPECT ile interiktal d�nemde odak b�lgesinde
      hipoperf�zyon ve iktal d�nemde tipik hiperperf�zyon saptan&#305;r.
      Saptanan hipoperf�zyon b�lgesi genellikle t�m temporal lobu i�ine alacak
      &#351;ekilde geni&#351; bir alandad&#305;r. <o:p></o:p></span></li>
 </ul>
</ol>

<ul type=disc>
 <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
     text-align:justify;mso-list:l8 level1 lfo82;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma'>Patofizyoloji <o:p></o:p></span></li>
</ul>

<ol start=1 type=1>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l10 level2 lfo85;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Temporal lobun i� yan
      yap&#305;lar&#305; olan amigdala ve hipokampusda sklerotik
      de&#287;i&#351;ikliklerle karakterizedir (Mezyal temporal skleroz MTS).
      Tipik paternde hipokampusda %30 oran&#305;ndan fazla h�cre kayb&#305;
      g�r�l�r. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l10 level2 lfo85;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Dentat gran�ler h�cre
      yosunsu liflerinde dallanma vard&#305;r. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l10 level2 lfo85;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Somatostatin ve NPY
      i�eren h�crelerin se�ici olarak kayb&#305; s�z konusudur. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l10 level2 lfo85;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Dual patoloji olarak
      heterotopi ve hamartomalar e&#351;lik edebilir. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l10 level2 lfo85;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Mikrodisgenezis
      s&#305;kt&#305;r. <o:p></o:p></span></li>
 </ul>
</ol>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>MTLE tan&#305;s&#305; klinik planda konduktan sonra,
iyi planlanm&#305;&#351; bir MRG incelemesi ve noninvazif video-EEG
incelemeleriyle n�bet kayd&#305; yap&#305;larak hastan&#305;n operasyona
haz&#305;rlanmas&#305; s�z konusudur. Tipik MTLE olgusunda invazif
giri&#351;imlere genellikle gerek duyulmaz ama bazen hipokampal sklerozun iki
yanl&#305; olmas&#305; durumu g��le&#351;tirir. Hastalar&#305;n n�ropsikolojik
testleri mutlaka detayl&#305; &#351;ekilde yap&#305;lmal&#305;d&#305;r. WADA
testi olarak adland&#305;r&#305;lan anjiografik olarak sodyumamital verilmesi
ile bir hemisferin ge�ici blokaj&#305; sonras&#305;nda �e&#351;itli
n�ropsikolojik testlerin uygulanarak hastan&#305;n postoperatif defektlerinin
ge�ici olarak belirlenmesi kimi olgularda gerekmektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>MTLE tan&#305;s&#305; ile incelemeleri sonucunda operasyona verilen
hastalar&#305;n %80 kadar&#305;nda anteromedial temporal lob rezeksiyonu ya da
selektif amigdalo-hipokampektomi giri&#351;imleriyle hastalar n�betsiz kalmakta
ya da �ok belirgin oranda n�betleri azalmaktad&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Neokortikal temporal lob epilepsisi (NTLE)<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Klinik ve EEG �zellikleri MTLE ile birbirine �ok benzeyebilir. NTLE
olgular&#305; interiktal EEG bulgular&#305;na g�re anterior, posterior ve
yayg&#305;n olarak ayr&#305;labilir. Olfaktor, gustatuvar ve deja vu gibi
auralar daha �ok anterior oda&#287;&#305; g�sterirken g�rsel karma&#351;&#305;k
aura posterior oda&#287;&#305; d�&#351;�nd�r�r. Kompleks otomatizmalar anterior
grupta s&#305;k g�r�l�rken n�rolojik muayene anormallikleri olanlar posterior
grupta yer al&#305;r. &#304;&#351;itsel, vertijin�z ve g�rsel aura daha �ok
NTLE�de olurken epigastrik aura, viseral duyumsama, korku MTLE�de olur. Bu
ipu�lar&#305;na ra&#287;men NTLE�yi MTLE�den ay&#305;rmak yine de zordur.
Klinik olarak distonik hareketler MTLE�de �zellikle MTS olan grupta s&#305;k
iken, NTLE�de y�zde seyirme ve y�z�n� ek&#351;itmek gibi hareketler daha �ok
g�r�l�r. EEG �zellikleri a�&#305;s&#305;ndan genelde MTLE�den fark&#305; yoktur.
&#304;ktal kay&#305;tlar i�in k���k farklar bildirilmi&#351;tir. G�r�nt�leme
�zellikleri olarak tipik hastalarda hipokampal atrofi g�r�lmez, e&#287;er
g�r�l�rse �dual patoloji� olarak ele al&#305;nmal&#305;d&#305;r. Semptomatik
NTLE olgular&#305;nda s&#305;k olarak t�m�r, kortikal malformasyonlar ve
vask�ler lezyonlar g�r�l�r. Cerrahi sonu�lar %60-75 hastada n�betsizlik olarak
bildirilmektedir. G�r�ld�&#287;� gibi MTS hastalar&#305;na g�re relatif olarak
daha d�&#351;�k cerrahi ba&#351;ar&#305; bulunmaktad&#305;r. Bu olgularda
otozomal dominant lateral temporal epilepsi sendromunu ay&#305;r&#305;c&#305;
tan&#305;da unutmamak gereklidir. Aileseldir ve ortalama ba&#351;lang&#305;�
ya&#351;&#305; ikinci ony&#305;ld&#305;r. NTLE�den klinik �yk� olarak
fark&#305; yoktur. Genellikle n�betler ila�la kontrol alt&#305;na al&#305;n&#305;r.
Ba&#287;lant&#305; analizlerinde kromozom 10 q b�lgesinde ba&#287;lant&#305;
g�sterilmi&#351;tir, hen�z bir gene ula&#351;&#305;labilmi&#351; de&#287;ildir.
<o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Bazal frontal lob epilepsisi</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> <o:p></o:p></span></i></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Fonksiyonel olarak heterojen olan bu multimodal alanda yer alan
epileptojenik oda&#287;&#305;n lokalizasyonu genelde zordur. Y�zeyel EEG
genellikle yan&#305;lt&#305;c&#305;d&#305;r. Orbitofrontal b�lgenin limbik
yap&#305;larla ili&#351;kileri nedeniyle n�betler frontal veya temporal
loblardan kaynaklan&#305;yormu&#351; gibi g�r�nd�&#287;�nden bu hastalarda
operasyona karar verirken �ok dikkatli olunmal&#305;d&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Mezyal frontal lob epilepsisi</span></i></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Anatomik olarak karma&#351;&#305;kt&#305;r, i�erdi&#287;i alanlar alt
ekstremitenin primer motor korteksi, suplementer motor alan ve anterior
singulat motor aland&#305;r. Bilateral asimetrik tonik n�bet semiyolojik
olarak; ani ba&#351;lang&#305;�l&#305; bilateral asimetrik tonik post�rde 10-40
saniye s�ren postiktal konf�zyon ve stuporun olmad&#305;&#287;&#305; bir
n�bettir. Nadiren suplementer motor alandan kaynaklanan bu n�bet lateral
frontal, parietal veya oksipital b�lgelerden de ba&#351;layabilir. Cerrahi
�ncesi incelemelerde n�bet ba&#351;lang&#305;� yeri kesinlik
kazanmal&#305;d&#305;r. Bilateral asimetrik tonik n�bet d&#305;&#351;&#305;nda
hipermotor n�bet (�ok h&#305;zl&#305; ve hareketli kol bacak
otomatizmalar&#305;) (<b style='mso-bidi-font-weight:normal'>&#350;ekil 11</b>),
frontal lob tipi �absans� ve negatif miyoklonus da bu b�lgenin en s&#305;k
g�r�len n�betleridir. Verteks veya anterior frontal y�zeyel EEG anormallikleri
bazen yan&#305;lt&#305;c&#305; olabilir. Bu b�lgenin cerrahi tedavisi �ncesinde
invazif monitorizasyon &#351;artt&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>&#304;nsuler epilepsi<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'><span style='mso-spacerun:yes'>�</span>&#304;nsuler n�betler de ancak
invazif kay&#305;tlamalar sonras&#305;nda tan&#305;n&#305;r. Be&#351; iktal
�zelli&#287;i i�eren bu n�betlerde bilin� korunur, ikinci �zellik ise
parestezidir. Peri- veya intraoral alan ya da geni&#351; bir k�tan�z b�lgeye
(y�z-omuz-kol, g�vde)<span style='mso-spacerun:yes'>� </span>ait paresteziler
tipiktir.<span style='mso-spacerun:yes'>� </span>&#304;nsuler
de&#351;arjlar&#305;n kar&#351;&#305; taraf&#305;nda parestezi vard&#305;r.
Motor ve duysal farengo-larengeal semptomlar di&#287;er bulgulard&#305;r. Buna
e&#351;lik eden retrosternal veya abdominal a&#287;&#305;rl&#305;k hissidir.
Disfonik ve dizartrik konu&#351;ma ba&#351;ka bir bulgusudur. Son bulgu olan
motor semptom ile n�bet biter. Tonik spazm, ba&#351;-g�z deviyasyonu veya
jeneralize distoni olur. Derin yerle&#351;imli bir b�lge oldu&#287;u i�in sa�l&#305;
deri EEG�si ile n�bet kayd&#305;n&#305; yapmak zordur. &#350;u an i�in cerrahi
sonras&#305; n�betsizlik oran&#305; kesin olarak bilinmemektedir. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Singulat epilepsi<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'><span style='mso-spacerun:yes'>�</span>Anterior singulat girusta
kompleks motor, hipermotor ve bilateral asimetrik tonik n�betler g�r�l�rken
posterior singulat girusta ise otomotor ve dialeptik n�betler s&#305;k g�r�l�r.
Aura olarak her iki grupta da parestezik semptomlar olabilir.
�o&#287;unlu&#287;unda bilin� kayb&#305; olur. Anterior grupta n�bet s�resi
sekonder jeneralize olmayanlarda 30-70 sn iken sekonder jeneralize oldu&#287;unda
ortalama 90 sn s�rer. Posterior grupta ise n�bet s�resi 25-80 sn iken sekonder
jeneralize oldu&#287;unda ortalama 85 sn s�rer. Lateralizan bulgu olarak
anterior grupta fokal tonik klonik aktivite ve kontralateralden n�bet
kayd&#305; olur. Posterior grupta fokal klonik ve versif n�betler
s&#305;ras&#305;nda kontralateral n�bet kayd&#305; veya lezyonu vard&#305;r.
N�bet yay&#305;l&#305;m&#305; a�&#305;s&#305;ndan anterior singulatta frontal
loba yay&#305;l&#305;m olurken, posterior grup temporal yay&#305;l&#305;m
g�sterir. Y�zeyel EEG�nin interiktal ve iktal bulgular&#305; lateralize veya
lokalize etmesi olgular&#305;n %50�sinden az&#305;nda olur. Geni&#351;
rezeksiyon cerrahi sonras&#305; n�betsizlik oran&#305;n&#305;
artt&#305;r&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Parietooksipital epilepsi<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'><span style='mso-spacerun:yes'>�</span>Semiyolojik �zellikleri parietal
ve oksipital lob epilepsisi ba&#351;l&#305;&#287;&#305; alt&#305;nda yukarda
anlat&#305;lm&#305;&#351; olan bu tabloda n�bet yay&#305;l&#305;m&#305;na
ba&#287;l&#305; olarak %29-88 oran&#305;nda TLE�de izlenen tipik otomatizmalar
g�r�l�r ve %38-47 fokal motor aktivite vard&#305;r. Baz&#305; hastalarda bu
yay&#305;l&#305;m birden fazla b�lgeye olur. N�rolojik muayenede g�rme
alan&#305; defisiti %20-59 iken kranyal g�r�nt�lemede anormal bulgu %37-72
bulunur. EEG�de s&#305;kl&#305;kla posterior temporooksipital interiktal
epileptiform de&#351;arjlar izlenirken iktal ba&#351;lang&#305;� posterior
temporal b�lgeyi i�ine al&#305;r. Parietal lob epilepsilerde %94 aura vard&#305;r.
A&#287;r&#305; &#351;eklinde olmak �zere �o&#287;unlukla somatosensoryeldir.
Bazen v�cut alg&#305;lamas&#305; ile ilgili auralar da olur. N�betin
yay&#305;l&#305;m&#305;na ba&#287;l&#305; tonik kas&#305;lma, oral-el
otomatizmas&#305; ve fokal motor aktivite izlenir. Skalp EEG�si lokalize
etmekten �ok lateralize eder. Cerrahi �ncesi, invazif inceleme gerektirir.<span
style='mso-spacerun:yes'>�� </span><o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Hipotalamik hamartom<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Tuber sinereum ve/veya mamiller cisimciklerde geli&#351;en t�m�r
benzeri malformasyondur. Klinik olarak jelastik n�betlerle karakterize epilepsi
ve prekoks puberte �nemli �zelliklerdir. Jelastik n�betler ya&#351;am&#305;n
ilk y&#305;llar&#305;nda hatta do&#287;umla birlikte ba&#351;lar. Mekanik ve
uygunsuz olarak at&#305;lan kahkahalar g�r�l�r. Genellikle bilin� korunur.
Pupil dilatasyonu, y�zde k&#305;zarma gibi otonomik �zellikler ve nefes tutma
buna e&#351;lik eder. Bazen hipermotor, oroalimenter otomatizmalar, g�z deviyasyonu,
tonik veya klonik fasyal kontraksiyonlar da jelastik n�bet s&#305;ras&#305;nda
g�r�lebilir. Hastalar&#305;n yar&#305;s&#305;ndan fazlas&#305;nda n�betlerde
progresyon olur. Jeneralize tonik/atonik n�betler, baz&#305;lar&#305;nda
Lennox-Gastaut sendromu geli&#351;ir. Davran&#305;&#351; ve kognitif problemleri
s&#305;k g�r�l�r. Y�zeyel EEG�nin iktal bulgular&#305; yan&#305;lt&#305;c&#305;
olabilir. &#304;nvazif video EEG incelemesinde derinlik elektrodlar&#305; iktal
de&#351;arjlar&#305;n hamartomdan kaynakland&#305;&#287;&#305;n&#305; g�sterir.
Kranyal MRG�de tipik lokalizasyonda T2 ve FLAIR�de hiperintensite ve T1 a&#287;&#305;rl&#305;kl&#305;
kesitlerde hipointensite olur. AE&#304;�lar genellikle yetersiz kal&#305;r.
Cerrahi olarak bir�ok farkl&#305; yakla&#351;&#305;m vard&#305;r. Olgu
say&#305;s&#305; az oldu&#287;undan kar&#351;&#305;la&#351;t&#305;rma �al&#305;&#351;mas&#305;
bulunmamaktad&#305;r. �Gamma Knife� veya stereotaktik radyasyon cerrahisi
ya&#351;&#305; b�y�k hastalarda ve hamartomu k���k olanlarda tercih
edilmektedir</span><a name="Belli_bir_lezyona_ba&#287;l&#305;_parsiyel"></a><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Cerrahi yolla tedavi edilebilen di&#287;er �nemli bir epilepsi de belli
bir lezyona ba&#287;l&#305; olarak geli&#351;en ve bu lezyon
�&#305;kar&#305;ld&#305;&#287;&#305;nda ek bir defisit geli&#351;meyen parsiyel
epilepsilerdir. Bu tip lezyonlar genellikle k���k neoplazmlar, hamartomalar,
vask�ler malformasyonlar, travmatik skarlar, fokal kortikal displazi gibi
�e&#351;itli konjenital bozukluklard&#305;r. Bu lezyonlar genellikle iyi bir
MRG incelemesi ile saptan&#305;r. Ancak detayl&#305; cerrahi �ncesi
�al&#305;&#351;mas&#305; ile s�z konusu lezyonun epilepsinin ger�ek nedeni olup
olmad&#305;&#287;&#305;n&#305;n belirlenmesi gerekmektedir. Baz&#305; olgularda
lezyon birden fazlad&#305;r ve ger�ek epileptik odak zorlukla bulunur. Bazen de
epileptik olguda g�r�len lezyonun asl&#305;nda epilepsi s�reciyle ilgisi
yoktur, tesad�fen bulunmu&#351; masum bir lezyondur. MRG'de saptanan lezyonun
klinik ve EEG ile n�betlerin kayna&#287;&#305; oldu&#287;u g�sterildi&#287;inde
cerrahi sonu�lar&#305; yine MTLE'ye benzer &#351;ekilde y�z g�ld�r�c�
olmaktad&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:black'>Semptomatik Epilepsilerde Di&#287;er Baz&#305;
S&#305;k Etyolojik Nedenler</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p style='margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l8 level2 lfo82'><![if !supportLists]><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma;mso-bidi-font-style:italic'><span style='mso-list:Ignore'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Kortikal geli&#351;imsel
bozukluklar</span></i></b><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>:</span></i></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> Epilepsi genellikle �ocukluk �a&#287;&#305;nda ortaya
�&#305;kar ve diren�li seyreder. <b><i><o:p></o:p></i></b></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Hamartoma:<b> </b></span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>N�ronal, meningeal, glial
veya bunlar&#305;n kombinasyonunun neoplastik �zellik g�stermeyen
proliferasyonundan olu&#351;an yap&#305;d&#305;r. Kitle etkisi olmayan iyi
s&#305;n&#305;rlanm&#305;&#351; lezyonlarla kolayca tan&#305;n&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Lisensefali:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> D�z beyin, beyin y�zeyinde
girus ve sulkus geli&#351;iminin olmamas&#305; anlam&#305;na gelir. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Agiri:</span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> Komplet lisensefali ile e&#351; anlaml&#305;d&#305;r.
Giruslar hi� g�r�lmez. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Pakigiri:</span></i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> &#304;nkomplet lisensefali ile e&#351;
anlaml&#305;d&#305;r. Birka� k&#305;sa, kaba girus saptan&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Heterotopi<b>:</b></span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Ektopik n�ronlar&#305;n
serebral korteks d&#305;&#351;&#305;nda bulunmamalar&#305; gereken bir alana
yerle&#351;mesi anlam&#305;na gelir <b>(&#350;ekil 13B)</b>. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>&#350;izensefali</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>: Agenetik porensefali
olarak da adland&#305;r&#305;l&#305;r. Korteksten derinlere uzanan bir
yar&#305;k izlenir. <b>(&#350;ekil </b></span><st1:metricconverter
ProductID="13C"><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma'>13C</span></b></st1:metricconverter><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>)</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Hemimegalensefali<b>: </b></span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Serebral hemisferin t�m�
veya bir k&#305;sm&#305;n&#305;n hamartomat�z a&#351;&#305;r&#305; b�y�mesidir
ve etkilenen hemisferde migrasyon defekti vard&#305;r <b>(&#350;ekil 13E)</b>. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Tuberoz skleroz:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Ailevi m�ltipl organ
hastal&#305;&#287;&#305;d&#305;r. Mental retardasyon, epilepsi ve deri
lezyonlar&#305; ile karakterize klasik triad&#305; vard&#305;r. Anormal genler
9. ve 16. kromozomlara (s&#305;ras&#305;yla hamartin ve tuberin isimli genler<span
style='mso-spacerun:yes'>� </span>yerle&#351;mi&#351;tir (<b style='mso-bidi-font-weight:
normal'>Tablo 11</b>). Do&#287;umdan itibaren hastal&#305;k belirtileri g�r�lebilir.
Geli&#351;me gerili&#287;i ilk y&#305;llarda dikkati �eker. 2-3
ya&#351;lar&#305;nda epilepsi ve mental retardasyon g�r�l�r. Deri
lezyonlar&#305; ge� �ocukluk d�nemlerinde belirginle&#351;ir. &#304;lk
y&#305;llarda �selam�<span style='mso-spacerun:yes'>� </span>spazmlar&#305;,
hipsaritmiyle fleksiyon miyoklonusu g�r�l�r. EEG'de y�ksek voltajl&#305; diken
ve yava&#351; dalga, d�zensiz disritmik burstler s&#305;kt&#305;r. N�betler
karakter de&#287;i&#351;tirir, jeneralize konv�lziyonlar, psikomotor n�betler
g�r�l�r. Fakoma, kalpte selim rabdomiyoma, b�brek, karaci&#287;er, dalak, akci&#287;er,
tiroid, testiste selim t�m�rler g�r�l�r. Patognomonik olan adenoma sebaseum
d&#305;&#351;&#305;nda, hipomelanotik mak�ller, Shagreen lekeleri, subungual
fibromalar gibi deri belirtileri g�r�l�r. T�m bu �zelliklere ra&#287;men
tan&#305;da g��l�k �ekilebilir. En i&#351;e yarar tan&#305; y�ntemi kranyal BT
veya MRG dir. Periventrik�ler kalsifik lezyonlar ve kortikal tuberler tipiktir <b>(&#350;ekil
</b></span><st1:metricconverter ProductID="12C"><b><span lang=TR
 style='font-size:10.0pt;font-family:Tahoma'>12C</span></b></st1:metricconverter><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>)</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-bidi-font-weight:bold'>Fokal kortikal displazi<b> </b></span></i><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>(&#350;ekil 13A): </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Epileptik n�betler en
s&#305;k ve en �nemli semptomudur, ancak olmas&#305; &#351;art de&#287;ildir.
Bu anomali kortikal gri ve ak madde anomalisi, kortikal laminasyon ve
organizasyonda bozulma, geni&#351; displastik n�ronlar ile karakterizedir.
N�ronlar kortekse ula&#351;&#305;r ancak anormal da&#287;&#305;l&#305;m
g�r�l�r. Hemisferin k���k veya geni&#351; bir k&#305;sm&#305; tutulabilir. En
s&#305;k etkilenen b�lge Silviyen fiss�r�n posterior
yap&#305;lar&#305;d&#305;r. Ancak her b�lge etkilenebilir. Herhangi bir
ya&#351;ta epilepsi ba&#351;layabilirse de, s&#305;kl&#305;kla 6
ya&#351;&#305;ndan �nce ba&#351;lar. Konjenital CMV enfeksiyonu sonucu ve
Aicardi sendromunda da fokal kortikal displazi (X'e ba&#287;l&#305; dominant
kal&#305;t&#305;ml&#305;, infantil spazm, kallozal agenezi, korioretinopati ve
EEG bozuklu&#287;u) g�r�lebilir. G�r�nt�leme �al&#305;&#351;malar&#305;nda
displastik korteks tipik olarak normal korteksle izointens g�r�n�mdedir. % 20
olguda displastik korteksin alt&#305;ndaki ak maddede uzam&#305;&#351; T2
relaksasyon zaman&#305; saptan&#305;r. Kortikal displazilerin %5'ten
az&#305;nda kalsifikasyon g�r�lebilir. <o:p></o:p></span></p>

<p style='margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l8 level2 lfo82'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Neoplazmlar</span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'> <o:p></o:p></span></i></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Astrositik t�m�rler:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Belirgin kitle etkisi veya
yay&#305;l&#305;m g�steren lezyonlard&#305;r. MRG'nin sensitivitesi %100'd�r.
En s&#305;k g�zlenen tipi fibriler astrositomad&#305;r (%75). Genellikle homojen
kitle g�r�n�m� verir fakat kistik g�r�n�m de olabilir. %20 oran&#305;nda
kalsifikasyon saptan&#305;r. Lokalizasyonu de&#287;i&#351;kendir. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Oligodendroglioma:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Bu lezyon genellikle
temporal lob yerle&#351;imli olup, amigdalay&#305; kapsama e&#287;ilimindedir. Daha
nadirdir, diren�li epilepsilerde %2.5 oran&#305;nda bildirilmektedir. MRG�de
genellikle heterojen kitle, kistik komponent ve hemoraji g�r�l�r. Kalsifikasyon
daha s&#305;kt&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Mikst glial t�m�rler:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Temporal lobda daha
s&#305;kt&#305;r. Ganglioglioma veya gangliositomalarda solid kitle g�r�n�m�
vard&#305;r. Bazen kistik g�r�n�m olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-weight:bold'>DNET </span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>(Disembriyoblastik
n�roepitelyal t�m�r): Diren�li parsiyel n�betlerle s&#305;k birlikteli&#287;i
nedeniyle dikkati �ekmi&#351;tir. Genellikle gen� hastalarda g�r�l�r ve
temporal loba lokalizedir (%62), frontalde ise % 30 oran&#305;nda
yerle&#351;ir. Gri ve ak maddeyi kaplar. Histolojik olarak h�cresel pleomorfizm
ve astrosit, oligodendrosit, ve n�ronlar gibi �e&#351;itli h�cre tiplerinden
olu&#351;ur. Bu a&#351;amada gliomalardan ayr&#305;m&#305; tedavi
yakla&#351;&#305;m&#305; a�&#305;s&#305;ndan �zellikle �nem ta&#351;&#305;r.
Selim olarak kabul edilir. 15 ya&#351;&#305;ndan �nce olgular&#305;n % 85'i
n�bet ile ba&#351;vurur. Zeka normaldir ve fakomatozis ile uyumlu stigmat
bulunmaz. G�r�nt�leme bulgular&#305; karakteristiktir (<b style='mso-bidi-font-weight:
normal'>&#350;ekil 18</b>). <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:35.4pt;text-align:justify'><b style='mso-bidi-font-weight:normal'><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'><a
href="sekil18.jpg">&#350;ekil 18.</a></span></u></b><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;color:blue'> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Diren�li epilepsi nedeniyle
izlenen bir olguda sa&#287; temporal b�lgede disembriyoblastik n�roepitalyal
t�m�r (DNET) d�&#351;�n�len MRG lezyonu<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:35.4pt;text-align:justify'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:0cm;text-align:justify;text-indent:0cm;
mso-list:l8 level2 lfo82'><![if !supportLists]><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Tahoma'><span
style='mso-list:Ignore'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Vask�ler </span></i></b><i
style='mso-bidi-font-style:normal'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></i></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>Vask�ler malformasyonlarda n�bet s&#305;kt&#305;r.
Temporal lobda di&#287;er b�lgelere g�re daha nadirdir. Arteryo-ven�z
malformasyon ve kavern�z anjiom d&#305;&#351;&#305;nda n�betle pek
ba&#287;&#305;nt&#305;s&#305; olmayan kapiler teleanjiektazi ve ven�z
anjiomlar&#305;n da olabilece&#287;ini hat&#305;rlamak gerekir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>&#304;nme de �zellikle ya&#351;l&#305;da en s&#305;k
epilepsi etyolojileri aras&#305;nda yer al&#305;r. Semptomatik olarak ilk
g�nlerde n�bet daha s&#305;kken kronik epilepsi geli&#351;imi nispeten
nadirdir. Hangi hastada n�bet olaca&#287;&#305;n&#305; belirlemek kolay
de&#287;ildir, genetik fakt�rlerin rol� oldu&#287;u d�&#351;�n�lmektedir.
Genelde seyir ve tedaviye yan&#305;t olumludur. Nadiren diren�li olgular
g�r�l�r.<o:p></o:p></span></p>

<p style='margin-left:0cm;text-align:justify;text-indent:0cm;mso-list:l8 level2 lfo82'><![if !supportLists]><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span></b><![endif]><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>&#304;nfeksiyonlar <o:p></o:p></span></b></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Viral, bakteriyel, paraziter ve fungal intrakranyal infeksiyonlar
hastal&#305;k s&#305;ras&#305;nda akut olarak veya uzun bir aradan sonra
n�betlere neden olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>&#304;ntrakranyal t�berk�loz:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Kortikal ve meningeal
t�berk�lomlar medikal tedaviye diren� g�sterebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Fungal infeksiyonlar:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> Epilepsinin nadir
nedenlerindendir (Kriptokokkozis ve blastomikozis). Genellikle imm�nitesi
d�&#351;�k insanlarda olur. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Viral ensefalitler:</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> �zellikle herpes simpleks
ensefalitinin erken ve ge� d�neminde n�betler g�r�lebilir. Akut fazda
jeneralize tonik-klonik n�bet s&#305;kt&#305;r ve status epileptikusa
e&#287;ilim g�r�l�r. Ge� d�nemde ise tedaviye diren�li parsiyel n�betler
g�r�l�r. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><i style='mso-bidi-font-style:normal'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>&#304;ntrauterin ve perinatal
infeksiyonlar:</span></i><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'> Toksoplazma, rubella, sifiliz ciddi hasara neden olur ve e&#287;er
�ocuk ya&#351;arsa parsiyel epilepsi g�r�l�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'><span style='mso-tab-count:1'>����������� </span>Beyin
abseleri de s&#305;k olarak n�bete neden olur. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><a name="Status_epileptikus_ve"></a><b><span
lang=TR style='font-family:Tahoma'>D&#304;&#286;ER TEDAV&#304;
ALTERNAT&#304;FLER&#304;<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><i style='mso-bidi-font-style:normal'><span lang=TR style='font-family:
Tahoma'>Vagal Sinir Stim�lasyonu (VSS):</span></i></b><span lang=TR
style='font-family:Tahoma'> &#304;laca diren�li epilepsisi olan ancak epilepsi
cerrahisi a�&#305;s&#305;ndan uygun bulunmayan ki&#351;ilerde uygulan&#305;r.
&#304;lk kez 1997 y&#305;l&#305;nda ABD�de onayland&#305;ktan sonra
ya&#351;&#305; 12den b�y�k olan ki&#351;ilere uygulanmaya
ba&#351;lam&#305;&#351;t&#305;r. Hayvan deneylerinde VSS�nun antikonv�lzan
etkisinin kortikal ritimlerin desenkronizasyonu ile olu&#351;tu&#287;u
belirtilmektedir. S&#305;�anda parietal korteksin piramidal n�ronlar&#305;nda
VSS�nun d�&#351;�k uyaran&#305;yla hiperpolarizasyon bulunmu&#351;tur. Etki
mekanizmas&#305; tam olarak bilinmemektedir. Stim�lasyonlar insan EEG�si
�zerinde g�r�lebilir de&#287;i&#351;iklikler meydana getirmemektedir.
Yap&#305;lan fonksiyonel g�r�nt�lemelerle VSS�nun etki mekanizmas&#305;
anla&#351;&#305;lmaya �al&#305;&#351;&#305;lm&#305;&#351;t&#305;r. PET ile
bilateral talamusta kan ak&#305;m&#305;nda de&#287;i&#351;iklikler n�bet
say&#305;s&#305;ndaki azalma ile korele edilmi&#351;tir. fMR�da bilateral
talamus (sol&gt;sa&#287;) ve ins�ler kortekste aktivasyon klinik yan&#305;t ile
de uyumlu bulunmu&#351;tur. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'>Cihaz sol n. vagusa genel anestezi veya servikal lokal anestezi
alt&#305;nda yerle&#351;tirilir. Sa&#287; taraftaki vagusda daha fazla miktarda
kardiyak eferent dallar oldu&#287;u ve bradikardi yapabilece&#287;i i�in VSS
uygulanmas&#305; tercih edilmez. &#304;ki spiral elektroddan biri vagusa di&#287;eri
ise infraklavik�ler b�lgeye konacak olan pile tak&#305;l&#305;r. Deneyimli
ellerde iki saatten k&#305;sa s�ren bir cerrahi i&#351;lemdir. Operasyon
komplikasyonlar&#305; olarak vagus siniri veya karotis zedelenmesi ya da
infeksiyon olabilir. Stimulat�r d&#305;&#351;ar&#305;dan programlanabilir ve
istenirse pil kapat&#305;labilir veya supraklavik�ler b�lgeye magnetin
tutulmas&#305; ile etkisi artt&#305;r&#305;labilir. �zellikle auras&#305; olan
hastan&#305;n n�betini durdurmak i�in magneti kullanmas&#305; �ok �nemlidir.
VSS iyi tolere edilebilen ve �ok nadir yan etki veya komplikasyon olabilen
g�venilir bir alternatif tedavidir. VSS tak&#305;ld&#305;ktan
yakla&#351;&#305;k iki hafta sonra etkisi ba&#351;lamaktad&#305;r.
Hastalar&#305;n %35-40�&#305;nda n�betlerinin %50�den fazla azalmas&#305;
&#351;eklinde sonu�lar vard&#305;r, ancak sadece %2 hastan&#305;n VSS ile
n�betsiz kald&#305;&#287;&#305; bildirilmi&#351;tir. Be&#351; y&#305;ldan uzun
s�reli �al&#305;&#351;malarda ortalama n�bet say&#305;s&#305;n&#305;n %60-70
azald&#305;&#287;&#305; belirlenmi&#351;tir. �ocuklarda yap&#305;lan
�al&#305;&#351;malarda da benzer sonu�lar izlenmi&#351;tir. Yan etkiler
a�&#305;s&#305;ndan bak&#305;l&#305;nca en s&#305;k ses
k&#305;s&#305;kl&#305;&#287;&#305;, �ks�r�k, parestezi, dispne, laringismus
g�r�l�r. <span style='mso-bidi-font-weight:bold'>VSS uyku apne sendromu,
kardiyak aritmi ve ast&#305;m bron&#351;iyalesi olanlarda<span
style='mso-spacerun:yes'>� </span>kontrendikedir. VSS olduk�a pahal&#305; bir
y�ntem olmas&#305; nedeniyle s&#305;n&#305;rl&#305; kullan&#305;labilmektedir. <o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>Ketojenik Diyet:</span></i></b><b><span
lang=TR style='font-family:Tahoma'> </span></b><span lang=TR style='font-family:
Tahoma;mso-bidi-font-weight:bold'>Alternatif tedavi olarak 1920�li
y&#305;llar&#305;n ba&#351;&#305;ndan beri ilaca diren�li epilepsilerde y�ksek
ya&#287;, d�&#351;�k karbonhidrat ve protein i�erikli diyetin
al&#305;nmas&#305; �nerilmektedir. A�l&#305;kla ortaya �&#305;kan ketozisin
n�betleri bask&#305;lad&#305;&#287;&#305; g�r�&#351;�yle ortaya konmu&#351; bir
tedavi y�ntemidir. Mekanizmas&#305; tam olarak bilinmemektedir. VSS�da
oldu&#287;u gibi epilepsi cerrahisi i�in uygun aday olamayan ve antiepileptik
ila�lara diren�li olan hastalarda veya antiepileptik ila�lara ba&#287;l&#305;
ciddi yan etki g�sterenlerde denenir, ayr&#305;ca glikoz ta&#351;&#305;ma
eksikli&#287;i (GLUT-1) veya pir�vat dehidrogenaz eksikli&#287;i olanlarda ilk
se�enektir. �ocuk ve ergenlerde tercih edilmekte olan bir tedavidir. Kalorinin
%75�i verilir ve sa&#287;lanan g�nl�k s&#305;v&#305; miktar&#305; normalin
%80�i kadard&#305;r, ancak hastan&#305;n �rolitiazisi varsa ya da topiramat
veya zonisamid gibi �rolitiyazisi kolayla&#351;t&#305;racak ila�lar
al&#305;yorsa s&#305;v&#305; k&#305;s&#305;tlamas&#305; yap&#305;lmaz. Verilen
ila�lar&#305;n i�indeki karbonhidrat (ni&#351;asta miktar&#305;)<b> </b>diyetten
d�&#351;�r�l�r. Ketozise ba&#287;l&#305; olu&#351;abilecek yan etkiler
a�&#305;s&#305;ndan �ncesi ve sonras&#305;nda yak&#305;n takip
yap&#305;lmal&#305;d&#305;r. Ketozise ba&#287;l&#305; hipoglisemi, kusma,
metabolik asidoz, hipopotasemi, dehidrastasyon, ishal ve kab&#305;zl&#305;k
olabilir. Uzun d�nemdeki yan etkiler ise geli&#351;me gecikmesi ve
hipoproteinemi olabilir. Az say&#305;da hastada ise hemolitik anemi, Fanconi
renal t�b�ler asidozu, karaci&#287;er fonksiyon testlerinde y�kselme,
pankreatit, artm&#305;&#351; �f�r�m, uzam&#305;&#351; QT intervali ve koma
ciddi yan etkiler olarak bildirilmi&#351;tir. Ketojenik diyet i�in
kontrendikasyonlar olarak ya&#287; asitlerinin oksidasyon ve transport
eksikli&#287;i, karnitin eksikli&#287;i, piruvat karboksilaz eksikli&#287;i,
akut intermitan porfiri, organik asid�riler say&#305;labilir.</span><span
lang=TR style='font-family:Tahoma;mso-fareast-font-family:+mn-ea;color:black;
mso-font-kerning:12.0pt'> </span><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Zor uygulanabilen ketojenik diyette hasta ve aile
ile iyi i&#351;birli&#287;i sa&#287;lanmal&#305;, dikkatli ve titiz bir
e&#287;itim verilmelidir. Ketojenik diyetin ikinci ay&#305;nda n�betlerdeki
yan&#305;ta g�re tedaviye devam konusunda karar verilir. 1925-1998
aras&#305;nda yap&#305;lan �al&#305;&#351;malar&#305;n metaanalizlerinde
hastalar&#305;n %37�sinde n�betlerinin %90�dan fazla ve %30�unda ise %50-90
oran&#305;nda azald&#305;&#287;&#305; g�sterilmi&#351;tir. <o:p></o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Derin Beyin Stim�lasyonu:</span></i></b><b><span
lang=TR style='font-family:Tahoma'> </span></b><span lang=TR style='font-family:
Tahoma;mso-bidi-font-weight:bold'>Epilepside alternatif tedavi olarak denenmeye
son y&#305;llarda ba&#351;lanm&#305;&#351;t&#305;r. Hareket
bozukluklar&#305;nda uzun s�reden beri ve s&#305;k kullan&#305;lan bu y�ntem
i�in epilepside deneyim hen�z �ok azd&#305;r. Mekanizmas&#305; bilinmemektedir.
En �ok tercih edilen b�lgeler talamusun anterior nukleusu, kaudat nukleus,
talamusun santromedyan nukleusu, serebellum, hipokampus ve subtalamik
nukleustur. Bu konuda yay&#305;nlanan �al&#305;&#351;malar �ift k�r olmadan
yap&#305;lm&#305;&#351; ve �ok az say&#305;da hastadan olu&#351;an serilerdir.<span
style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:14.0pt;
font-family:Tahoma'>STATUS EP&#304;LEPT&#304;KUS VE TEDAV&#304;S&#304;</span></b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Bir�ok
epileptik n�bet bir giri&#351;im gerektirmeden kendili&#287;inden dakikalar
i�inde sonlanmaktad&#305;r. Bir n�betin 30 dakikadan uzun s�rmesi ya da bu s�re
i�inde hasta d�zelmeden birden �ok n�betin ard arda tekrarlamas&#305;na <i
style='mso-bidi-font-style:normal'>status epileptikus (SE)</i> ad&#305;
verilir. Son y&#305;llar i�inde status epileptikus tan&#305;s&#305; i�in
gereken s�re giderek k&#305;salm&#305;&#351; ve baz&#305; yay&#305;nlarda 5
veya 10 dakikadan uzun s�ren n�betler bile bu tan&#305;m i�inde ele
al&#305;nm&#305;&#351;t&#305;r. Ancak s�re konusunda fikir birli&#287;i yoktur.
Jeneralize konv�lzif status epileptikus (JKSE) en s&#305;k
kar&#351;&#305;la&#351;&#305;lan, en iyi tan&#305;nan ve en tehlikeli tipidir.
Hayat&#305; tehlikeye sokan bu tablonun h&#305;zl&#305; ve do&#287;ru tedaviye
cevap vermesi konunun �nemini artt&#305;rmaktad&#305;r. <i style='mso-bidi-font-style:
normal'>Diren�li status epileptikus</i> tan&#305;m&#305; ise status epileptikus
tedavisinde ikinci veya ���nc� ilaca yan&#305;t al&#305;namam&#305;&#351;
hastalar i�in ge�erlidir. Ancak tan&#305;m&#305; konusunda tam bir fikir
birli&#287;i yoktur. T�m status epileptikuslar i�inde %10-40 gibi y�ksek bir
g�r�lme oran&#305; vard&#305;r. Agresif tedavi edilmesi gerekir.<o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Hemen
t�m epileptik n�bet tiplerinin status epileptikus tarz&#305;nda belirmesi
m�mk�nd�r. En basit s&#305;n&#305;flama <i style='mso-bidi-font-style:normal'>konv�lzif
SE</i> ve <i style='mso-bidi-font-style:normal'>nonkonv�lzif SE</i>
&#351;eklinde yap&#305;labilir. &#350;u an kullan&#305;lan ��
s&#305;n&#305;flama (2001 ve 2006 y&#305;llar&#305;nda ILAE�nin ve 2005
y&#305;l&#305;nda L�ders ve ark yapt&#305;&#287;&#305; s&#305;n&#305;flamalar)
vard&#305;r.<o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>1) S�regiden n�bet tipleri 2001 ILAE
s&#305;n&#305;flama �nerisi:<o:p></o:p></span></i></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=661
 style='width:496.0pt;margin-left:35.4pt;border-collapse:collapse;mso-yfti-tbllook:
 1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-row-margin-right:35.4pt'>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>1-Jeneralize
  status epileptikus<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:17.85pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Jeneralize tonik-klonik status epileptikus<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:17.85pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Klonik status epileptikus<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:17.85pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Absans status epileptikus<span
  style='mso-spacerun:yes'>���� </span><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:17.85pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Tonik status epileptikus<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:17.85pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Miyoklonik status epileptikus<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-row-margin-right:35.4pt'>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>2-Fokal
  status epileptikus<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:18.0pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Kojevnikov epilepsia parsiyalis kontinua<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:18.0pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Aura kontinua<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:18.0pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Limbik status epileptikus (psikomotor status)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;mso-row-margin-left:35.4pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm 0cm'
  width=47><p class='MsoNormal'>&nbsp;</td>
  <td width=614 colspan=2 valign=top style='width:460.6pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p style='margin-left:18.0pt;text-align:justify'><span lang=TR
  style='font-family:Tahoma'>Hemiparezili hemikonvulzif status<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=47 style='width:35.25pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt;mso-ansi-language:EN-US;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=567 style='width:15.0cm;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt;mso-ansi-language:EN-US;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=47 style='width:35.25pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span style='font-size:10.0pt;mso-ansi-language:EN-US;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><i style='mso-bidi-font-style:normal'><span lang=TR style='font-family:
Tahoma'>2) Status Epileptikus 2006 ILAE revizyonu:<o:p></o:p></span></i></b></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>I. <span style='mso-bidi-font-weight:bold'>Epilepsia
parsiyalis kontinua</span> (Kojevnikov) <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:71.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>(Rasmussen ensefaliti, fokal lezyon, do&#287;umsal
metabolik)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>II. <span style='mso-bidi-font-weight:bold'>SMA
status epileptikusu </span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>III. <span style='mso-bidi-font-weight:bold'>Aura
kontinua </span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>IV. <span style='mso-bidi-font-weight:bold'>Diskognitif
fokal SE (Kompleks parsiyel SE) </span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:107.4pt;text-align:justify'><span
lang=TR style='font-family:Tahoma'>(Meziyal, neokortikal)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>V. <span style='mso-bidi-font-weight:bold'>Tonik
klonik SE</span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>VI. <span style='mso-bidi-font-weight:bold'>Absans
SE</span> (Tipik/ atipik, miyoklonik absans)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>VII. <span style='mso-bidi-font-weight:bold'>Miyoklonik
SE</span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>VIII. <span style='mso-bidi-font-weight:bold'>Tonik
SE</span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-align:justify'><span lang=TR
style='font-family:Tahoma'>IX. G�� farkedilen (�<span style='mso-bidi-font-weight:
bold'>Subtle�) SE </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><i style='mso-bidi-font-style:
normal'><span lang=TR style='font-family:Tahoma'>3) Status Epileptikusun
semiyolojik s&#305;n&#305;flamas&#305; 2005:<o:p></o:p></span></i></p>

<p class=MsoNormal style='margin-left:53.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level1 lfo87;tab-stops:list 53.4pt'><![if !supportLists]><span
lang=TR style='font-family:"Wingdings 2";mso-fareast-font-family:"Wingdings 2";
mso-bidi-font-family:"Wingdings 2"'><span style='mso-list:Ignore'>&#151;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Aura statusu</span><span lang=TR style='font-family:
Tahoma'> (somatosensoryal, g�rsel, i&#351;itsel, olfaktor, gustatuvar,
psi&#351;ik, otonomik, abdominal)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:53.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level1 lfo87;tab-stops:list 53.4pt'><![if !supportLists]><span
lang=TR style='font-family:"Wingdings 2";mso-fareast-font-family:"Wingdings 2";
mso-bidi-font-family:"Wingdings 2"'><span style='mso-list:Ignore'>&#151;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Otonomik status </span><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:53.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level1 lfo87;tab-stops:list 53.4pt'><![if !supportLists]><span
lang=TR style='font-family:"Wingdings 2";mso-fareast-font-family:"Wingdings 2";
mso-bidi-font-family:"Wingdings 2"'><span style='mso-list:Ignore'>&#151;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Diskognitif status</span><span lang=TR
style='font-family:Tahoma'> (dialeptik, deliryum, afazik)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:53.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level1 lfo87;tab-stops:list 53.4pt'><![if !supportLists]><span
lang=TR style='font-family:"Wingdings 2";mso-fareast-font-family:"Wingdings 2";
mso-bidi-font-family:"Wingdings 2"'><span style='mso-list:Ignore'>&#151;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Motor</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:89.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level2 lfo87;tab-stops:list 89.4pt'><![if !supportLists]><span
lang=TR style='font-family:Verdana;mso-fareast-font-family:Verdana;mso-bidi-font-family:
Verdana'><span style='mso-list:Ignore'>&#9702;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Basit</span><span lang=TR style='font-family:Tahoma'>
(tonik, epileptik spazm, versif, miyoklonik, klonik, tonik-klonik)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:89.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level2 lfo87;tab-stops:list 89.4pt'><![if !supportLists]><span
lang=TR style='font-family:Verdana;mso-fareast-font-family:Verdana;mso-bidi-font-family:
Verdana'><span style='mso-list:Ignore'>&#9702;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Kompleks </span><span lang=TR style='font-family:
Tahoma'>(otomotor, hipermotor, jelastik)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:53.4pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level1 lfo87;tab-stops:list 53.4pt'><![if !supportLists]><span
lang=TR style='font-family:"Wingdings 2";mso-fareast-font-family:"Wingdings 2";
mso-bidi-font-family:"Wingdings 2"'><span style='mso-list:Ignore'>&#151;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>�zel status tipleri</span><span lang=TR
style='font-family:Tahoma'> (atonik, astatik,hipomotor, akinetik, negatif
miyoklonik)<o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Nonkonv�lzif
Status Epileptikus</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Davran&#305;&#351;lar
ve mental durumda yava&#351;lama, konf�zyon, hatta stupor ve komayla giden,
devaml&#305; elektrografik n�bet aktivitesinin e&#351;lik etti&#287;i tablo
olarak tan&#305;mlanabilir. &#304;ki ana b�l�mde ele al&#305;nabilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>1)Absans
status epileptikus <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>2)Kompleks
parsiyel status epileptikus <o:p></o:p></span></p>

<p style='text-align:justify'><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>Petit mal status,
diken-dalga stuporu, minor epileptik status, epileptik alacakaranl&#305;k
durumu, status piknoleptikus, uzam&#305;&#351; petit mal otomatizma</span></i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> gibi �ok �e&#351;itli
isimlerle ayn&#305; tablo adland&#305;r&#305;lmaktad&#305;r. Yeni
�al&#305;&#351;malarda insidensi %3 olarak belirmektedir. %75 olgu ilk 20
ya&#351; i�indedir, ama her ya&#351;ta g�r�lebilir. &#304;lk ba&#351;vuru
nedeni olabilir ama �o&#287;u olgu �nceden epileptiktir. Jeneralize konv�lz�yonlar&#305;
izleyerek NKSE geli&#351;ebilir, idyopatik veya kriptojenik olabilece&#287;i
gibi etyolojide psikotrop ila� kullan&#305;m&#305;, klorokin, ifosfamid,
propofol, baklofen, seftazidim gibi ila�lar, hipokalsemi, hiponatremi gibi
metabolik problemler, kronik alkolizm, metrizamid, amitriptilin intoksikasyonu,
hipertiroidizm, benzodiazepinlerin ani b&#305;rak&#305;lmas&#305;, beyne ok�lt
metastaz, paraneoplastik sendrom, primer jeneralize epileptiklerde hatal&#305;
karbamazepin kullan&#305;m&#305;, IV kontrast madde kullan&#305;m&#305;,
trombotik trombositopenik purpura gibi �ok say&#305;da neden olabilmektedir. </span><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma'>Absans status epileptikus ile kompleks parsiyel
status epileptikusun ayr&#305;m&#305; genelde g��t�r. KPSE daha siklik bir
patern g�sterirken ASE daha devaml&#305;d&#305;r, ASE'de tam
cevaps&#305;zl&#305;k g�r�lmez, KPSE'de ise bir d�nemde cevaps&#305;zl&#305;k
genellikle vard&#305;r. KPSE'de otomatizmler daha belirgin, zengin ve uzundur.
Anksiyete, agresyon, korku vb. KPSE�de daha s&#305;kt&#305;r. Tedaviye cevap
her iki tablo i�in etyoloji ve tipe ba&#287;l&#305;d&#305;r <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Atipik ve tipik absans status tablolar&#305;n&#305; da ay&#305;rmak
kimi zaman �ok g��t�r. Ancak bu iki tablonun etyoloji ve prognozlar&#305; �ok
farkl&#305; oldu&#287;u i�in ay&#305;rma gayreti anlaml&#305; g�r�nmektedir.
Atipik absans statusu sekonder jeneralize epilepsilerde veya Lennox-Gastaut
sendromunda g�r�len uzam&#305;&#351; atipik absans n�betidir. Tipik absans
statusundan farklar&#305; mental retardasyon, geli&#351;me gerili&#287;inin
e&#351;lik etmesi, anormal interiktal EEG saptanmas&#305;, de&#287;i&#351;ik
n�bet tipleriyle birliktelik, 3-6 Hz�den yava&#351; (ya da daha
h&#305;zl&#305;) diken-dalga paroksizmleri, tablonun ba&#351;lamas&#305; ve
biti&#351;inin sinsi olmas&#305;d&#305;r. </span><span lang=TR
style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Nonkonv�lsif status epileptikusun en �nemli yan&#305; tan&#305;
g��l�&#287;�d�r. Ayr&#305;c&#305; tan&#305;s&#305;nda �ok say&#305;da tablonun
yer almas&#305; bu g��l�&#287;� kan&#305;tlamaktad&#305;r. </span><span
lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Nonkonv�lsif status epileptikusun ay&#305;r&#305;c&#305;
tan&#305;s&#305;</span></b><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'> <o:p></o:p></span></p>

<ul type=disc>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l54 level2 lfo90;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>Di&#287;er n�betle ili&#351;kili de&#287;i&#351;mi&#351; mental
      durum nedenleri</span><span lang=TR style='font-size:10.0pt;font-family:
      Tahoma'> <o:p></o:p></span></li>
  <ul type=square>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l54 level3 lfo90;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma'>Uzam&#305;&#351;
       postiktal konf�zyon <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l54 level3 lfo90;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma'>Periyodik lateralize
       epileptiform de&#351;arjlar (PLED) ile ili&#351;kili
       de&#287;i&#351;mi&#351; mental durum <o:p></o:p></span></li>
  </ul>
 </ul>
</ul>

<ul type=disc>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l46 level2 lfo93;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>Ensefalopatiler</span><span lang=TR style='font-size:10.0pt;
      font-family:Tahoma'> <o:p></o:p></span></li>
  <ul type=square>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l46 level3 lfo93;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Toksik-metabolik</span><span lang=TR style='font-size:10.0pt;
       font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l46 level3 lfo93;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Hipoglisemi</span><span lang=TR style='font-size:10.0pt;
       font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l46 level3 lfo93;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Mitokondriyal ensefalopatiler</span><span lang=TR
       style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l46 level3 lfo93;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Hiperamonyemi</span><span lang=TR style='font-size:10.0pt;
       font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l46 level3 lfo93;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;<span
       style='mso-bidi-font-style:italic'>la� intoksikasyonu</span> <o:p></o:p></span></li>
  </ul>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l46 level2 lfo93;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Post-travmatik <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l46 level2 lfo93;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>Vask�ler <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l46 level2 lfo93;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;skemik <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l46 level2 lfo93;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma'>&#304;nflamatuvar <o:p></o:p></span></li>
 </ul>
</ul>

<ul type=disc>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l53 level2 lfo96;tab-stops:list 72.0pt'><span
      lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
      italic'>Psikiyatrik sendromlar</span><span lang=TR style='font-size:10.0pt;
      font-family:Tahoma'> <o:p></o:p></span></li>
  <ul type=square>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l53 level3 lfo96;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Disosiyatif reaksiyonlar</span><span lang=TR style='font-size:
       10.0pt;font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l53 level3 lfo96;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Akut psikoz</span><span lang=TR style='font-size:10.0pt;
       font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l53 level3 lfo96;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Histerik konversiyon reaksiyonu</span><span lang=TR
       style='font-size:10.0pt;font-family:Tahoma'> <o:p></o:p></span></li>
   <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
       auto;text-align:justify;mso-list:l53 level3 lfo96;tab-stops:list 108.0pt'><span
       lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-bidi-font-style:
       italic'>Katatoni</span><span lang=TR style='font-size:10.0pt;font-family:
       Tahoma'> <o:p></o:p></span></li>
  </ul>
 </ul>
</ul>

<p style='text-align:justify'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma'>Standart status epileptikus tedavisi (IV k&#305;sa s�reli
benzodiazepin) uygulan&#305;r. N�ks g�r�len olgularda valproat ve etos�ksimid
�nerilir. Tipik absans statusunda tedaviyle veye tedavisiz prognoz iyidir. N�ks
durmlar&#305;nda da mortalite ve morbidite bildirilmemi&#351;tir. Atipik absans
statusu tedaviye daha zor cevap verir. KPSE �nceleri seyrek
san&#305;l&#305;rken, &#351;imdi daha s&#305;k bildirilmektedir. KPSE genelde
temporal lob k�kenli olarak d�&#351;�n�l�r ama extra-temporal, �zellikle de
frontal lob k�kenli oldu&#287;u kan&#305;tlanm&#305;&#351; olgular vard&#305;r.
</span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><b style='mso-bidi-font-weight:normal'><span
lang=TR style='font-family:Tahoma'>Etyoloji<o:p></o:p></span></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Status
epileptikusun etyolojisi di&#287;er epilepsi n�betleriyle benze&#351;ir. Ancak
en s&#305;k saptanan nedenler antiepileptik ilac&#305; aniden b&#305;rakma veya
d�zensiz kullanma, alkol kullan&#305;m&#305;, serebrovask�ler hastal&#305;k,
ila� intoksikasyonlar&#305;, metabolik bozukluklar, �e&#351;itli nedenlere
ba&#287;l&#305; olarak geli&#351;en kardiyak arrest, beyin t�m�r�, kafa
travmas&#305;, MSS ve di&#287;er sistemik infeksiyonlar &#351;eklinde
say&#305;labilir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>JKSE,
fokal motor veya miyoklonik SE g�r�ld�&#287;�nde klinik tan&#305; konmas&#305;
kolay olgulard&#305;r. Ancak gene de bu hastalar&#305;n EEG�lerinin �ekilmesi
ve SE�un tedavi ile hem klinik hem de elektrofizyolojik olarak
durdurdu&#287;unun g�sterilmesi gereklidir. Bazen klinik n�bet durmu&#351;
g�r�nebilir. Hastan&#305;n uyan&#305;kl&#305;&#287;&#305;nda problem olabilir.
Postiktal konf�zyon demeden �nce EEG �ekilmeli ve EEG�de elektrofizyolojik
n�betinin devam edip etmedi&#287;i belirlenmelidir. Ayr&#305;ca tedavinin
takibi a�&#305;s&#305;ndan da EEG �nemlidir.<span style='mso-spacerun:yes'>�
</span>Ay&#305;r&#305;c&#305; tan&#305;da JKSE i�in EEG normalse epileptik
olmayan psikojen n�bet d�&#351;�n�lmelidir. NKSE tan&#305;s&#305; akla ilk
geldi&#287;inde hemen EEG yap&#305;lmas&#305; gereklidir. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Status
epileptikusu �ok �nemli k&#305;lan durum bu tablonun y�ksek oranda �l�mle
sonu�lanmas&#305; veya kal&#305;c&#305; hasar b&#305;rakmas&#305;d&#305;r. Bu
nedenle status epileptikusun tan&#305; ve tedavisi �ok �nemli bir dahili ve
n�rolojik acil durum olarak belirmektedir. Status epileptikus ard&#305;ndan
�len 20 ki&#351;ide yap&#305;lan otopsi �al&#305;&#351;malar&#305; beyinde en
hassas b�lgelerin s&#305;ras&#305;yla hipokampus, kortikal n�ronlar, talamus,
korpus striatum ve serebellum Purkinje h�creleri oldu&#287;unu
g�stermi&#351;tir.</span><span lang=TR style='font-size:13.5pt;font-family:
Tahoma'> </span><span lang=TR style='font-family:Tahoma'><o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>Status
epileptikusun olu&#351;um mekanizmas&#305;n&#305;n inhibit�r sistemin
yetmezli&#287;i ve eksitat�r sistemin aktivasyonu oldu&#287;u
d�&#351;�n�lmektedir. NMDA ve nonNMDA resept�rlerinin status epileptikusdaki
aktivasyonu sonucunda a&#351;a&#287;&#305;daki zincirleme olaylar&#305;n
ger�ekle&#351;ti&#287;i bilinmektedir : <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-H�cre
membran&#305; depolarize olur <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-Voltaja
ba&#287;&#305;ml&#305; Ca <sup>+2</sup> kanallar&#305; aktifle&#351;ir <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-&#304;ntrasell�ler
Ca<sup>+2</sup> artar <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>-H�cre
i�i y&#305;k&#305;m enzimleri aktive olur. <o:p></o:p></span></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma'>&nbsp;Bu
olaylar&#305;n sonucunda n�ron �l�m� ger�ekle&#351;ir. Status epileptikusda
hasar&#305;n ve �l�m�n en �nemli nedeni geli&#351;en sistemik
komplikasyonlard&#305;r. <o:p></o:p></span></p>

<p style='text-align:justify'><i><span lang=TR style='font-family:Tahoma'>Status
epileptikusta sistemik komplikasyonlar:</span></i><span lang=TR
style='font-family:Tahoma'> <o:p></o:p></span></p>

<ul type=disc>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Hipoksi <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Laktik asidoz <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>CO<sub>2 </sub>narkozu <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Hiperkalemi <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Hipoglisemi <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Hipertansiyon izleyerek ileri d�nemde
      hipotansiyon ve &#351;ok <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Kardiyak aritmi <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Pulmoner �dem <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Akut tubuler nekroz <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Aspirasyon pn�monisi <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>L�kositoz <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l7 level2 lfo99;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Otonomik disfonksiyon <o:p></o:p></span></li>
 </ul>
</ul>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-family:Tahoma;mso-bidi-font-style:italic'>Status
Epileptikus Tedavisinde &#304;zlenmesi Gereken Basamaklar <o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:72.0pt;text-align:justify;text-indent:-18.0pt;mso-list:l68 level2 lfo102;
tab-stops:list 0cm 72.0pt'><![if !supportLists]><span lang=TR style='font-size:
10.0pt;mso-bidi-font-size:12.0pt;font-family:"Courier New";mso-fareast-font-family:
"Courier New"'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>K&#305;sa s�rede etkili bir benzodiazepin
t�revinin IV yolla verilmesi.</span></i><span lang=TR style='font-family:Tahoma'>
Lorazepam burada ilk tercih olarak belirtilmektedir, ancak yurdumuzda
bulunmamaktad&#305;r. Klonazepam (Rivotril amp) IV formu da art&#305;k
bulunmamaktad&#305;r. Tek se�enek olarak kalan IV diazepam amp�l 5 dakika
i�inde uygulanabilir. Burada i.m. yolla uygulaman&#305;n kesinlikle yeri
yoktur. &#304;lac&#305;n �zellikle solunum depresyonu yap&#305;c&#305; yan
etkisi nedeniyle ent�basyona haz&#305;rl&#305;k yap&#305;lmas&#305;
gerekmektedir. Etyolojik ara&#351;t&#305;rmalar da tedavi ile paralel
y�r�melidir. <o:p></o:p></span></p>

<ul type=disc>
 <ul type=circle>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>&#304;kinci ve tedavinin
      ba&#351;ar&#305;s&#305;n&#305; devam ettiren �nemli basamak yine <i
      style='mso-bidi-font-style:normal'>IV yolla fenitoin</i> (20mg/kg dozunda
      ve en �ok 50mg/dakikada olacak &#351;ekilde) y�klenmesidir. Yurdumuzda
      hen�z bulunmayan fosfenitoinde kullan&#305;labilir. Ya&#351;l&#305;
      ki&#351;ilerde ve kalp hastalar&#305;nda verilirken monitorize
      edilmelidir. Kardiyak aritmi ve hipotansiyon yapabilir, bu a�&#305;lardan
      dikkatle izlenmelidir. Hastan&#305;n idyopatik jeneralize epilepsisi
      varsa (absans, miyokloni) fenitoin verilmemelidir. N�betlerini daha da
      artt&#305;r&#305;r. Burada se�enek IV valproatt&#305;r. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><i
      style='mso-bidi-font-style:normal'><span lang=TR style='font-family:Tahoma'>Jeneralize
      epilepsilerde tercih valproatt&#305;r</span></i><span lang=TR
      style='font-family:Tahoma'>. IV y�kleme sonras&#305; hiperamonyemik
      ensefalopati olgular&#305; bildirilmesi nedeniyle takip edilmelidir. �re
      siklus bozukluklar&#305;nda verilmemelidir. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>N�betler 20 dakika sonra hala devam
      ediyorsa fenitoin 5-10mg/kg ek doz verilmesi baz&#305; kaynaklarda
      �nerilmektedir. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Bu a&#351;amada bir <i
      style='mso-bidi-font-style:normal'>reanimasyon �nitesine hastan&#305;n
      nakledilmesi</i> ve midazolam veya propofol ile acilen anestesi
      uygulanmas&#305; gerekmektedir. Bu �zellikle sistemik komplikasyonu
      geli&#351;en ve n�betleri 1 saatten uzun s�redir devam eden hastalarda
      �ok b�y�k gereklilik ta&#351;&#305;maktad&#305;r. Baz&#305; merkezlerde
      midazolam d�&#351;�k dozlarda diazemin yerine de
      kullan&#305;labilmektedir.<o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Yo&#287;un bak&#305;m �nitesi
      bulunmayan bir yerde ilk bir saat hen�z dolmam&#305;&#351; ancak
      n�betlerde devam ediyorsa, bir yandan transport olanaklar&#305;
      zorlan&#305;rken IV yolla fenobarbital (20mg/kg; dakikada 50-75mg olacak
      &#351;ekilde) uygulanabilir. <o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Refrakter SE olan olgularda
      nazogastrik t�pten 300-1600mg/g topiramat verilebilir.<o:p></o:p></span></li>
  <li class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:
      auto;text-align:justify;mso-list:l68 level2 lfo102;tab-stops:list 72.0pt'><span
      lang=TR style='font-family:Tahoma'>Levetirasetam da topiramat gibi nazogastrik
      t�pten 500-3000mg/g verilebilir. K&#305;sa bir s�re sonra
      levetirasetam&#305;n intraven�z formu �lkemizde kullan&#305;ma
      sunulacakt&#305;r.<o:p></o:p></span></li>
 </ul>
</ul>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
margin-left:54.0pt'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><b><i style='mso-bidi-font-style:normal'><span
lang=TR style='font-family:Tahoma'>Epilepsili hastalarda ani beklenmedik �l�m
(SUDEP - Sudden unexpected unexplained death in epilepsy)<o:p></o:p></span></i></b></p>

<p style='text-align:justify'><span lang=TR style='font-family:Tahoma;
mso-bidi-font-weight:bold'>Epilepsiye ba&#287;l&#305; �l�mlerin i�inde en
�nemlisini olu&#351;turmaktad&#305;r, nedeni bilinmemektedir.<span
style='mso-spacerun:yes'>� </span>Di&#287;er �l�m nedenleri n�bet
s&#305;ras&#305;ndaki yaralanma, bo&#287;ulma ve status epileptikusa
ba&#287;l&#305; �l�mlerdir. �ok merkezli �al&#305;&#351;malar yap&#305;larak
etyopatogenezi belirlenmeye �al&#305;&#351;&#305;lmaktad&#305;r. �o&#287;u
olguda tan&#305;k yoktur. En son yatmadan �nce sa&#287;l&#305;kl&#305; olan
ki&#351;i sabah yata&#287;&#305;nda �l� bulunur.<span
style='mso-spacerun:yes'>� </span>SUDEP insidans&#305; 45 ya&#351; alt&#305;nda
0.05-0.1/1000 iken 45 ya&#351; �st�nde 3/1000 olarak belirlenmi&#351;tir. Ancak
n�betleri erken ya&#351;ta ba&#351;layanlarda, diren�li epilepsisi olan, politerapi
alanlarda, IQ &lt;70 olanlarda, epilepsi cerrahisi yap&#305;lm&#305;&#351; ve
ba&#351;ar&#305;s&#305;z olmu&#351; ki&#351;ilerde ve beraberinde ba&#351;ka
hastal&#305;klar&#305; olanlarda risk artmaktad&#305;r. En y�ksek risk ila�
uyum sorunu olan, s&#305;k jeneralize tonik-klonik n�bet ge�iren
ki&#351;ilerdir. Nedeni bilinmemekle birlikte pulmoner, kardiyak, otonomik
mekanizmalar&#305;n biri veya birden fazlas&#305;n&#305;n etkili oldu&#287;u
ileri s�r�lmektedir. N�bet ile birlikte santral ve obstr�ktif apne,
a&#351;&#305;r&#305; bron&#351;iyal ve oral sekresyon, pulmoner �dem ve hipoksi
gibi nedenler solunumda de&#287;i&#351;ikliklere neden olmaktad&#305;r.
Pulmoner �dem �o&#287;u olguda g�r�lmektedir. Di&#287;er bir olas&#305;l&#305;k
ta kardiyak otonomik kontrolun bozulmas&#305; sonucu kardiyak aritmilerin
izlenmesidir. Etyopatogenezi bilinmedi&#287;i i�in �nleyici tedavi de
verilememektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma'><o:p>&nbsp;</o:p></span></p>

<p style='text-align:justify'><a name="Epilepsinin_sosyal"></a><b><span
lang=TR style='font-size:14.0pt;font-family:Tahoma'>EP&#304;LEPS&#304;N&#304;N
SOSYAL Y�NLER&#304;</span></b><span lang=TR style='font-size:14.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Epileptik
hastan&#305;n normal bir hayat s�rd�rmesi baz&#305; basit noktalara dikkat
edilerek �o&#287;u zaman m�mk�nd�r. Ancak toplumdaki genel e&#287;itimsizlik
bazen bu hastalar&#305;n hayat&#305;n&#305; gereksiz &#351;ekilde
zorla&#351;t&#305;rmakta ve verimsizle&#351;tirmektedir. T�m ad&#305;mlar,
hastan&#305;n m�mk�n oldu&#287;unca normal bir hayat s�rmesi, yani e&#287;itim,
evlenme, meslek sahibi olma ve bo&#351; zamanlar&#305;n&#305;
de&#287;erlendirme gibi �e&#351;itli sosyal olaylar&#305; normal bir
&#351;ekilde s�rd�rmesi amac&#305;yla at&#305;lmal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><b><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Epilepsi ve
Gebelik</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi ve
gebelik bir �ok y�nden etkile&#351;im g�sterir. Gebelik ve �ocuk do&#287;urma
epileptik kad&#305;nlar&#305;n b�y�k �o&#287;unlu&#287;unda ciddi bir soruna
yol a�maz. �ocuk sahibi olmak isteyen epileptik bir kad&#305;nda ilk �nce
tan&#305;n&#305;n do&#287;ru olup olmad&#305;&#287;&#305; ve ila�
kullan&#305;m&#305;n&#305;n gerekli olup olmad&#305;&#287;&#305;n&#305;n
belirlenmesi gereklidir. Hastaya ve e&#351;ine olas&#305; fetal anomaliler
hakk&#305;nda sa&#287;l&#305;kl&#305; bilgi verilmelidir. Antiepileptik ila�
kullan&#305;m&#305; normal pop�lasyonda % 2-5 civar&#305;nda olan fetal anomali
riskini yakla&#351;&#305;k 2-3 kat artt&#305;rmaktad&#305;rlar (%7-10). S�z
konusu anomalilerin �o&#287;u yar&#305;k dudak gibi min�r anomalilerdir, ancak
antiepileptikler az oranda da olsa ciddi n�ral t�p defektleri ve konjenital
kalp hastal&#305;klar&#305;na yol a�abilmektedir. Valproat&#305;n n�ral t�p
defekti olu&#351;turma riski di&#287;er ila�lara g�re biraz daha y�ksektir.
Fenitoin ve fenobarbital ise yar&#305;k dudak ve kalp anomalileri ile daha
s&#305;k ili&#351;kilendirilmektedir. Yeni AE&#304; ile ilgili bilgi
eksi&#287;i vard&#305;r. Lamotrijin ile ilgili ilk veriler olumlu iken
topiramat konusunda olumsuzdur. Risk politerapiyle ve artan dozlara paralel
olarak y�kselmektedir. Gebelik daha ger�ekle&#351;meden, n�betlerin iyi bir
&#351;ekilde kontrol edilebildi&#287;i minimal ila� dozunun ayarlanmas&#305; ve
gereksiz ila� kombinasyonlar&#305;ndan ka�&#305;narak, m�mk�n oldu&#287;unca
monoterapiye ge�ilmesi uygun ad&#305;mlard&#305;r. T�m hastalara 5 mg g�nl�k
folik asid tedavisi verilmesi gerekmektedir. Hastan&#305;n gebelik s�resince
n�bet s&#305;kl&#305;&#287;&#305; a�&#305;s&#305;ndan dikkatle ve s&#305;k
kontrollerle izlenmesi gerekir, ��nk� gebelik s&#305;ras&#305;nda ila� kan
d�zeylerinde dalgalanmalar olmaktad&#305;r. Hastan&#305;n jinekologuyla
n�rologunun ila� tedavisi, gebeli&#287;in gidi&#351;i ve do&#287;um
s&#305;ras&#305;ndaki tedavi d�zenlemeleri a�&#305;s&#305;ndan s&#305;k&#305;
bir i&#351;birli&#287;i i�inde olmalar&#305; �nerilmelidir. Fetal riskler
nedeniyle anne aday&#305;n&#305;n aniden antiepileptik ila�lar&#305;n&#305;
kesmesi %50 oran&#305;nda n�bet n�ks� ve daha da tehlikelisi status epileptikus
riskini beraberinde getirir. Bu nedenle anne aday&#305;n&#305;n
bilin�lendirilmesi ve b�yle bir durumun bebe&#287;e antiepileptik ila�lardan
daha fazla zarar verebilece&#287;i, hatta annenin de status epileptikus s&#305;ras&#305;nda
ya&#351;am&#305;n&#305; yitirebilece&#287;inin anlat&#305;lmas&#305;
gerekmektedir. Epileptik gebelerde ila�lar&#305;n metabolizmas&#305;nda
de&#287;i&#351;iklikler olmaktad&#305;r, bu nedenle 1/3 olguda n�betlerin
kontrol� k�t�ye gider ve yeni doz ayarlamalar&#305; gerekli olabilir. Ancak
�o&#287;u hasta normal bir gebelik ge�irir. Emzirmeye genelde bebe&#287;i
izleyerek izin verilmelidir. Bir �ok AE&#304; s�te ge�er ama klinik etki
g�r�lmez, fenobarbitalin bebe&#287;i uyutarak beslenmesini olumsuz
etkiledi&#287;i bilinmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Epilepsi ve
Meslek Se�imi <o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi ani
bilin� kayb&#305; ve hareketlerde kontrol kayb&#305; nedeniyle baz&#305;
meslekler a�&#305;s&#305;ndan risk olu&#351;turur. �rne&#287;in y�ksekte
�al&#305;&#351;ma, tehlikeli olabilecek i&#351; makinelerinin
kullan&#305;m&#305;, araba kullanma gerektiren meslekler epileptik
hastalar&#305;n tam n�bet kontrol� sa&#287;lanmadan se�memeleri gereken
mesleklerdir. Baz&#305; sendromlarda (�rne&#287;in j�venil miyoklonik epilepsi)
uykusuzluk n�bet riskini artt&#305;rd&#305;&#287;&#305; i�in uyku d�zenini
bozan meslekler ve vardiyal&#305; gece �al&#305;&#351;mas&#305; sak&#305;nca
do&#287;urabilir. Fotosensitivite saptanan olgular parlak &#305;&#351;&#305;k,
TV, bilgisayar ekran&#305;n&#305;n n�bet riski yaratma
olas&#305;l&#305;&#287;&#305; nedeniyle meslek se�iminde
uyar&#305;lmal&#305;d&#305;rlar, ancak bu durumun epileptiklerin sadece ufak
bir b�l�m� i�in ge�erli oldu&#287;u da g�z ard&#305; edilmemeli ve hastaya
gereksiz sosyal hayat&#305;n&#305; k&#305;s&#305;tlay&#305;c&#305; �neriler
getirilmemelidir. Epileptik bir �ocu&#287;un ciddi bir mental gerili&#287;i
olmad&#305;&#287;&#305;nda normal okullara devam etmesi ve
ba&#351;ar&#305;s&#305; �l��s�nde e&#287;itimini s�rd�rmesi ve y�ksek
�&#287;renim gerektiren bir �ok mesle&#287;i bile sorunsuz bir &#351;ekilde
y�r�tmesinin m�mk�n oldu&#287;u unutulmamal&#305;d&#305;r. Bu a�&#305;dan
gereksiz sosyal �ekinceler veya korkular nedeniyle ailelerin epileptik
�ocuklar&#305;n �&#287;renime devam etme isteklerini engellememeleri
�&#287;�tlenmelidir. A&#351;&#305;r&#305; koruyucu tav&#305;r ilerde
hastan&#305;n sosyal a�&#305;dan izole kalmas&#305;na, sa&#287;l&#305;kl&#305;
sosyal ili&#351;kiler olu&#351;turamamas&#305;na ve e&#287;itim eksikli&#287;i
nedeniyle i&#351; bulmas&#305; a�&#305;s&#305;ndan da sorunlar
ya&#351;amas&#305;na neden olabilmektedir. Ancak epileptik hastan&#305;n
i&#351; bulma a�&#305;s&#305;ndan ya&#351;ad&#305;&#287;&#305; en b�y�k sorun
toplumun bu hastal&#305;&#287;a kar&#351;&#305; bilin�siz ve bilgisiz
yakla&#351;&#305;m&#305;n&#305;n s�rmesi nedeniyle olmaktad&#305;r. Bu nedenle
�lkemizde bir �ok epileptik hasta kalifikasyonlar&#305;na uygun i&#351;
bulamamakta, hastal&#305;klar&#305;n&#305; saklamak zorunda kalmakta ve i&#351;
yerinde n�bet ge�irince i&#351;ten at&#305;lma stresiyle
ya&#351;amaktad&#305;rlar. Bu a�&#305;dan halk&#305;n ve i&#351;verenlerin
hastal&#305;&#287;&#305;n ger�ek do&#287;as&#305; hakk&#305;nda bilgilendirilmeleri
ancak �ok geni&#351; �apl&#305; e&#287;itim ad&#305;mlar&#305;n&#305;n
at&#305;lmas&#305; ile m�mk�n olabilecektir. <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Epilepsi ve
Askerlik</span></b><span lang=TR style='font-family:Tahoma'> <o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Aktif epilepsisi
olan hastalar askerlik yapmazlar. Askerlik yoklamas&#305; s&#305;ras&#305;nda
durumunu bildiren hastalardan takip edildikleri birimlerden t&#305;bbi
belgeleri istenerek incelenmekte veya askeri hastaneye yat&#305;r&#305;larak
ilac&#305; kesilmekte ve n�beti askeri doktorlarca g�zlenmektedir. Bu durum
baz&#305; olgularda tedavi s�recini olumsuz etkileyebilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><b><span lang=TR style='font-family:Tahoma'>Epilepsi ve
Ara� Kullan&#305;m&#305; <o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsi nedeniyle
sosyal a�&#305;dan hastan&#305;n ya&#351;ad&#305;&#287;&#305; en �nemli
s&#305;k&#305;nt&#305;lardan biri de, ne zaman gelece&#287;i belli olmayan
n�betler nedeniyle hastan&#305;n n�betsiz d�neminde rahat�a y�r�tebilece&#287;i
baz&#305; aktivitelerin n�bet an&#305;nda ya&#351;am tehlikesi
yaratmas&#305;d&#305;r. Araba kullanmak bunlar aras&#305;nda g�ndelik
ya&#351;am ve i&#351; bulma a�&#305;s&#305;ndan belki de en �nemlisidir.
�lkemizde epilepsi hastas&#305;n&#305;n ehliyet almas&#305; kanunen
yasakt&#305;r. Bu konuda kanunlar �lkeden �lkeye de&#287;i&#351;im
g�stermektedir. Bir�ok �lkede son n�betten itibaren 1 veya 2 y&#305;l&#305;n
n�betsiz ge�mi&#351; olmas&#305; ko&#351;ulu aranmaktad&#305;r. Sadece basit
parsiyel n�bet ya da miyokloni risk olu&#351;turmayabilir ve baz&#305;
sendromlar remisyona girebilir. Bir doktorun epileptik hastas&#305;n&#305;n
ara� kulland&#305;&#287;&#305;n&#305; farketti&#287;inde kanuni yollara
ba&#351;vurmas&#305; baz&#305; �lkelerde zorunlu tutulmu&#351;tur.<span
style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify'><span lang=TR style='font-family:Tahoma'>Epilepsili
hastalarda s&#305;k g�r�len psikiyatrik sorunlar i�in <i style='mso-bidi-font-style:
normal'><u><span style='color:#0070C0'><a href="../psikiyatrik/Psikiyatrik.htm">N�rolojik
Hastal&#305;klar&#305;n Psikiyatrik Yans&#305;malar&#305;</a> </span></u></i>b�l�m�ne
bak&#305;n&#305;z. <o:p></o:p></span></p>

<p style='text-align:justify'><a name="Epilepsinin_ay&#305;r&#305;c&#305;"></a><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'>KAYNAKLAR:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma'> <br>
&nbsp; <o:p></o:p></span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Commission on Classification and Terminology of the International
     League Against Epilepsy. Proposal for revised classification of epilepsies
     and epileptic syndromes. Epilepsia 1989; 30: 389-399. <o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Commission on Classification and Terminology of the International
     League Against Epilepsy. Proposal for revised clinical and electroencephalographic
     classification of epileptic seizures. Epilepsia 1981; 22: 489-501. <o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Dam M, Gram L (eds). Comprehensive Epileptology. New York: Raven
     Press, 1990. <o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma'>Engel J Jr, Pedley TA. Epilepsy: A
comprehensive Textbook. Wolters Kluwer Lippincott-Raven, 2008.<o:p></o:p></span></p>

<p class=authors1 style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Engel J Jr; International League Against Epilepsy (ILAE). <a
href="http://www.ncbi.nlm.nih.gov/pubmed/11422340?ordinalpos=28&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum"><span
style='color:windowtext;text-decoration:none;text-underline:none'>A proposed diagnostic
scheme for people with epileptic seizures and with epilepsy: report of the ILAE
Task Force on Classification and Terminology.</span></a> <span
class=journalname>Epilepsia</span>. 2001; 42:796-803. <o:p></o:p></span></p>

<p class=authors1 style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Epilepsi: Edit�rler; Bora &#304;, Yeni N, G�rses C. Nobel
T&#305;p Kitabevleri 2008, &#304;stanbul. <o:p></o:p></span></p>

<p class=authors1 style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Karceski S, Morrell M, Carpenter D. Treatment of epilepsy
in adults: expert opinion. Epilepsy Behav 2005 (suppl1): 65-67.<o:p></o:p></span></p>

<p class=authors1 style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Kellinghaus C, Loddenkemper T, Najm IM, et al. Specific
epileptic syndromes are rare even in tertiary epilepsy centers: a
patient-oriented approach to epilepsy classification. Epilepsia 2004; 45:
268-275. <o:p></o:p></span></p>

<ol style='margin-top:0cm' start=8 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Luciano D. Partial seizures of frontal and temporal origin. Neurol
     Clin 1993; 11: 805-822. <o:p></o:p></span></li>
</ol>

<p class=authors1 style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>L�ders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A,
Burgess R, Dinner DS, Ebner A, Foldvary N, Geller E, Hamer H, Holthausen H,
Kotagal P, Morris H, Meencke HJ, Noachtar S, Rosenow F, Sakamoto A, Steinhoff
BJ, Tuxhorn I, Wyllie E. <a
href="http://www.ncbi.nlm.nih.gov/pubmed/10100955?ordinalpos=9&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum"><span
style='color:windowtext;text-decoration:none;text-underline:none'>A new
epileptic seizure classification based exclusively on ictal semiology.</span></a>
<span class=journalname>Acta Neurol Scand</span>. 1999; 99:137-41.<o:p></o:p></span></p>

<ol style='margin-top:0cm' start=10 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D;
     Medical Research Council MESS Study Group. <span style='mso-bidi-font-weight:
     bold'>Immediate versus deferred antiepileptic drug treatment for early
     epilepsy and single seizures: a randomised controlled trial. Lancet; 2005:
     </span>365: 2007-13 <o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Sander JW, Hart YM. Epilepsy: Questions and answers. Merit
     Publishing International, Hampshire 1999. <o:p></o:p></span></li>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Selzer ME, Dichter MA. Cellular pathophysiology and pharmacology
     of epilepsy. In: Asbury AK, Mc Khann GM, Mc Donald WI.(eds). Diseases of
     the Nervous System: Clinical Neurobiology. Philadelphia: WB Saunders
     Company, 1992: 916-931. <o:p></o:p></span></li>
</ol>

<p class=title1 style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;
mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>13.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Stefan H, Feuerstein TJ. <a
href="http://www.ncbi.nlm.nih.gov/pubmed/17030393?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Novel
anticonvulsant drugs.</span></a> <span class=journalname>Pharmacol Ther</span>.
2007; 113: 165-83. <o:p></o:p></span></p>

<p class=title1 style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;
mso-list:l26 level1 lfo107;tab-stops:list 36.0pt'><![if !supportLists]><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Tahoma'><span style='mso-list:Ignore'>14.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]><span lang=TR style='font-size:10.0pt;
font-family:Tahoma'>Weber YG, Lerche H. <a
href="http://www.ncbi.nlm.nih.gov/pubmed/18754913?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Genetic
mechanisms in idiopathic epilepsies.</span></a> <span class=journalname>Dev Med
Child Neurol</span>. 2008; 50: 648-54. <o:p></o:p></span></p>

<ol style='margin-top:0cm' start=15 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l26 level1 lfo107;
     tab-stops:list 36.0pt'><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma'>Westbrook GL, Seizures and Epilepsy. In: Kandel ER, Schwartz JH,
     Jessell TM (eds). Principles of neural science. McGraw-Hill Co. 2000:
     910-934. <o:p></o:p></span></li>
</ol>

</div>

</body>

</html>
